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Analyses of the PrP gene of several mammalian species have found that it exhibits a 
high degree of DNA sequence homology. However, exon III of the sheep gene is 
much larger than that found in other species due to insertions of ruminant-specific 
elements within the PrP 3 'UTR. The ovine 3 'UTR is also differentially processed to 
produce at least two mRNA transcripts (4.6 and 2.1kb) by alternative 
polyadenylation. Differential expression of the two transcripts is observed with 
respect to tissue specificity and level of transcription. 
The primary objective of this study has been to examine the hypothesis that regions 
specific to the sheep 3 'UTR act as an inhibitor. In a previous thesis, in vitro 
expression in mouse N2a cells using reporter gene constructs with the 
chloramphenicol acetyl transferase (CAT) gene linked to PrP sequences had 
suggested that there might be an inhibitor of translation in the PrP gene 3'UTR. 
Transient transfection methods were developed to generate optimal levels for in vitro 
expression of the CATIPrP-3'UTR constructs in immortalised Cheviot fetal brain-
derived cell lines from both scrapie resistant and susceptible genotypes and primary 
cell lines derived from cerebellum and liver tissues of the Icelandic sheep breed, Ovis 
brachyura borealis pall. Expression of a series of CATIPrP-3 'UTR vectors in cell 
lines derived from different PrP genotypes found that sequence between nucleotides 
2000-2700 on the PrP 3 'UTR may show a tendency to reduce protein expression in 
the cells derived from brain tissue of scrap ie-resistant genotype and in a tissue 
specific manner. 
Additional vectors were produced to express ovine PrP mRNAs, similar to the 
endogenous 4.6kb and 2.1 mRNAs transcripts, but altered to display a monoclonal 
epitope site (3F4) enable transiently expressed PrP protein within ovine cell cultures 
to be detected. Expression of the PrP constructs in mouse neuroblastoma (N2a) cells 
has shown that both constructs were viable. However, the immunodetection methods 
employed in this thesis could not distinguish between transiently expressed 3F4-
labelled ovine PrP and endogenous PrP within sheep cell lines. 
Results presented here confirm that the 3' UTR found in the 2.1kb mRNA is capable 
of supporting gene expression. A role for a specific sequence in the ovine PrP gene 
3 'UTR in controlling protein expression in brain-derived cell lines has been 
proposed. Also, the function of the regulatory sequence may be dependent on tissue 
origin. PrPC  is vital for the replication of the TSE agent. Controlling the amount of 
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Chapter 1 :Transmissible Spongiform Encephalopathies. 
1.1 General Introduction. 
Transmissible spongiform encephalopathies (TSEs), also known as prion diseases, 
are fatal degenerative disorders of the central nervous system (CNS) affecting both 
humans and animals. TSEs are characterised by disturbances in behaviour and 
movement, spongiform changes in the brain and the deposition of an abnormal 
isoform of a host-encoded protein (PrP) in the CNS and to a lesser degree in 
lymphoid tissue. There appears to be no immune response to infection and potential 
therapeutics investigated to date have only delayed the onset of disease in animal 
studies. 
Transmission of TSEs to laboratory animals has highlighted the unusual properties of 
the pathological agent such as long incubation period and resistance to chemical and 
physical inactivation. The identity of the TSE agent has remained an enigma for 
more than 60 years due to the failure to isolate a particle which conforms to the 
criteria of TSE: transmissibility, replication, propagation of strain characteristics, 
neuronal loss, and accumulation of an abnormal host encoded protein. Suggested 
aetiologies for the TSE agent include that of a proteinaceous infectious particle 
(prion), a DNA/protein hybrid (virino) or an unconventional virus. The prion 
hypothesis suggests that a partially protease-resistant abnormal isoform (designated 
PrP) of a normal host encoded glycoprotein (PrPC)  (Bolton et al, 1982; McKinley 
et al, 1983; Oesch eta!, 1985) is the major, or sole, component of the TSE infectious 
agent (Prusiner, 1982; Prusiner eta!, 1982). It is proposed that the agent can 
replicate, without a nucleic acid (Griffith, 1967; Prusiner, 1982), by converting the 
normal host-encoded isoform to the disease isoform (Prusiner, 1991 ;Jarrett and 
Lansbury, 1993). According to the prion hypothesis, strain characteristics of TSEs 
are encoded for in the conformation of PrPSC  (Caughey etal., 1998; Safar etal., 
1998). Whether PrPSC  is the infectious agent still has to be proven. The virino and 
virus theories both predict that the TSE agent has an independent informational 
molecule encoding strain specific characteristics. The virino model suggests that the 
TSE agent-specific molecule, probably a nucleic acid (Dickinson and Outram, 1988), is 
protected by PrP. Formation 0fppSC  may be due to the association of the virino 
nucleic acid with the host PrPC  protein. The virus model suggests that the agent-
specific nucleic acid encodes strain-specific characteristics and the viral coat contains 
PrPSC (Rohwer and Gajdusek, 1980) 
The normal PrP isoform, PrPC,  is detectable in many uninfected and TSE-infected 
tissues (Bendheim etal., 1992). In contrast, PrPSis  only associated with TSE infection 
(Rubenstein et al., 1987, Ikegami etal., 1991). The PrP gene structure and organisation 
is known to be highly conserved between species suggesting that it may play a 
fundamental physiological role. However, the precise function of PrP is still unclear. 
To investigate the role of PrP, both in the cell and as a factor of TSE development, 
panels of transgenic mice have been created by several laboratories. Analysis of 
transgenic models has revealed the importance of host genetics (Race, 1990) for 
susceptibility to TSEs. Mice lacking the PrP gene (PrP null) develop normally and 
show no severe phenotype (Bueler etal., 1992;Manson etal., 1996). Furthermore, 
when inoculated with scrapie these PrP null mice appear to be resistant to disease 
(Bueler etal., 1993; Sailer etal., 1994). Conversely, animals over-expressing PrP 
are more susceptible to TSEs (Scott etal., 1989; Prusiner, 1990; Bueler etal., 1992). 
Expression of the PrP gene therefore seems to be vital to the development of TSEs. 
This thesis deals primarily with the expression of the PrP gene within sheep, the 
natural host of scrapie, and attempts to correlate the importance of control 
mechanisms of PrP gene expression to disease susceptibility, transmission and 
development. The aim of this first chapter is to introduce the complexities of the TSE 
agent and the host PrP gene products. 
Table 1.1 : TSE diseases of humans and animals 
Natural Host Disease Occurrence 
Sheep,Goats Scrapie Unknown' 
Cattle Bovine Spongiform Encephalopathy (BSE) I atrogen i cb 
Mule deer Chronic Wasting Disease (CWD) U n knownc 
Mink Transmissible Mink Encephalopathy (TME) U nknown   
Cats Feline Spongiform Encephalopathy (FSE) l atrogen ice 
(domestic, captive) 
Human Creutzfeldt-Jakob disease (CJD) Sporadic 
Inherited9 
I atrogen ic" 




Fatal Familial Insomnia (FF1). Inherited' 
a(Cuille J. and Chelle, P.L., 1936; Parry, 1983;Chelle, 1942; Dickinson, 1976), 
b(Wells et al, 1987; Fraser et al, 1988), c(Williams  and Young, 1980), d(Hasough  and 
Burgher, 1965), e(WyaU  etal. 1990), (Creutzfe1dt, 1920; Jakob, 1921), g  "'(review 
Prusiner, 1993), '(Will et al, 1996; Chazot et al, 1996), i(  Gerstmann, 1928), k(Gajdudesk  and 
Zigas, 1957), '(Lugaresi eta!, 1986) 
1.2 TSEs of Humans and Animals. 
TSE diseases have been described in both animals and humans (Table 1.1). 
Characteristic pathology of TSEs is generally confined to the CNS, particularly the 
brain. Examination of TSE-infected brain reveals a neuropathology which can vary 
in localisation and severity depending on the infecting strain of TSE. Pathological 
markers for TSE infection commonly include accumulation and deposition of an 
amyloid protein (PrPSc)  in specific brain areas, vacuolation (spongiform appearance) 
and astocytic gliosis(Beck etal., 1969; Gibbs etal., 1968; Bruce and Fraser, 1975; 
Chou et al., 1980; Wisniewski et al., 1981; Tateishi et al., 1984). Spongiform 
lesions are thought to be the result of formation of intracellular vacuoles (Prusiner, 
1993). 
Scrapie, which occurs naturally in sheep and goats, has been recognised in Europe 
for more than 250 years and is the best studied of animal TSEs. Clinical signs of 
scrapie include trembling, loss of motor control, intense itching, and paralysis, death 
due to scrapie in sheep most frequently occurs between the ages of 2-5 years. 
Generally, neuropathological examination of a scrapie infected brain reveals 
widespread deposition of PrP, vascular degradation and gliosis (Wood etal., 1997). 
Since early demonstrations of its transmissibility (Cuille and Chelle, 1936), scrapie 
has become the experimental model for TSEs in general and is usually studied in 
both sheep and laboratory rodents. 
TSEs have been identified in other animal species based on transmission, clinical and 
neuropathological symptoms familiar to scrapie (Table 1.1). The appearance of 
Bovine spongiform encephalopathy (BSE), first identified in 1986, coincided with 
changes in rendering procedures and the feeding of cattle of meat and bone-meal in 
Britain (Bradley and Matthews, 1992). Although not proven, the BSE outbreak is 
considered to be the result of cattle being fed meat and bone-meal derived from 
ruminant sources contaminated with scrapie (Wilesmith, 1991). Since 1988, feeding 
ruminants with ruminant derived bone meal has been banned and as a result reported 
cases of BSE have fallen in number (Wilesmith, 1993). Neuropathologically, BSE in 
cattle shares similar features to scrapie in sheep: astrocytosis, vacuolation, neuronal 
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loss and PrP amyloid plaque formation (Wells and Wilesmith, 1995). However, 
significant differences in the pattern of neuronal loss within specific brain regions are 
observed following inoculation of inbred lines of mice with scrapie and BSE (Bruce, 
1998). Although BSE is clearly a distinct strain of TSE, changes in the rendering 
process which occurred just prior to the appearance of BSE may have allowed the 
selection of a rare strain of TSE. TSEs have also been reported in domestic cats 
(FSE) and captive zoo animals (Wyatt etal., 1990; Jeffrey and Wells, 1988; 
Kirkwood etal., 1990). These cases are thought to have arisen through the animals 
being fed BSE-contaminated-meat derived from bovine sources. Transmissible 
Mink Encephalopathy (TME), first observed in farmed mink in 1965 (Hartsough and 
Burger, 1965) was caused by an agent with similar physiochemical properties to that 
of the scrapie agent (Marsh et al., 1969; Marsh et al., 1979). 
Human TSEs can be described as inherited (GSS, CJD, FF1), sporadic (CJD), 
infection (Kuru) or iatrogenic (CJD) (Table 1,1). Most forms, like scrapie, are 
experimentally transmissible to various animal species(Gibbs etal., 1969). The 
clinical and pathological features of the different human TSEs can vary greatly but 
most show degrees of dementia, ataxia, spongiform degeneration and amyloid 
deposits composed of PrP protein fragments (Prusiner, 1993). However, the age 
groups in which these TSEs occur can vary. Generally, the age of onset for CJD is 
50-60 years, although cases in young patients have been identified (Brown, 1985). 
For GSS the age of onset can be 24-63 years (Prusiner, 1993) and FF1 has presented 
in 40-60 year olds (Lugaresi et al., 1986: Reder etal., 1995). 
Although sporadic CJD (sCJD) occurs more frequently than other forms, it is still 
very rare (approximately 1 case per 106  per year world wide), and factors involved in 
the cause of sCJD are unknown. Approximately 15% of CJD cases and almost all 
GSS (occurrence rate of 1-2 per 10-100 million (Master et al., 1979, Prusiner 1993)) 
cases occur in a familial context, both showing an autosomal dominant pattern of 
disease segregation (Masters et al., 1979). latrogenic forms of human TSEs are 
thought to result from accidental inoculation, transplantation of TSE infected 
material. Kuru for example, a unique neurodegenerative disorder among the Fore 
Tribe of Papua New Guinea, is thought to have been transmitted through ritual 
cannibalism (Gajdusek, 1977). However, since the practice of cannibalism ended in 
1955, the numbers of recorded Kuru cases have fallen significantly, although cases 
are still occurring almost 40 years after the last known ritual. A new variant of Cii) 
(nvCJD, now known as vCJD) was identified in the UK in young patients who had a 
unique, clinical and pathological phenotype (Will et al., 1996; Chazot etal., 1996). 
vCJD cases all shared early onset of disease, initial psychiatric disturbances, 
prolonged duration of illness and unusual pathology: all characteristics which had 
never been described in UK CJD cases before. Recently it was shown that a similar 
TSE agent is responsible for both BSE and vCJD (Collinge eta!, 1996; Bruce et al., 
1997; Hill etal., 1997) (section 1.5.2.1). 
1.3 The TSE Infectious Agent. 
Originally, the scrapie agent was believed to be an unconventional slow virus that 
had so far eluded detection but this is now thought unlikely. A similar difficulty in 
agent identification was seen with the hepatitis C virus (Choo etal., 1989). Intensive 
immunological methods failed to identify specific viral antibodies and antigens in 
hepatitis cases arising from blood transfusion. It was not until 1989 that Choo eta!, 
cloned an antigen associated specifically with a blood-borne non-A, non-B, hepatitis 
(NANBH) and so identified the hepatitis C virus. 
A curious feature of the TSE agent is the persistence of infectivity after treatment 
with methods effective of viral inactivation. Infectivity is resistant to nuclease 
treatment and high doses of ultraviolet and ionising radiations (Alper etal., 1967; 
Latarjet, 1970; Milison et a!, 1976) but is susceptible to procedures that denature, 
modify, hydrolyse or degrade proteins such as protease K or trypsin (Bolten et al., 
1982; Mckinley etal., 1983). Inactivation of TSEs and the repercussions of 
accidental transmission first became apparent during a large scale vaccination 
programme of sheep against louping-ill virus, when at least 10% of the sheep 
developed scrapie. The louping-ill vaccine, assumed to be contaminated with scrapie 
had been treated with 0.35% formalin (Greig, 1950). In humans, transmission of 
CJD was recorded after instruments used on a suspect CJD patient for brain surgery 
were "sterilised" by ethanol and formaldehyde before being used on other patient 
who later developed C ((Bernoulli eta!, 1977). 
No single method has been found which completely inactivates TSEs e.g. 
autoclaving, detergents, acids, oxidising agents (review Taylor, 1999). For example 
after autoclaving, scrapie strain, 22A, and BSE strain, 301V, both show enhanced 
survival at 138 °C compared with 134°C. The failure to decontaminate tissue or 
surfaces by these methods has led to the suggestion that the TSE agent is 
thermostable under conditions which appear to fix the protein component PrP, and 
hence protect the agent from inactivation. Only one method to date has been shown 
to successfully inactivate TSEs. A combination of autoclaving and exposure to 
sodium hydroxide can apparently inactivate CJD and scrapie infectivity (Taguchi et 
al., 1991 ;Taylor etal., 1997; Ernst and Race, 1993). However, this method does 
pose its own hazards, especially to the operator with regards to autoclaving, and 
contact, with sodium hydroxide. Future studies on this inactivation method may 
provide a solution to decontamination. 
1.3.1 Association of PrPSC  with TSEs. 
Post-mortem investigation of scrapie and CTh infected brain tissue revealed the 
deposition of an amyloid protein in rods and scrapie associated fibrils (SAF), fibre-
like structures 100-1000nm in length (Merz etal., 198 1) which are not found in 
healthy controls. These filaments, when purified, enriched scrapie infectivity from 
several hundred fold to several thousand fold (Bolton etal., 1982; Prusiner, 1982a) 
and were found to consist largely of a single protein 27-30 kDa (PrP 27-30) which 
appeared to be derived from a larger protein by proteinase K digestion (Prusiner, 
1982a). PrP 27-30 was uniquely associated with TSE infected hosts and designated 
PrPS (PrP Scrapie). The discovery of PrPSC  allowed for the isolation of cDNAs from 
libraries constructed from scrapie infected hamsters and mice (Oesch et al., 1985; 
Chesebro et al., 1985; Basler et al., 1986; Locht etal., 1986) revealing that PrPSC  was 
the product of a conversion from host gene, designated PrPC  (PrP Cellular), and not 
virally encoded (Oesch et al., 1985; Basler et al., 1986). Furthermore, when 
proteolysis was avoided, a PrP protein with the larger relative mass of 33-35kDa was 
identified in both infected and normal brains. Therefore PrPC  was expressed in both 
TSE infected and uninfected animals whereas PrP sc was uniquely associated with 
TSE infection. Similarities between PrPC and PrPSC  included SDS-PAGE mobility 
and antigenicity (Oesch etal., 1985; Barry and Prusiner, 1986), N-terminal signal 
peptide cleavage (Basler etal., 1986; Hope etal., 1986), glycosylation (Caughey et 
al., 1988) an addition of a glycosyiphophatidylinositol (GPI) anchor at the C-
terminus (Stahl et al., 1990). However, distinct biochemical and physical properties 
were found to differentiate between PrPC  and  PrPSC  (section 1.6. 1) which lead to the 
suggestion that PrPSC  was post-translationally derived from PrPC  (Borchelt et al., 
1990). 
PrPse appeared to accumulate in TSE-infected hosts in the absence of a detectable 
nucleic acid and opinion grew that perhaps the scrapie agent was fundamentally 
different from other infectious agents. One view was that the major or sole component 
of the TSE agent was PrP itself which was capable of self-replication (prion). 
Alternatively, an agent-specific nucleic acid may still exist and so the term virino was 
introduced to distinguish the agent from conventional viruses and viroids. 
1.3.2 The Prion hypothesis. 
A prion is defined as an infectious, disease-specific isoform of a cellular protein 
which is capable of replication and accumulates during the disease process (Prusiner, 
1982). The prion hypothesis predicts that replication occurs through the post-
translational conversion of PrPC  to PrPSC  via direct interaction of the two proteins to 
generate more PrPS.  Passage of PrPS  from one host to another then constitutes 
"infection" by initiating PrPSC  formation in a new host and the presence of PrPC  is 
fundamental to this theory. Two ideas for prion replication have been proposed: the 
nucleated (or seeded) polymerisation model (Jarrett and Lansbury, 1993) and the 
conformational model (Prusiner, 199 1) (Figure 1.1). 
The nucleated polymerisation models states that PrPC  is in equilibrium with a PrPS(like 
monomer, which, under physiological conditions, is low in concentration. PrPSC  only 
accumulates when the equilibrium shifts because of an incoming high concentration of 
PrPSC oligomers that form and stabilise new PrPS  (Jarrett and Lansbury, 1993). In 
contrast, the conformational model requires the direct interaction of stable PrPC  and 
PrPsc monomers (Prusiner, 1991) to form a heterodimer and catalyse the conversion of 
PrPC to  PrPS.  The resulting PrPsc:PrPsc homodimer then dissociates to capture further 
PrPC monomers. The high-energy requirement for this reaction may be overcome by 
the assistance of chaperones and pre-existing PrPSC  monomers. Consistent with the 
nucleation model, cell free studies have shown that the conversion of PrPC  to  PrPSc 
requires the presence of particles containing oligomers of PrPSC  much larger than 
monomers or dimers. 
Supporters of the prion hypothesis argue that the apparently spontaneous conversion of 
PrPC to  PrPSC,  as would have to occur with genetic human TSE disease, is the result 
of destabilisation of the PrPC  protein by associated specific point mutations. Indeed 
analogous disease associated PrPC  variants produced in cell culture displayed a 
number of biochemical characteristics of PrPSC,  suggesting aberrant folding of the 
molecules in vivo (Huang etal., 1994; Cohen etal., 1994; Cappai eta!, 1999). 
However, thermodynamic stability studies on recombinant murine PrP variants have 
shown that not all pathologically linked amino acid replacements destabilise the 
protein structure (Liemann, et al., 1999). 
Conversion of recombinant PrPC  to  PrPSc  has been demonstrated in vitro (Kocisko et 
al., 1994; Caughey etal., 1995) and characteristic biochemical properties (proteinase 
K resistance) of PrPSC  from different strains of TME were also transmitted to PrPC  in 
the cell free system (Bessen etal., 1995). These examples proved that information 
could be transmitted by non-nucleic acid molecules and would seem to be strong 
evidence in favour of the prion theory. However PrPSC  synthesised in vitro has not 
yet been shown to be infectious and transmissible (Caughey etal., 1995). 
Nucleated polymerisation model 
PrPC 	P rPScl,ke 




PrPC 	PrPsc 	Heterodjmer 	Homodimer 
0O 
Figure 1.1: Proposed model for prion replication. 
Self-replication of PrPSC  has been proposed by two models. a) Nucleated 
polymerisation model (Jarrett and Lansbury, 1993) asserts that PrPC  (orange 
cylinder) conversion occurs when PrPSC  (green cube) is at a critical concentration 
which favours incorporation of a PrP-like monomer into the PrPSC  oligomer. 
b) Conformational model states that stable monomers of PrPC  and PrPSC interact 
directly to form PrPSC  homodimer which can dissociate into active PrPSC  monomers. 
(Prusiner, 1991). 
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1.3.3 The Virino hypothesis. 
The virino theory suggests that PrP is a component of the infectious agent recruited 
into the infectious particle by an as yet unidentified host- independent informational 
molecule (Dickinson and Outram, 1988) which is expected to be an untranslated 
nucleic acid as nucleic acids are the only known biological molecules proven to be 
capable of carrying genetic information and propagating strain characteristics. TSEs 
have been exposed to nuclease treatment (Milison et al., 1976), more extreme than 
would be required to inactivate most conventional micro-organisms. However rather 
than proving the absence of a nucleic acid, the property of resisting the effects of 
nucleic acid denaturants may simply indicate that the nucleic acid is either very small 
or is enveloped and thus protected by the PrP protein. It is hypothesised that the 
informational molecule of the TSE agent interacts with the host PrPC  protein 
(Farquhar etal., 1998) and as a result of the conversion of PrPC  to  PrPSC  the nucleic 
acid is protected from degradation. 
The virino hypothesis states that PrPC  exists in an equilibrium of ordered complexes 
that may act as a receptor or precursor for the infectious agent (Figure 1.2). The 
binding of the infectious agent to the PrPC  complex, and perhaps other molecules, 
would alter the three-dimensional structure of PrPC  such that it becomes PrP sc causing it 
to accumulate in and around cells as scrapie associated fibrils (SAF) (Hope, 1986). The 
calculated target size of the agent, determined by ionising radiation, is in line with 
the size of nucleic acid genomes in small viruses: estimated at 1.5x10 6 Da (d5DNA) 
or 0.9xl06 Da (ssDNA) (Rohwer, 1991). For example the porcine circovirus virus 
has a ssDNA nucleic acid genome ofO.58x10 6 Da (Tischer et al., 1982). 
Attempts to identify TSE-specific nucleic acids have been largely unsuccessful, 
perhaps because they are too small, low in concentration or of an unusual structure. 
However, viral-like structures have been observed in TSE-affected brains (Diringer 
et al., 1997). In another study, nucleic acids extracted from CJD brain tissue showed 
high infectivity levels and did not correlate to nucleic acids found in the mouse 
genome or uninfected brains (Dron and Manuelidis, 1996). The virino theory has yet 
to be disproved and is supported experimentally firstly by the existence of many strains 
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to be disproved and is supported experimentally firstly by the existence of many strains 
(difficult to reconcile with protein etiology, refer to section 1.4) and secondly by data 










Figure 1.2: Proposed model for virino replication 
The virino hypothesis states that PrP' (orange cylinder) is in equilibrium 
as monomers and higher complexes (Hope, 1986). The TSE strain encoding 
molecule (blue ribbon) interacts with the complex and alters it properties, causing it 
to accumulate in the form of amyloid fibres which contain PrPSC  (green cube). 
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1.3.4 Protein  
Protein X is an as yet unknown macromolecule which, according to supporters of the 
prion hypothesis may be involved in the conversion process of PrPC  to  PrP&.  The 
concept of protein X was first described by Telling et al. (1995) when they observed 
that mice transgenic for a chimeric human-mouse PrP gene, Tg(MHu2M) mice, were 
highly susceptible to human TSEs (Telling etal., 1995). Furthermore, expression of 
human PrP (HuPrP) on a null background (Tg(HuPrP)PrnpOl'O  mice) also resulted in 
mice susceptible to inoculation with human TSEs (Telling etal., 1995). Previously it 
had been observed that Tg(HuPrP) mice were relatively resistant to inoculation with 
human TSEs (Telling et al., 1994). The overall conclusions from these studies were 
that: 1) mouse PrPC  (MoPrP) inhibited conversion of HuPrPC  to HuPrP; 2) a second 
mouse protein, designated protein X, was necessary for the conversion process, and; 
3) mouse protein X binds to mouse PrPC  with higher affinity than it binds to H uPrPC, 
thus inhibiting HuPrPS  formation. Although several ligand binding studies have 
identified proteins capable of binding to PrPC  (Oesch et al., 1990; Kurschner and 
Morgan, 1995; Yehiely et al., 1997) their role, if any, in PrPC  conversion has not 
been examined. 
Alternatively, subtle differences in the amino acid sequence between the host P rPC 
and the infecting PrPSC  protein may prevent prion replication by the host PrPC  protein 
"end blocking" the growing PrPSC  polymer (Masel et al., 2000). According to the 
nucleated polymerisation model oligomers of PrPSC  are the result of PrP-like 
monomers incorporated into the growing chain. Using mathematical modelling, 
Masel et al. (2000) proposed that the host PrPC  protein could bind to growing PrPS 
oligomer and block the addition of further PrPSC  molecules. Both protein X and the 
end-blocking theory were based on observations where there was only one amino 
acid difference between the host PrPC  and the infecting PrPS  protein (Priola et al., 
1994; Kaneko et al., 1997; Zulianello et al., 2000). However, studies have shown 
that more than one point mutation difference existing between the host PrPC  and the 
infecting PrP sc protein does not protect the host from infection with TSEs from 
different species (Zulianello et al., 2000). To date both theories should be considered 
until further studies reveal the full pathway for PrP sc synthesis. 
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1.4 TSE Strains. 
The major argument against the prion theory is the existence of multiple scrapie 
strains and this is often used as evidence for the other proposed etiologies. Many 
strains from naturally occurring scrapie cases in sheep and goats have been passaged 
through inbred mice. Each rodent-adapted scrapie strain has its own distinctive 
incubation period, clinical presentation, neuropathology, PrPSC  deposition, and 
glycoform profile on Western blots (Fraser, 1976; Bruce etal., 1991; Somerville, 
1999). The incubation period and pathology is routinely used to identify the strain, 
or type, of TSE when passaged in inbred mouse lines. Furthermore, strain-specific 
neuropathology has lead to the development of a quantitative assay, lesion profiling 
(Fraser and Dickinson, 1968; Bruce etal., 1991), which in contrast to the incubation 
period is not dose-dependent. 
Another characteristic used to identify strains is the molecular heterogeneity of P rPS 
which appears to retain a strain-characteristic glycosylation pattern when resolved 
on SDS-PAGE (Collinge etal., 1996; Parchi etal., 1996). This property of P rPS 
led supporters of the prion hypothesis to argue that strain-specific properties of the 
TSE agent were enciphered within the attached carbohydrate moieties. However, the 
glycosylation pattern of PrPSc  purified from different tissues, and cell types within a 
tissue, within a single host has been shown to differ (Hill et al., 1999a; Rubenstein et 
al., 1991; Somerville, 1999). This suggests that glycosylation is not dictated solely 
by the TSE strain but by co- and post- translational event and may be a result of the 
cell type of the species in which it occurs (Somerville, 1999). 
1.4.1 Scrapie strain and the prion hypothesis. 
In context of the prion theory, strain characteristics would have to be enciphered in 
the stable conformation of PrP sc and strain differences could therefore be explained 
by variations in the conformational state of the PrPSC  protein (Bessen, 1994; Bessen 
1995; Telling etal., 1996; Caughey etal., 1998; Safar etal., 1998). PrPSC 
interacting directly with PrPC  would function as a template for replication of nascent 
PrPSC molecules and variations in incubation periods would be related to the 
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characteristic rate of conversion of PrPC  to  PrPSC  with the correct conformation for 
each strain. No high-resolution structures have yet been determined for PrPSC  due to 
its tendency to form aggregates, which is incompatible with current NMIR and X-ray 
diffraction techniques. Conformational studies using Fourier transform infrared 
(FTIR) spectroscopy have shown that PrPSC  preparations from various hamster-
adapted scrapie isolates have differences in the amount of 13-sheet secondary 
structure (Caughey et al., 1998). Additionally, a novel conformation-dependent 
immunoassay has claimed to characterise several hamster-adapted scrapie strains 
(Prusiner et al., 1999). Neither system has yet been tested on strains of naturally 
occurring sheep scrapie where PrP sc levels can vary greatly between individual cases 
and different brain regions. It remains unclear what mechanisms enable the PrP 
protein alone to specify and retain biological TSE characteristics. 
1.4.2 Scrapie strains and the virino theory 
Supporters of the virino theory argue that the diversity of strains seems more 
plausibly explained by the existence of a nucleic acid which determines TSE strain 
characteristics rather than a single rogue protein. Western blot studies on PrP 
glycosylation patterns of TSE-infected laboratory rodents revealed that whereas the 
degree of glycosylation of PrP varied according to the TSE strain there was little 
effect on the glycosylation pattern of PrPC  (Somerville, 1999). These findings 
suggest that PrPSC  is not the result of a conformational change in PrPC.  Instead PrPSC 
may be metabolised separately from PrPC  with the TSE agent directing P rPSC 
metabolism independently of the host PrPC  synthetic pathway. 
1.4.3 Strain characteristics. 
TSE strain characteristics after passage in hosts of different species have been used 
to examine possible links between TSEs. Transmission studies using eight unrelated 
BSE sources from cattle resulted in similar incubation periods and lesion profiles in 
mice suggesting that a single major strain of BSE was present in each source (Bruce, 
1996). Other TSE sources i.e. cats, Nyala and Kudu also showed similar results 
supporting the suggestion that they too had been infected with the BSE strain (Bruce 
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etal., 1994; Fraser et al., 1994) . Western blot analysis of PrPSC  isolated from 
Cheviot sheep infected with BSE and experimental scrapie (CH 1641) revealed 
striking glycoform similarity (Hope et al, 1999). However transmissions of natural 
scrapie from sheep to mice have given variable lesion profiles, with no individual 
source resembling BSE. This does not prove that BSE was not derived from scrapie 
or that BSE has not spread to sheep as TSE strain characteristics can change when 
passaged through a new species (Dickinson and Meikle, 1971). 
The number of strains responsible for natural sheep scrapie is unknown and it may 
be that more than one strain is present in an affected flock at the same time. Limited 
strain typing studies on UK sheep scrapie isolates have so far revealed predominantly 
three scrapie strain types (Bruce, 1993) and a similar investigation of Icelandic 
scrapie showed a further three scrapie strains (Fraser, 1983). Knowledge gained 
from sheep PrP genotyping studies (section 1.7.2) has linked host genetics with 
susceptibility to different experimental scrapie isolates. This suggests that, in 
addition to scrapie strain and route of infection, host genetics plays a vital role in 
disease development. However, identification of high or low-risk PrP gene alleles 
can not totally explain the observed occurrence of natural scrapie in particular sheep 
breeds or PrP genotypes. 
1.5 ScraDie Transmission. 
1.5.1 Ovine transmission. 
The natural route for scrapie infection is still unclear although there is evidence for 
acquired infection (lateral transmission) shown by healthy sheep and goats 
developing scrapie when housed in contact with scrapie sheep (Brotherston et al., 
1968; Haralambiev et a!, 1973). In Iceland, scrapie management involved culling of 
scrapie affected flocks and establishing areas that remained scrapie free for 1-3 years 
after which farms were restocked with sheep from areas where scrapie had never 
been recorded. However, over the next 10 years, scrapie reoccurred on several of the 
farms suggesting either long term survival of the agent or an intermediate host 
(vector) (Paisson and Sigurdsson, 1959). 
16 
There is a clear possibility of maternal transmission of TSEs. Maternal transmission 
of BSE in cattle was thought to be one way of maintaining infection in BSE-affected 
herds at a low level with transmission occurring at a rate of 10% (Wilesmith et al., 
1997). Furthermore, BSE was observed not to be transmitted to embryos derived 
from BSE-infected goat donors (Foster et al., 1999). The strongest evidence 
supporting maternal transmission of scrapie was recorded by Dickinson et al (1965) 
who observed that lambs born from infected ewes were seven times more likely to 
develop disease than lambs born to non-infected ewes. However, the precise route of 
maternal transmission is unknown. Several studies considering maternal 
transmission appear contradictory. Foote et al. (1993) showed that scrapie could not 
be transmitted via the embryo whereas studies at the NPU were not conclusive in that 
embryos donated from infected and non-infected ewes went on to develop scrapie 
(Foster et al., 1992, 1996). The subsequent failure to detect infectivity in the uterus, 
ovary or mammary glands of clinically affected ewes supported the theory that 
maternal transmission did not occur. However recent studies have found evidence of 
infection in placenta. Therefore, one source of infection to newborn lambs may be 
at, or around, the time of birth. Such studies are being repeated in scrapie-free 
conditions in order to establish whether maternal transmission of scrapie really 
occurs (Hunter, personal communication). 
1.5.2 Inter-species transmission of TSE5 
Under normal conditions when scrapie is passaged between species, disease occurs 
only after a very long incubation period if at all and on subsequent serial sub-
passages in the new species the incubation period shortens to a constant duration 
(Pattison and Jones, 1968; Dickinson, 1976; Kimberlin, 1979) and is known as the 
species barrier. The effect of the species barrier varies from apparent absolute 
resistance to increased incubation period dependant on: the species being infected, 
the host PrP gene, the species in which the TSE inoculum originated, route of 
infection and the strain of TSE. There are also situations where there appears to be 
no species barrier i.e. transmission of scrapie from sheep to goats (Greig, 1950; 
Brotherston et al., 1968). 
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1.5.2.1 Transcienic analysis of the species barrier. 
Experimental transmission of TSE from one host to a new host species is 
characterised by a prolonged incubation period (Table 1.2). This is known as the 
species barrier. For instance Chandler mouse scrapie can be transmitted to mice with 
incubation periods of approximately 120 days, while Syrian hamsters have an 
incubation period of up to 380 days with the same inoculum (Kimberlin and Walker, 
1878; Kimberlin et al., 1987). In contrast, hamster scrapie (263K) does not appear to 
transmit to mice despite a short incubation period of about 65 days when passaged in 
hamsters. To determine the controlling factors of the species barrier several lines of 
transgenic mice have been created (Scott etal., 1989; Prusiner etal., 1990). 
Transgenic (Tg) mice carrying the hamster PrP gene (Tg(SHa) mice), are susceptible 
to hamster scrapie but propagate neuropathology and PrPSC  deposition characteristic 
of Syrian hamsters infected with hamster scrapie. (Scott 1989, Prusiner, 1990). 
Conversely Tg(SHa) mice inoculated with mouse scrapie show a prolonged 
incubation period compared to normal mice but similar neuropathology and P rPS 
deposition (Scott et al., 1989). 
There is growing evidence that BSE has passed from cattle to humans causing an 
atypical new variant of CJD (vCJD). Recent emergence of vCJD was first 
recognised in young adults and showed a novel pathological phenotype (Will et al, 
1996; Chazot eta!, 1996). Lesion profile studies and glycoform analysis have reveal 
similarities between the BSE agent and vCJD (Collinge eta!, 1996; Hill etal., 1997; 
Bruce etal., 1997). Transmission studies of BSE and vCJD have been completed in 
lines of Tg mice and would appear to support this theory (Telling etal., 1994; Hill et 
al., 1997;Scott eta!, 1997). A recent study showed Tg mice expressing bovine PrP 
gene were highly susceptible to infection from primary passage BSE and vCJD and 
propagated incubation periods, neuropathology and PrPSC  proteins which were 
indistinguishable by Western blotting analysis (Scott et a!, 1999). It was generally 
assumed that humans would benefit from some degree of protection from the species 
barrier between cattle and humans however accumulating data suggests that the TSE 
agent responsible for BSE, and consequently vCJD, is highly adaptable at infecting 
new hosts. 
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Recipient Mean incubation Period 
(days) 
P rPSC type 
Mouse' hamster 378 Mouse 
Tg mouse (hamster PrP 175 Mouse 
gene )c 
Wild type mouse 120 Mouse 
Hamsterb Hamster 65 Hamster 
Tg mouse (hamster PrP 75 Hamster 
gene )c 
Wild type mouse >720 ? 
Note: '(Kimberlin and Walker, 1978; Kimberlin etal., 1987) , b(Scott etal., 1989; 
Kimberlin etal., 1989; Prusiner etal., 1990), C  Transgenic mice encoding at least one copy 
of the Syrian hamster PrP gene. 
The transgenic studies have shown that neuropathology and synthesis of PrPSc  is 
species specific and reflects the genetic origin of the inoculum. According to the 
prion hypothesis, TSE agent replication requires the interaction of the host PrPC  and 
the donor derived PrP, the species barrier effect is caused by differences in the 
primary sequence of the host PrPC  which reduced efficient PrP sc formation (Scott et 
al., 1989; Prusiner et al., 1990). In contrast, the virino hypothesis suggests that the 
species barrier is the result of agent adaptation to the new host. If PrPC  is the site for 
replication of the TSE agent differences between the host PrPC  primary sequence and 
the donor PrPC  primary sequence may prevent efficient interaction of the agent 
informational molecule (which encodes strain specific characteristics) and hence 
prolong incubation period (Dickinson and Meikie, 1971; Dickinson and Outram, 
1979). 
The species specificity observed in cell free conversion of radiolabelled recombinant 
PrPC to PrP sc reflects the known species barriers in TSE transmission in animals 
(Kocisko et al., 1994; Caughey et a! 1995). In the cell free system PrPSC  isolated 
FL'] 
from scrapie-infected hamster brain tissue induced the conversion of hamster PrPC  to 
PrPsc but was unable to convert mouse PrPC  to  PrPS  (Kocisko, 1995). This 
correlates with the fact that hamster scrapie strain 263K can infect hamsters but not 
mice. 
1.6 Characterisation of the PrP Isoforms. 
1.6.1 Biochemical and physical properties. 
Comparative studies of PrPC  and  PrPSC  have highlighted many distinct features of the 
normal and disease-associated protein isoforms (summarised in Table 1.3). These 
properties are generally used to determine the type of PrP protein within tissues and 
the presence of PrPSC  is assumed to be a marker for infectivity (section 1.6.4). P rPSC 
deposition has to date been detected mainly in the CNS, peripheral nervous system 
and (to a lesser extent) lymphoid tissue of scrapie affected sheep, mice and humans 
(Prusiner, 1993; Ikegami et al., 1991;Prusiner, 1998) 
1.6.2 Function of PrPC. 
Although widely expressed in a variety of different cell types, the function of PrPC  is 
still unclear, although the apparent high conservation observed across all species 
analysed to date suggests a key role for PrP in the metabolic process of the cell. This 
proposal is supported by housekeeping features of the PrP gene; wide spread 
expression, developmental regulation (section 1.9) and promoter structure (section 
1.8). Its position on the cell surface of neurones has also suggested an involvement 
in synaptic function, cell-cell communication and/or adhesion (Manson et al., 
1992a). It was expected that mice deficient for the PrP gene (PrP null, Prnp 0/0) 
would show a phenotype distinct for the loss of PrPC  function, however the first null 
lines generated appeared to be normal (null line designated Zrchl, Bueler et al., 1992; 
null line designated Npul, Manson et al., 1994). Subsequently, it was found that 
these mice showed altered circadian activity (Tobler et al., 1997) and 
electrophysiological (synaptic function) abnormalities (Collinge et al., 1994). The 
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defects in synaptic function however, have never been reproduced and remain 
uncertain. The lack of phenotype due to PrP knockout may be the result of P rPC 
being replaced by proteins with similar functions (Tremblay et al., 1998, section 
1.6.2.1). 
Recently PrPC  was shown to bind copper ions (Cu 2 ) through histidine residues 
within octarepeats near the N-terminus (figure 1.3, section 1.6.2.1). In PrP null mice, 
the activity of CuJZn superoxide dismutate (SOD, a major antioxidant enzyme) has 
been found to be substantially lower compared to wild type mice. These 
observations suggest that PrP may have a physiological function in controlling stress 
as a result of the generation of oxygen free radicals (Brown etal., 1997; Stockel et 
al., 1998; Viles etal., 1999). 
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Table 1. 3: Summary of the biochemical and physical properties of PrPC and PrPSC . 
PrPC PrPS 
Mr 33-35kDa Mr 3335kDaa 
Mature protein —210 amino acids Mature protein —210 amino acids 
Predominantly a helix structure Predominantly 13-sheet structure   
Completely sensitive to proteolysis Protease resistant core, Mr 2730kDaa 
Soluble in detergent Forms insoluble aggregates in 
detergenta 
2 glycosylation sites 2 glycosylation sitesc 
Attached to cell surface by GPI anchor   Primarily located within cells as fibrils or 
deposits 
GPI anchor sensitive to cleavage by 
PIPLC 
GPI anchor only sensitive to cleavage 
after denaturation e 
Synthesis and degradation rapid (-6 
hours) 
Synthesis slow, degradation unknown 
'(Meyer etal., 1986), "(Pan etal., 1993), c(Oesch  et al., 1985), d(Stahl;  etal., 
1990a), '(Stahl; et al., 1990b), (Caughey, 1993) 
1.6.2.1 Prnd (DoDDle) - the novel PrP-like gene 
The lack of a severe phenotype for two Prnp null mice (Prnp 010) lines first gave rise 
to the suggestion that proteins might exist with functions that overlap with P rPC . 
The development of two further mouse lines, Ngsk (Sakaguchi et al., 19996) and 
RcmO (Moore, 1997), showed normal development but displayed late-onset ataxia. 
Furthermore, Ngsk Prnp 0'0  mice also showed loss of Purkinji cells (Sakaguchi etal., 
1996). Studies of the regions flanking the Prnp gene in mouse soon discovered a 
novel PrP-like gene, designated Prnd (Moore etal., 1999). The Prnd gene contains 
an ORF encoding a protein named dopple (Dpl) which has 25% sequence identity to 
the C-terminal 2/3"' of PrPC  and is predicted to contain 3 a-helices and 2 disulphide 
bonds but lacks an octapeptide repeat domain found in PrP (section 1.6.4). Prnd 
homologues have been identified in rats, humans, sheep and cattle (Mead et al., 
2000). 
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Inappropriate expression of Pend may be linked to neurodegeneration. In normal 
mice, like PrP, Dpi mRNA is expressed during development but, unlike PrP does not 
seem to be abundant in the CNS. It was proposed by Moore etal. (1999) that loss of 
Purkinje cells in the Zrch 1 and Rmo 1 lines was due to long-range perturbations in 
gene expression as a result of cloning methods to create the PrP ° '° mice. The 
expression pattern of Dpi mRNA in normal mice was also observed in the PrP null 
line Zrch 1. In contrast, Dpi was up-regulated in the CNS of Ngsk and RcmO P rnpOl'O 
mice both of which displayed signs of neurological illness and Purkinje cell loss 
(Moore et al., 1999). Crossing Ngsk Pmp°"° mice with Tg mice over-expressing 
mouse PrP prevented neurodegeneration (Nishida et al., 1999). These findings 
suggest that over expression of Prnd in the CNS is toxic to Purkinje cells, the Dpi 
and PrP may have similar biological functions but also that expression of Prnp and 
Prnd may be linked to neurodegeneration. 
1.6.3 Synthesis of PrP'. 
Synthesis of PrPC (figure 1.3) appears to follow the secretory pathway (Caughey etal., 
1989). During biosynthesis the N-terminal signal sequence is cleaved (Basler et al., 
1986) and the C-terminal sequence replaced by a gylcosyl phosphatidylinositol (GPI) 
anchor (Stahl etal., 1990). In most species, the mature PrPC  protein contains five 
glycine-rich octa/nona-peptide repeats and two hexapeptide repeats near the N-
terminal region. The number of the octalnona-repeats can vary between species with 
most having five but some, like bovine, can have five or six repeats (Goldmann et 
al., 1991b) although an extra octarepeat in cattle does not seem to be associated with 
differences in BSE susceptibility. In goats, a short PrP allelic variant with only 3 
octarepeats has been reported as causing no spontaneous pathological effect 
(Goldmann et al., 1998). Within the PrP translation product, the N-terminal signal 
sequence targets the product to the endoplasmic reticulum where the C-terminal signal 
sequence promotes the addition of a GPI anchor (Oesch et al., 1985). The modified 
protein is then transported to the golgi where glycosylation may occur at two sites, 
Asni 81 and Asn 197. The C-terminal signal sequence is also thought to be involved in 
the targeting of PrPC  to caveolae-like domains on the cell membrane (Kaneko etal., 
1997). Deletion of the C-terminal signal sequence prevents attachment of PrPC  to the 
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cell surface and results in its secretion into the cell medium. Transport of PrPC  between 
the plasma membrane and endocytic vesicles has been observed in cell cultures and 
soluble forms of PrPC  have also been found in the medium of cultured cells and human 
cerebrospinal fluid (Tagliavini etal., 1992; Shyng et al., 1995). The metabolism of 
PrPC is considered to be associated with non-acidic compartments bound by 
cholesterol-rich membranes (Taraboulos et al., 1995) and has a half-life estimated at 
3-6 hours in cultured cells (Caughey et al., 1993). There is no evidence for PrPS 
turn over in cells which may account for PrPSC  accumulation in vivo (Caughey et al., 
1993). Once formed PrPSC  accumulates in secondary lysosomes, on the cell surface 
or in the extracellular space. 
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a) Molecular events of PrPC synthesis 
PrP Gene transcription 
PrP mRNA translation 
1 25 55 94 	 233 256 
jWC 
ss 	r 	 ss 
Post-translational modifications 
25 	 181 	1.i/3197 233 
NH = 
179 1 	1214 GPI -s-s- 	anchor 








Figure 1.3: Proposed model for PrP ° and PrPSC  synthesis 
a) Maturation of the primary PrP translation product involves cleavage of signal 
sequences (ss) from the N and C terminal, addition of the GPI anchor, the 
formation of a disulphide bond (-s-s-) and glycosylation at one or two sites 
(residues 181 and 197). The octarepeat region is showed by r b) Synthesis of PrPC 
()is considered to follow the secretory pathway: mature mRNA is transported from 
the nucleus (N) to be translated in the endoplasmic reticulm (ER) where it then 
moves to the golgi apparatus (G) in vesicles where it undergoes further 
modification. It is then transported to the cell membrane by secretory vesicles. 
Conversion of P rPCto  PrPSC (#) may occur at the cell surface or in endocytotic 
vesicles (EV) according to the prion hypothesis. Alternatively the agent may 
intercept the PrPC  synthetic pathway to create PrPSC  independently. SAF; scrapie 
associated fibrils. AP: amyloid plaque. 
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1.6.3.1 	Topology of PrPC . 
Biosynthetic studies of the PrP protein have suggested that two distinct forms are 
synthesised in the endoplasmic reticulum (ER): one that is fully translocated 
(secretory) and one which is transmembrane (Hay etal., 1987;Yost etal., 1990;). 
Digestion of the transmembrane form with proteases, in the absence of detergent, 
yields two fragments suggesting two topologies for the transmembrane PrP protein 
(Hay etal., 1987; Lopez etal., 1990). One topology with the COOH-terminal in the 
lumen (ctmPrP)  the other with the NH2-terminal in the lumen (Ntmprp)  Both 
transmembrane forms appeared to span the membrane over the same hydrophobic 
stretch of PrP (residues Ala 11 3-Ser 135) which has been designated the TM  domain. 
Mutations, deletions and insertions into the TM 1 and a second region, the stop 
transfer effector domain (STE, Lysj04-Meti 12)  can alter the amounts of each 
topological form of PrP (Yost et al., 1990). The role of these topological forms in 
vivo was investigated in PrP °'° mice expressing transgenes with various mutation in 
the STE-TM 1 domain. Those expressing the ctmprp  form showed neurological signs 
of illness and neurological pathology similar to those in scrapie, but PrPSC  was found 
to be absent (Hedge et al., 1998). Mice expressing Ntmprp  transgene did not show 
any signs of illness. ctmprp  was also found to accumulate in brain tissue from GSS 
affected patients who had a mutation of alanine to valine at codon 117 which is in the 
STE domain. The hypothesis proposed was that distinct topological forms of P rPC 
may be involved in TSE disease pathogenesis. 
1.6.4 Structural characteristics of PrPC  and PrPSC . 
The PrP protein amino acid sequence is highly conserved between species with 
generally more than 90% amino acid identity (Schatzl et al., 1997), and containing 
around 250 amino acids, the exact number depending on the species e.g. 256 in 
sheep, 254 in human and 253 in rodents. Both PrPC  and  PrPSC  are the product of the 
same host gene with no apparent TSE-associated differences in either the amounts of 
PrP mRNA or primary structure. Although the pattern of glyscosylation observed in 
PrPC and PrP within a host has been shown to be distinct (Somerville, 1999), pulse-
chase metabolic labelling studies have shown that PrPS  may be derived from PrPC 
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(Borchelt et al., 1990; Caughey and Raymond, 1991), Therefore, the primary 
difference between the two isoforms may simply be conformational. 
Nuclear Magnetic Resonance (NMR) studies on recombinant forms of mouse and 
hamster PrPC  have determined the N-terminal region (residues 23-120) of PrPC  to be 
flexible in solution while the C-terminal segment (residues 121-231) has a defined 
tertiary structure of three a-helices and a short two-stranded antiparallel n-sheet 
(Riek etal., 1996; Rick eta!, 1997; Donne etal., 1997;James etal., 1997). The C-
terminal structure is independent of the flexible N-terminal tail as the structure is 
preserved in N-terminally truncated recombinant PrP forms. 
The tertiary structure of PrP sc has not yet been determined because of the insolubility 
of this protein isoform. Limited X-ray diffraction studies have indicated that PrPSC  is 
primarily in n-sheet conformation (Inouye and Kirschner, 1997). This finding has 
been confirmed using a synthetic polypeptide spanning amino acids 90 to 145 
(Nguyen et al., 1995) that was also found to form n-sheet complexes with PrP C in 
vitro. Further studies using recombinant antibody Fab fragments against epitopes of 
PrPC and  PrPSC  indicated that major conformational differences exist between the two 
isoforms in the region between amino acid residues 90 and 120 whereas the C-
terminal structure may be the same in both (Peretz et al., 1997). The protease 
resistance of PrP sc therefore may be conferred within the 90-120 segment of PrPSC  as 
enzyme cleavage sites in this region are protected or hidden within the P rPSC 
structure. 
1.6.5 PrPSC  and the association with infectivity. 
While protease resistance of PrPSC  seems to be the marker for prion infectivity, a 
number of experiments appear to dissociate PrPSC  from infectivity. Lasmezas et a! 
(1997) reported that mice injected with BSE infected cattle brain homogenate 
showed symptoms of a neurological disease after an incubation period of one to two 
years, but biochemical analysis of the mouse brains did not detect PrPSC  in more than 
55% of cases (PrP). Histological examination of the brain samples revealed neural 
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cell death in all mice, however, other classic changes associated with TSEs, such as 
neuronal vacuolation and astrocytosis, were limited to those mice with detectable 
PrPSC, (PrPS). On sub-passage, mice inoculated with PrPSC+  mouse brain 
homogenate showed a shortened incubation period and PrPSC  was detectable in all 
mice. During serial passage with homogenate from PrP 5 brains, inoculated mice 
showed classic TSE changes, had shorter incubation periods and PrPSC  was readily 
detectable in brain extracts. The similarity of clinical disease seen in the sub-
passages from PrP Sc-  and PrP Sc+  mice supports the idea that neuronal death is a 
major factor in TSE disease, and that the presence of lesions and gliosis is directly 
linked to the accumulation of PrP. Lasmezas eta! (1997) raised the possibility that 
TSEs can be transmitted without detectable PrPS,  supporting the theory that an 
infectious entity in addition to PrPSC  may transmit TSE. However the failure to 
detect PrPSC  in the initial B SE-inoculated mice may have been reduced sensitivity of 
the anti-PrP antibodies to a low level of PrPSC  present in the brain tissue. 
More recently, two separate studies have shown that the protease resistance acquired 
by PrP in its conversion from PrPC  to  PrPSC  is not a sufficient marker for infectivity. 
It is known that, in contrast to normal mice, Tg mice expressing chimeric hamster-
mouse PrPC  are susceptible to infection with hamster scrapie (section 1.5.2.1). Hill 
et al. (1999) expressed [35 S]-radiolabelled chimeric hamster-mouse PrPC  that 
acquired protease resistance following incubation with purified hamster scrapie in 
mouse erythroleukaemia cells. Transmission studies with the protease resistant 
chimeric PrPC  did not produce a scrapie-like disease in Swiss CD-i mice. 
Additionally, Shaked etal. (1999) in the presence of dimethyl sulfoxide (DMSO) 
purified a fraction of protease resistant PrP sc that was resistant to high speed 
purification and aggregation. These soluble PrP27-30 molecules were able to 
aggregate on removal of DMSO but not into the characteristic rod structures of SAF. 
Furthermore when inoculated into hamster brains the purified PrP27-30 fraction 
proved to be 99% less infective compared to equivalent untreated PrP27-30 rods. 
These data argue that the conversion of PrPC  to protease resistant PrP 5' alone is not 
responsible for the production of infectivity, and that protease resistance may not be 
a suitable test for the presence of the TSE agent. 
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1.7 Host Genetics: PrP Gene PolvmorDhisms and Mutations 
1.7.1 Human PrP gene polymorphisms and mutations. 
To date, approximately 20 different PRNP point mutations or insertions of 
octapeptide repeats regions are known to segregate with inherited human TSE 
diseases (Prusiner, 1998). Some of these mutations are illustrated in Figure 1.4. The 
linkage between GSS and PRNP polymorphisms was realised with the discovery of a 
mutation, substituting proline to leucine at codon position 102 (Hsiao etal., 1989), 
which has since been found in several GSS-affected families (Goldgaber et al., 
1989; Kretzschmar etal., 1991). Three mutations have also been identified in 
patients with familial CJD (Goidgaber etal., 1989; Owen etal., 1989;Collinge etal., 
1989) and one for FF1. FF1 and CJD are pathologically distinct from GSS. A silent 
mutation at codon 129 was found to modulate susceptibility to CJD(Palmer et al., 
199 1) but also determine whether carriers of a pathological mutation at codon 178 
will develop CJD or FF1 (Medori et al., 1992). 
The mechanism by which these mutations cause TSE disease (if they do) is unclear. 
One explanation is that the mutations may cause the spontaneous conversion of P rPC 
to PrPSC  by destabilising the protein structure enabling a conformational change to 
PrPS. Structural studies have shown that some of the PRNP mutations have the 
same stability as PrPC  suggesting that destabilisation of PrPC  does not lead to PrPSC 
formation (Huang etal., 1994; Cohen et al., 1994). Several lines of transgenic mice 
(Tg) have been created which appear to show spontaneous development of 
neurodegeneration (Westaway et al., 1994a; Muramoto et al., 1997; Hedge et al., 
1998; Shmerling etal., 1998; Chiesa etal., 1998). One line which over-expressed 
the mouse homologue (proline to leucine at position 10 1) of the human GSS-related 
proline to leucine mutation at 102 (Hsiao etal., 1990; Telling etal., 1996) showed 
signs of TSE pathology, PrP deposition and transmission of disease to similar Tg 
mice but not wild type mice (Hsiao etal., 1994). However, PrP deposited in these 
mice was not proteinase K resistant (Telling etal., 1996). A second mouse Tg line, 
developed to express the GSS mutation of 9 octapeptide repeat insertion into the PrP 
protein coding region, showed similar pathology to GSS and produced a PrP protein 
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which shared limited properties with PrPS  (Chiesa etal., 1998). The possibility 
exists that over-expression of these transgenes may explain the observed phenotypes 
rather than expression of the mutation itself. For instance, following a gene targeting 
study to replace the wildtype mouse gene with a single copy of an allele with the 
proline to leucine mutation at position 102 no spontaneous degeneration was 
recorded (Moore et al., 1995). 
Codon 
Number 
0 	50 	100 	150 	200 	250 
I I I I I I 
ss 	 r 	 ss 
PrP primary 
structure V S-S 
Human TSE 	insertions! Deletions 
GSS 	 120bp-129M 
144bp-1 29M 
1 68bp-1 29V 




Prol O5Leu-1 29Met 
Aial 1 7VaI-1 29VaL 
Tyrl 45STOP- 1 29Met 
Vail 8011e-1 29Met 
Phel 98Ser-1 29Vai 
G1n21 7Arg-1 29VaI 
CJD 	 48bp-129? 	 Asp178Asn-129Val 
144bp=129M Glu2OOLys I 29Met 
Va121 0 lIe-i 29Met 
Met232Arg-1 29Met 
FF1 	 Asii78Asn-l29Met 
Fiqure 1 .4:Mutations and DolvmorDhisms of the human PrP orotein associated with I 
human TSEs. 
Several polymorphisms and mutations within the coding region or insertions in to 
region r (the octapeptide repeat region of the human PrP gene have been linked to 
TSE occurrence. Silent mutation at codon 129 (valine/ methionine) linked to 
susceptibility to CJD (129V/129M). Pathogenic mutations, shown in red, are known 
to be connected to TSE development in humans. ss denotes signal sequence., -S 
S -, identifies the disulphide bond and the glycosylation sites shown as t) 
.Adapted from Liemann and Glockshuber (1998). 
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1.7.2 Ovine PrP gene polymorphisms. 
Originally it was assumed that scrapie was a genetically inherited disease as disease 
appeared to segregate in the pattern of an autosomal recessive gene (Parry, 1962). 
However, controlled breeding experiments have shown that natural (Foster and 
Dickinson, 1988a) and experimental (Dickinson, 1974; Foster and Dickinson, 1988b) 
scrapie infections are dependant on a gene controlling scrapie susceptibility. To 
study scrapie susceptibility, a flock of South County Cheviots was founded in 1960 
and selected into two lines depending on response to challenge with a source of 
experimental scrapie known as SSBP/1; positive line sheep succumbed to 
subcutaneous challenge whereas negative line sheep survived (Dickinson et al., 1968 
a+b). Since 1962 the flock has been closed to any outside breeding and is known as 
the Neuropathogenesis Unit (NPU) Cheviot flock. Offspring the result of crossing 
positive and negative line sheep were found to be susceptible to SSPB/1 but had a 
prolonged incubation period compared to positive line sheep (Dickinson and Outram, 
1988). This finding suggested that a single autosomal gene, designated Sip, with 
two alleles was dominant for short incubation periods, was responsible for 
controlling scrapie incubation periods but the gene is now known to be much more 
complex than this. Restriction fragment length polymorphisms (RFLP) for the sheep 
PrP gene were found to be in accordance with the Sip genotype (Hunter et al., 1989). 
This discovery raised the possibility that, as in the mouse (Dickinson et al., 1968b; 
Carlson et al., 1986; Hunter etal., 1987), the PrP genotype has a major influence on 
scrapie susceptibility. From TSE transmission studies in mice the gene controlling 
scrapie incubation period, initially designated Sinc, was identified as the PrP gene 
(Moore etal., 1998). Therefore the equivalent gene in sheep, know as Sip, is also 
likely to be the PrP gene. 
In the PrP gene of sheep several polymorphisms have been detected (Goldmann et 
al., 1990; Goldmann etal., 1991a; La Planche etal., 1993), three of which (PrP 




0 	50 	100 	150 	200 	250 
	
I 1 	1 1 	11111 	I 








137 	.  
211 
Figure 1.5: Polymorphisims of the ovine PrP protein. 
Several polymorphisms within the ovine PrP gene have been linked to scrapie 
incidence. Variation at codons 136, 154 and 171 (red codons) have been linked to 
scrapie susceptibility. ss denotes signal sequence, r represents the repeat region, 
-S - S - identifies the disulphide bond and the glycosylation sites shown as 
To date, with respect to scrapie susceptibility and the three codons discussed above, 
there are five known allelic variations of the PrP gene. These are; 
A13(,R 154Q 171 
A 13 H 154Q 171 
A 1 36R154R 17 1, 
V 136R 154Q 171 
A136R 154H 171 . 
The PrP alleles and their frequencies within a particular breed of sheep are very 
specific with some alleles being more common in one breed compared to another 
(Table 1.4) (Dawson et al., 1998, review). The combination of PrP alleles 
(genotypes) is also important. For example, heterozygote genotypes carrying 
V 1 36R154Q 171 are at significant risk of scrapie incidence but not when paired with 
A 1 36R 1 54R171 . In some breeds V 1 36R154Q 171 is rare, e.g. Suffoiks where, although 
scrapie incidence is low, the allele A 1 36R 1 54Q 171 appears to confer highest risk of 
scrapie. (Hunter et al., 1994; Westaway et al., 1994). In most sheep breeds, 
homozygosity for alanine at codon 136, A 136, seems to offer resistance to scrapie 
development from both natural and experimental infection whereas valine at PrP 
codon 136, V 136 , leads to disease with a short incubation period after challenge with 
SSBPI1 (Hunter et al., 1996). To date only one PrP AA 136RR 1 RR171 sheep world 
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wide has been documented to be scrapie positive (Ikeda et al., 1995). Following 
subcutaneous (Sc) challenge with SSBP/1, NPU Cheviots homozygous for valine 
(positive line sheep) at codon 136 develop scrapie after an incubation period of 167 
days +1- 5, VA136 heterozygotes have an incubation period of 322 days +1- 10. AA 136 
homozygotes (negative line sheep) resist similar inoculation with SSBP/1. However, 
this is not the case when BSE or an alternative scrapie strain, i.e. CHI 641, is the 
source of TSE agent (Goldmann et al., 1994a; Goldmann etal., 1994b). When 
challenged with BSE or CHI 641 PrP codon 171 appears to be predominantly 
associated with scrapie incidence: glutamine homozygotes, QQI7I,  succumb to 
intracerebral (ic) challenge, QR171 heterozygotes have a longer incubation period and 
RR17 1 homozygotes are relatively resistant within their lifespan. In addition to 
highlighting the role of PrP polymorphisms, these data may suggest that particular 
polymorphisms or genotypes are associated with susceptibility to different strains of 
scrapie. 
Studies have shown that scrapie is not a spontaneous genetic disease in sheep. In a 
recent report scrapie-associated PrP genotypes were recorded in sheep from countries 
free of scrapie (Hunter et al., 1997) where rigorous methods are taken to protect 
sheep from scrapie. This would suggest that although the PrP genotype is important 
to the progression of the disease, scrapie infection relies on the additional factor of 
an infectious agent. There is, however, a genetic component in the control of disease 
incidence as described above which adds more controversy to the debate over the 
identity of the scrapie agent. If the prion theory is correct, the polymorphisms seen 
in sheep PrP protein may favour spontaneous conversion of PrPC  to  PrPSC.  However 
this does not explain the obvious lateral transmission of scrapie between sheep nor 
why scrapie is not observed in countries where susceptible genotypes have been 
identified? If however the virus/ virino theories are correct, how does this explain 
the incidence of TSEs in humans without apparent infection, why are some sheep 
seemingly resistant to scrapie development? Although the PrP gene has been proven 
to influence scrapie susceptibility, little is understood about the control of gene 
expression or the interaction of the PrP protein with other gene products or indeed 
the infectious agent. 
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Table 1.4: PrP alleles and their distribution in various sheep breeds. Scrapie 
susceptibility shown as high risk (red, bold) or low risk (blue bold). (Dawson et a!, 
1998) 
Breed Predominant allele Scrapie susceptibility 
Cotswold, Hampshire Down A1 R 1 Q 171 A136 R 1 Q 171 /A136 R 1 Q 171 
Soay Vendeen A1 R154R171 A 1 R 1 R 171 / A 136R 154 R 171 
Suffolk A1 R 1 4171 A 1 R 154 Q 1 	/A 13 R 14Q 1 7 1 
A1 R 1 H 171 
A136 R 1 R171 , 
Blue de Maine, Wensleydale A136R 1 Q 171 A136R1 Q 171 / V 136 R 154Q 171 
Border Leicester, Poll Dorset, A136R,54IR171 V1 36 R 1 54Q 1 71/ V1361R 1 Q 171 
V 136 R1 Q 171 A136 R 1 R 171 / A136 R 154R 171 
Charollais A136 R 1 4171 A 136 R 1 Q 171 / VI36RIQI7I 
A l R lMR lll V 136 R 1 0 171 / V 136 R154Q 171 
V 1 R1 Q171 A1361R154R171/ A136 R 1 R171 
A136 R1 H 171 
Bluefaced Leicester A136 R 1 4171 A1361R154Q171 /A136 R 154171 
A136 R 1 R 171 A136 R 1 R 171 / A136R 154 R 171 
A136 H 1 Q 171 
Cheviot, Dalesbred, Herdwick A136 R 1 Q 171 V 136 R 1 Q171 / V136R I 54Q 
A1 R 1 R171 A136RI54Q171/ V 136 R 1 0171 
Scottish Blackface, Shetland A1 H 1 Q 171 A136 R 154 R 171 / A136 R 154R 171 
Swaledale, Welsh Mountain Vj36Rj54Q171 
Texel, Lleyn A136 R 1 Q 171 A136 R 1 4171 / V136R154QI7I 
AI36R154HI71/ VlRl54Q171 
A136 H 1 Q 171 V136R 1 Q171 / V136R 1 4171 
V136 R1 4171 A 136 R 154 R 171 / A136 R 154R 171 
A1 R 1 H 171 
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1.7.2.1 PrP 3'untranslated region polymorDhisms. 
Three restriction fragment length polymorphisms (RFLP) for restriction digestion 
with the enzyme EcoRI, have been described in the PrP 3'UTR. The RFLP are 6.8kb 
(el), 5.2kb (e2) and 4.kb (e3), with el and e3 acting as differential markers for 
susceptibility (Goldmann etal., 1990; Hunter etal., 1991). The e  RFLP (relatively 
rare in healthy controls) has been associated with increased susceptibility to 
experimental and natural scrapie cases whereas the e3 RFLP is associated with 
relative scrapie resistance in studies across different sheep breeds throughout the 
world (Hunter et al., 1991; Hunter etal., 1992; Maciulis etal., 1992;Muramatsu et 
al., 1992). Hunter etal. (1992) described the distribution of the alleles in 167 sheep 
of different breeds and cross breeds affected with natural scrapie as el :73-75%, e2: 
3-1% and e3: 24%. The e3 allele was associated mainly with resistant genotypes, 
whereas the e2 allele did not appear to segregate preferentially with either 
susceptible or resistant genotypes. A comparative study of the Suffolk ci and e3 
3 'UTR highlighted several further differences between the two alleles (Cheung, 
1996). Amongst six polymorphic sites (including the EcoRI site) there was one extra 
instability motif present on the e 1 allele compared with the e3 allele. Although the 
ci allele does not have 100% association with scrapie occurrence, it may confer 
increased scrapie susceptibility in the presence of other known polymorphisms or to 
infection with specific scrapie stains (Hunter etal., 1991; Hunter etal., 1992). 
Disease-associated mutations of a 3 'UTR are not unique. A polymorphism in the 
3 'UTR sequence of the stromal cell-derived factor (SDF)- 1 gene of G to A (SDF 1-
3 'A) has been associated with increasing susceptibility to human immunodeficiency 
virus (HIV) type 1 (van Rij etal., 1998; John etal., 2000). Patients homozygous for 
the G-A polymorphism (SDF 1-3'A/3'A) display accelerated progression to AIDS but 
a prolonged disease process (Van Rij etal., 1998). The SDF-1 gene encodes the 
chemokine receptor ligand which binds the T-tropic HIV-corecpetor CXCR4 and 
may be one route of infection for the virus. In support of this theory, the presence of 
the SDF1-3'A allele in infected mothers increases the likelihood of transmission of 
the HIV virus to an infant, regardless of the infants SDF1 genotype (John et al., 
2000). 
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1.8 PrP Gene Structure. 
1.8.1 PrP gene structure. 
The genomic structure of the PrP gene is well conserved amongst different species 
and is described as containing three exons and two introns (Figure 1.6). The 
isolation and comparison of eDNA and genomic DNA clones has shown that mouse, 
sheep and cattle PrP genes contain three exons (Westaway et al., 1987; Puckett et 
al., 1991;Westaway etal., 1994; Horiuchi et al., 1998; Lee etal., 1998). Both exons 
I and II encode for 5' untranslated region (UTR, 1 4Obp) whereas exon III encodes 
5 'UTR (1 Obp), the full open reading frame (ORF, approximately 760bp depending 
on species) and a 3'UTR which can vary from 1.2 to 3.3kb in length (section 1.8.4) 
(Goldmann et al., 1990; Goldmann etal., 1993; Westaway etal., 1994; Inoue etal., 
1997; Horiuchi etal., 1998). Sequence adjacent to, and 5' from, exons I and II has 
been associated with promoter and regulatory elements (Baybutt and Manson, 1997). 
Exon II is transcriptionally expressed in most species, yet human PrP mRNA appears 
to contain only exons I and III (Westaway et al., 1994) despite strong homology for 
exon II in human genomic sequence when compared with other species (Lee et al., 
1997). The Syrian hamster (SHa) was once thought to express PrP mRNA containing 
only exons I and III until mRNAs containing exon II were observed in astrocytes 
from scrapie-infected hamster brain (Li and Bolton, 1997). The function of PrP 
exon II remains unclear and it may be that human exon II is expressed in mRNAs of 
certain cell types or tissues. 
The length of the mRNA 5'untranslated (UTR) region is known to vary in different 
species and may be due to variable transcription start sites or alternative splicing 
generating different transcripts but which code an identical protein. For example, in 
mice the transcription start site has been shown to vary between 30 and 60bp 
upstream of the exon Ilintron I boundary (Westaway etal., 1987). Similarly in 
bovine tissue, two mRNAs with 5'UTRs that vary by 100 nucleotides are thought not 
to be the result of transcription originating from one start site but alternative splicing 
at the exon I! intron I boundary (Horiuchi etal., 1997). No alternative 5'UTR has 
been identified in sheep. 
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Figure 1.6: PrP gene structure in different species 
The PrP gene shows essentially conserved structure across different species. 
Compiled from Goldmann etal., (1990); Li and Bolton (1997); Lee etal., (1998) 
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1.8.2 PrP promoter region. 
The promoter region of the PrP gene lacks typical regulatory elements known to 
control the precise initiation of transcription, for example TATA boxes. Instead, 
multiple copies of G-C rich repeats, similar to those present in house-keeping genes, 
have been found near the transcription start site in humans, ruminants and mouse PrP 
genes (Puckett etal., 199 1;Dynan etal., 1986; Westaway etal., 1994; Baybutt and 
Manson, 1997). These G-C rich motifs may function as recognition binding sites for 
the transcription factor SP  (Mcknight and Tjian, 1986). Binding sites for other 
transcription factors have been identified in the PrP promoter region but the number 
and location of these factors appeared to be species dependant (Lee etal., 1998). 
Recent analysis of the Cheviot and Suffolk sheep PrP promoter region at NPU 
discovered polymorphisms for an SP- 1 consensus site. However, it is unknown 
whether this polymorphism is linked to scrapie susceptibility (i.e. other PrP 
polymorphisms) or sheep breed (O'Neill et a!, in preparation). 
1.8.3 PrP introns. 
There is evidence that control of PrP gene expression may also extend to sequences 
within the intronic regions. Recent reporter analysis studies have shown that 
deletions within the mouse intron I can influence the level of gene expression due to 
the presence of two independent sequences capable of promoter activity and 
promoter suppressor activity (Baybutt and Manson, 1997). Deleting intron II from 
the PrP gene lead to undetectable levels of PrP expression in Purkinje cells of the 
cerebellum without affecting the level of PrP expressed in other brain areas (Fischer 
et al., 1996), implying that intron II may contain sequences necessary for cell-
specific PrP expression. The size of PrP intron I is typically 2 to 2.4kb. In humans, 
however this may be as great as 12.7kb, assuming the absence of a homologous exon 
II in the genomic sequence. Furthermore, the size of intron II is known to vary 
between, and within, species. In mice two variants of intron II have been observed 
as approximately 18kb (Prn-p") and 11kb (Prn-p") in length (Westaway et al., 
1994a). Originally the variation in length was interpreted as a 6kb deletion in the 
Prn-ji intron 2, however it has now been reported that it results from an insertion of 
WE 
a retroviral genome into the Pm-p0 allele, which has been identified as a typical 
LTR-gag-pol-env-LTR retroviral structure (Lee et al., 1998). 
1.8.4 The ovine PrP exon III. 
As described in section 1.8.1 the structure of the PrP gene in well conserved, 
however the size of exon III varies considerably between ruminants and other 
species. Exon III of the sheep gene (like that of cattle and goats) is much larger than 
that found in other species (Figure 1.6): ruminants 4000 nucleotides (Goldmann et 
al., 1990), rodents 2000 nucleotides (Chesebro etal., 1985), and humans 2350 
nucleotides (Puckett etal., 1991). The difference lies within the 3'UTR region of 
the sheep PrP gene which has apparent insertions of ruminant-specific elements 
(Goldmann et al., 1993; Lee etal., 1998) including long and short interspersed 
repetitive sequences reminiscent of transposable elements (Figure 1.7). Sequence 
analysis of the PrP 3'UTR from several Suffolk and Cheviot sheep PrP alleles has 
shown that the 3'UTR is polymorphic, contains several potential polyadenylation 
sites and a variable number of ATTTA instability motifs (Goldmann et al., 1990; 
Cheung, 1996; Goldmann, 1999). Whether these regions play any role in PrP 
expression is unknown and is the subject of this thesis. 
Despite the considerable differences in length of PrP 3 'UTRs between species there 
is a high degree of conservation in specific regions of the 3'UTR (Goldmann et al., 
1990) (Figure 1.7). On the basis of cross-species sequnce compariosns, sheep, 
human and mouse PrP gene 3"TRs have been divided into sections A to G. Only the 
sheep 4.6kb mRNA 3 'UTR encodes all seven regions, the human having A, B, C, E 
and G and the mouse having A, C, E and G. The sheep has two additional regions D 
and F which include SINE and LINE elements (Figure 1.7). SINE and LINEs, or 
Short and Long Interspersed Nuclear Elements, are repetitive DNA sequences found 
dispersed throughout the genome at high frequency. SINEs and LiNEs are 
considered to have originated from transposable or retroviral elements which can 
replicate by reverse transcription (Fanning et al., 1987). The mechanism of insertion 
of transposable elements is unclear but is though to involve a processes such as 
sequence-specific insertion, S-phase insertion, ectopic excision and recombinational 
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editing (Wichman et al., 1992). Unlike conventional single copy nuclear genes, the 
copy number of transposable elements can vary without apparent phenotypic effects. 
Transposable elements can also achieve horizontal transfer between species 
(Maruyama and Hard, 1991: review Hard et al., 1997). SINEs and LINES can exist 
as active or inactive transposable elements, where inactive forms are likely to have 
arisen from the loss of sequence necessary for transposition (Engels, 1989; Garza et 
al., 1991). Interestingly, inactive elements can become active in the presence of 
active elements which complement the defect in the inactive copies. However, often 
inactive forms do not appear to have obvious deletions to distinguish them from 
active copies (Moerman and Waterston, 1989; Harti,, 1989). 
Regarding the ovine PrP gene, the LINE element shows homology to a mariner DNA 
transposon relic from the Mellfera (honeybee) subfamily of mariner elements (Lee 
et al., 1998). Both the inactive and active form of the mariner element have been 
identified in certain Dresophila species (Jacobson etal., 1986; Hartl, 1989). The 
active mariner element is 1289 nt long and contains a single open reading frame 
encoding a putative protein of 345 amino acids (Jacobson et al., 1986). The effect of 
the SINE or LINE elements on ovine PrP gene expression will be considered in this 
thesis. 
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Figure 1. 7: Companson of PrP 3'UTR mRNA sequences of human and rodents I 
with sheep. A) Structure of the sheep PrP exon Ill displaying sheep specific inserts 
of LINE, SINE and Mariner sequences (Goldmann eta!, 1990; Lee etal., 1998) B) 
The ovine PrP3' UTR is the largest of the species due to the inserts. (Goldmann at 
al., 1990). Comparison of regions A to G in sheep PrP 3'UTR is shown between 
mouse and human, region of low homology marked by X. 
Key .  
= UTR - Coding region - LINE} - SINE 
Mariner element 	 50-80% homologous 
80-90% 	to sheep 
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1.9 PrP Gene Expression. 
The genetic organisation of the PrP gene has been determined but the mechanisms 
controlling gene expression are still unclear, although it is known that the PrP gene is 
regulated both developmentally and in a cell-specific manner. As mentioned in 
section 1.5.2.1, expression of the PrP gene is vital for TSE development in that no 
PrP expression offers apparent resistance to infection but over-expression increases 
TSE susceptibility. Understanding the mechanisms controlling PrP expression may 
led to further understanding of susceptibility and scrapie development 
1.9.1 PrPmRNA. 
In sheep, PrP mRNA isolated from brain has an apparent length of 4.6kb, cattle and 
goats have a similar transcript, whereas rodents and humans express mRNAs of 
approximately 2.5kb (Goldmann etal., 1990; Inoue et a!, 1997; Horiuchi et al., 1998, 
Goldmann et al., 1999). Furthermore, the ovine PrP gene produces more than one 
mRNA transcript (Hunter et al., 1994). In addition to a full length 4.6kb mRNA 
transcript, a second smaller mRNA species of 2.1kb can be detected and was first 
seen only in peripheral tissues. The 4.6 kb mRNA is found in all tissues, with the 
highest expression level in brain. The 2.1kb mRNA is found in all peripheral tissues 
at levels of up to 30% of total PrP mRNA, but only at very low levels in the brain 
(Goldmann et al 1 999).The smaller additional mRNA is also found in goats and at 
very low levels in cattle, although no equivalent mRNA has been found in mice and 
human tissues (Hunter et al., 1994; Goldmann et al., 1999). The smaller sheep 
mRNA transcript is the result of usage of an alternative polyadenylation signal at an 
upstream site in the 3'UTR, at nucleotide position 1523 in the mRNA transcript 
(Goldmann et al., 1999). The 2.1kb PrP mRNA lacks several features present in the 
4.6kb mRNA, such as repetitive sequences, long and short interspersed elements 
(LINES! SINES), a transposable element, instability motifs, and a highly conserved 
3' region (Cheung, 1996; Lee etal., 1997). 
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1.9.2 Tissue and cell type PrP expression. 
Expression of PrP mRNA in many species, detected by Northern analysis, is typically 
highest in the brain with intermediate levels found in heart and lung, whereas liver and 
spleen have low or barely detectable levels (Oesch etal., 1985; Caughey etal., 1988; 
Goldmann et al., 1999). In sheep peripheral tissues the 2.1kb mRNA contributes to a 
third of the total PrP transcripts but is barely detectable in the brain. In contrast, the 
4.6kb mRNA is found in all tissues with the highest expression level in brain. 
Furthermore, the apparent levels of PrP protein vary between brain and other 
peripheral tissues (Horiuchi eta!, 1995). Horiuchi eta!, (1995), reported that PrPC 
protein was abundant in neural and non-neural tissues such as spleen and lungs but 
the levels of detectable PrPC  protein in different tissues and individual sheep were 
not consistent. On comparison, the proportion of PrP mRNA to PrPC  varied between 
brain and other tissues. For example the amount of detectable PrP mRNA was 
expressed five times higher in the brain than in the kidney, however the amount of 
PrPC detected in brain was forty fold more than the kidney. Horiuchi eta! (1995), 
concluded that translation efficiency or the course of protein synthesis, including 
degradation, might differ between the brain and other tissues. An alternative 
explanation may be that in peripheral tissues the 2.1kb PrP mRNA could be favoured 
for translation over the 4.6kb mRNA (Goldmann et al.,1999) 
The level of PrPC  expression varies among the different cell types found within rodent 
brain, the highest expression estimated to be in the cortex and striatum (Sales et al., 
1998), Purkinje cells of the cerebellum (DeArmond etal., 1987), neurones of the 
septum, thalamus and caudate putaman (Manson etal., 1992). In contrast, the caudate 
nucleus, neocortex and granular layer of the hippocampus show little or no PrP 
expression in hamster brain (Kretzschmar et al., 1986; DeArmond et al., 1992). 
Furthermore, brain cells which express detectable PrP mRNA may not show significant 
levels of PrPC  protein (Manson et al., 1992). The differential expression pattern of PrP 
gene observed between tissues and within the brain displays tissue and cell-type 
transcriptional and translational control of the PrP gene. 
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1.9.3 Developmental regulation of PrP expression. 
Developmental regulation of the PrP gene has been demonstrated in several species 
(McKinley et al., 1987; Lazarini etal., 1991; Manson etal., 1992; Harris etal., 1993; 
Hunter etal., 1994;Moser etal., 1995). In the developing mouse embryo, prenatal 
expression of PrP can be detected using in situ hybridisation by day 13.5 in brain, spinal 
cord and peripheral tissue (Manson etal., 1992). Postnatally in the mouse brain, PrP 
expression was found to increase 4-fold from birth to day 20 to a level that was 
maintained throughout adult life (Lazarini, etal., 1991). 
In sheep, the 4.6kb and 2.1kb PrP mRNA transcripts can be detected throughout all 
developmental stages: foetus, lamb and adult (Goldmann etal., 1999). Northern 
hybridisation signals for PrP mRNA are detectable at day 98, increasing 100-fold by 
day 134 and a further 2-fold in the lamb to a level maintained throughout adult life. 
The ratio of the 2.1kb transcript to the 4.6kb mRNA varies between tissue types during 
development with the highest level of the 2.1kb mRNA in the spleen and kidney, 
intermediate in heart and lowest in the brain. 
1.9.4 Factors known to control PrP expression. 
From in vitro and in vivo studies there is evidence that PrP mRNA expression may 
increase in the presence of specific cytokines (Satoh et al., 1998) and 
growth/differentiation factors (Table 1.5) such as interluekan-6 (IL-6), nerve growth 
factor (NGF) (Mobley et al., 1988; Lazanni etal., 1994) and migratory inhibitory 
factor-related protein(MRP8) (Kniazeva etal., 1997). In contrast, PrP expression is 
inhibited in human fibroblasts by the presence of periodontal ligament growth factor 
(PDGF). Cytokines and growth factors are known to stimulate cell growth and 
differentiation, however they may also function as a chemoattractant. The growth 
factor PDGF is a known chemoattractant it also functions to signal for proliferation, 
therefore a signal for mitogenesis may suppress PrP mRNA synthesis (Kniazeva et al., 
1997). 
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Table 1.5: Factors known to be involved in regulating PrP expression 
Cell Type Factor Influence 
Cholinergic neurons Nerve Growth Factor Increases choline 
'NGF' acetyltransferase activity ' 	
/ coincidentally with PrP 	mRNA 
(Mobley et al., 98) 
Human Cytokines All increase PrP mRNA expression 
neuroblastoma e.g. IL-1b, TNF-a up to fourfold (Satoh etal., 1998) 
(SK-N-SH) 
IFN-y Decrease in PrP mRNA 
expression (Satoh et al., 1998) 
HL-60 cells Retinoic acid Down regulation of cell surface 
(human premyloid) PrPc concentration (Dodelet et al., 
1998) 
PC-12 cells lnterleukin-6 (IL-6) Increases the level of PrP mRNA 
expression (Lazarini, at al. 1994; 
Wion etai'., 1988) 
Nerve growth factor 
(NGF) 
Pancreatic endrocrine Recombinant hGH Both factors induces beta cell 
(beta cells) maturation and increasing PrP 
Dexamethasone mRNA levels (Atouf etal., 1994) 
Periodental ligament Migration inhibitory Stimulates PrP mRNA expression 
factor-related protein 
(MRP8) 
Platelet-derived Represses PrP mRNA expression 
growth factor (PDGF) (Kniazeva etal., 1997) 
Hepatic stellate cells Cardon tetrachloride Stimulation of PrP mRNA 
(liver)'  'CCI '11 
expression in response to 
oxidative stress (Ikeda etal., 1998) 
* Toxic chemical to liver cells, induces oxidative stress 
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1.9.5 PrP expression and TSE development. 
Northern analysis has not revealed any consistent differences in the level of PrP 
gene expression between normal and scrapie-infected tissue (Caughey etal., 1988). 
However, Northern analysis may not have detected subtle differences of less than 2-
fold which may have a major effect on disease development. Overexpression of the 
PrP gene is known to decrease the incubation period (time of inoculation to 
development of disease) of transgenic mice when inoculated with experimental 
scrapie. Therefore, any increase in PrP expression may increase susceptibility to 
scrapie infection and speed-up the disease process. Interestingly, in uninfected 
hamster the level of PrP mRNA containing all three exons (section 18.1) was 
estimated to be 30-50% of the total PrP mRNA, this level increased 2.5 fold during 
scrapie infection (Li and Bolton, 1997). This may suggest that although the level of 
PrP expression may not alter during scrapie infection, control over gene expression 
might. 
1.10 Role of the PrP 3'UTR in of Gene Expression. 
1.10.1 General 3'UTR formation. 
Correct formation of the mRNA 3'UTR is a key regulatory step in the expression of 
many eukaryotic genes. Defects in mRNA 3'UTR formation can significantly alter 
the growth, viability, development and health status of a cell. For example in 
humans, a loss of function of the EAAT2 glutamate transporter protein due to 
abnormal RNA polyadenylation leads to motor neurone degeneration (Lin et al., 
1998). In yeast cells, a failure to correctly modify the enzyme polyApolymerase 
(PAP) during the cell cycle is thought to slow down cell growth rate causing an 
accumulation of cells in the G0-G1 phase (Zhao and Manley, 1996). 
The molecular mechanisms of 3 'UTR formation and its interaction with other aspects 
of mRNA processing are slowly being understood. For instance, a functional 
polyadenylation signal is crucial for transcription termination by RNA polymerase II 
(Connelly and Manley, 1988; Proudfoot, 1989) and transport of the message from the 
47 
nucleus to the cytoplasm (Huang and Carmichael, 1996) which is also thought to 
involve an interaction with RNA polymerase (Long et al., 1995). In the cytoplasm 
the polyA tail mediates stability and translation efficiency of the message (Sachs et 
al., 1986; Ford et al., 1997; Preiss and Hentze, 1998; Wickens et al., 1997). Evidence 
exists therefore that the 3 'UTR formation and regulation plays a vital role in normal 
cell growth and development. Furthermore, controlling the amount of available 
mRNA, or translation efficiency, directly affects the amount of protein synthesised. 
Three sequence elements are required for efficient 3'UTR formation in mammalian 
pre-mRNA (Figure 1.8). Firstly, a highly conserved polyadenylation signal, 
AAUAAA. This hexanucleotide, required for both cleavage and poly(A) addition 
(Manley, 1988;Wahle and Keller, 1992; Wickens, 1990), is found attached to 80% 
of all pre-mRNAs. Mutations within this sequence greatly reduces the efficiency of 
3'UTR processing (Wickens and Stephenson 1984; Sheets et al., 1990). Secondly, 
cleavage occurs at the poly(A) addition site, 1 1-23nt downstream of the 
hexanucleotide. In most genes the poly(A) site is defined by a CA dinucleotide. 
Finally, the presence of a GU- or U-rich element downstream (approximately 30 
nucleotides, known as the downstream element, DSE) of the poly(A) site may affect 
the cleavage site position and the efficiency of cleavage (MacDonald et al., 1994; Gil 
and Proudfoot, 1987). Other sequence elements have been found to influence 3'UTR 
formation in both a positive and negative way. For example in viral pre-mRNAs, the 
presence of a U-rich upstream sequence element (USE) can greatly enhance poly(A) 
site recognition (Key et al.,, 1998; Carswell and Aiwine, 1989). USEs have only 
been identified in a few eukaryotic genes e.g. complement factor C2 and lamin B2 
(Brackenridge et al., 1997; Moreira et al., 1998). Many protein factors have also 
been identified as necessary for accurate cleavage and polyadenylation (refer to 
figure 1.8). 
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Figure 1.8: Schematic model for mammalian Tend formation 
Figure legend on page 48. 
Figre 1.8 Schematic model for mammalian Tend formation. The mammalian 
cleavage complex assembles through cooperative binding of 
Cleavage/Polyadenylation Specificity Factor (CPSF) at the AAUAAA site and 
Cleavage Stimulation Factor (CstF) at the Downstreamn Element (DSE, U- I GU-
rich). Interactions between CPSF and CstF define the region for cleavage, a 
process assited by Cleavage Factor I (CFI). The arrangement of the cleavage 
complex requires CF II and Poly(A)Polymerase (PAP), but the arrangement of CFI 
and CF II are unclear. After cleavage, CPSF and PAP remain bound to the RNA. 
CSPF recruits PAP to the AAUAAA containing sequence and slow polymerisation of 
a poly(A) tail begins. Cooperative interactions between CPSF, PAP and Poly(A)-
Binding protein II (PABII) promotes rapid poly(A) tail formation. When the tail 
reaches approximately 250 adenosine residues, elongation slows and poly(A) 
addition is terminated by a mechanism not yet understood (Figure adapted from 
Zhao et a!, 1999; Lodish et a!, 1995). 
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1. 10.2 Control of cleavage and polyadenylation - tandem poly(A) sites. 
Cleavage and polyadenylation can be regulated to vary the amount and type of 
mRNA a cell produces (Edwalds-Gilbert et al., 1997). The majority of eukaryotic 
genes have only a single polyadenylation signal, however the existence of numerous 
poly(A) sites at the 3' end of an exon can give rise to several possible outcomes for 
3'UTR formation (figure 1.9). Control over the efficiency and activity of the 
enzymes within the cleavage/ polyadenylation complexes (Figure 1.8) govern what 
3'end will be produced. Within the scope of this thesis only the tandem terminal 
poly(A) sites will be discussed further, for reviews on other mRNA 3 'end formation 
please refer to Edwalds-Gilbert et al. (1997) and Zhao et al. (1999). 
The alternative usage of poly(A) sites has been shown to be both tissue and 
developmentally regulated. When presented with several polyadenylation signals 
within the 3' -terminal exon, the choice of poly(A) site can be based on the strength 
of the signal sequences (conservation of the AAUAAA site, presence of DSE, USE) 
and the addition of poly(A) stabilising factors (Zhao et at., 1999). It is possible that 
differential regulation of the cis-acting acting proteins of the cleavage/ 
polyadenylation complex at different poly(A) sites may give rise to alternative 
transcripts. Hence, producing transcripts of different translation efficiency and 
stability directly affects the amount of protein produced. 
A recent observation of alternative usage of tandem poly(A) sites involved the 
eukaryotic initiation factor 2ct (eIF-2a, involved in protein synthesis) where two 
mRNAs, 1.6 and 4.2kb, were transcribed at varying ratios in different tissues (Ernst 
et al., 1987; Cohen et al., 1990). In vitro translation studies showed that the 1.6kb 
mRNA was less stable, but more efficiently translated than the 4.2kb transcript. 
Activation of T cells increased the abundance of the 1.6kb mRNA 11.5-fold and the 
4.2kb mRNA only 4-fold (Miyamoto et al., 1996). The activation of T cells initiates 
the cell cycle to proceed from G0 to S phase which is associated with an increase in 
PAP activity and rate of polyadenylation (Miyamoto et al., 1996) indicating that 
potyadenylation may respond to a change in cellular environment. These results 
indicate that for eIF-2a, alternative usage of the poly(A)site for the 1.6kb mRNA 
f 
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allows for increased efficiency of mRNA synthesis, translation and therefore 
increased protein levels. Additionally, in the testes a third poly(A) site is employed 
to produce a transcript of 1.7kb, suggesting that testes-specific polyadenylation 
factors may be recognising different elements within the eIF-2(x pre-mRNA 
transcript (Miyamoto et al., 1996). 
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Figure 1.9 :Alternative polyadenylation choices. Types of alternative 
polyadenylation for 3'UTRs in mammalian cells. A) Tandem poly (A) site; choice 
of more than one p(A) signal in the last exon. B) Composite exons; choice of 
defining the end of an exon by alternative 5' splicing. C) skipped exons; more than 
one terminal exon (Zhao et at., 1999). 
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1 .10.3 Differential expression of the ovine PrP gene. 
Expression of the ovine PrP gene may regulate the production of two or more mRNA 
transcripts through the process of polyadenylation. Conserved polyadenylation 
signals at nucleotide positions 1253, 1523, 4038 and 4063 have been confirmed in 
both the Cheviot and Suffolk sheep PrP gene, potentially signalling for PrP mRNAs 
of 1.5 -4.5kb in length (Goldmann unpublished data; Goldmann etal., 1999). In 
peripheral tissues of Cheviot sheep, PrP mRNAs of 2.1 kb and 4.6kb have been 
described, often at varying levels depending on the tissue (Horiuchi etal., 1995; 
Goldmann et al., 1999). For example, in spleen and uterus tissues the 2.1kb and 4.6b 
PrP mRNAs may both be expressed at high levels whereas in heart tissue the 2.1kb 
mRNA is expressed at a lower than the 4.6kb, as detected by Northern blot 
hybridisation (Goldmann et al., 1999). However the highest level of PrP mRNA 
expression can be found in brain tissue predominantly from the 4.6kb mRNA, where 
the 2.1kb mRNA is present at very low levels (0.5-2% total PrP mRNA, Goldmann, 
1999). The observed differential expression of the ovine PrP gene has been detected 
in both scrapie-resistant and scrapie-susceptible genotypes. Analysis by 3'RACE 
and SI nuclease protection assays of poly(A)- enriched mRNA from brain, kidney 
and spleen tissues confirmed that ovine PrP mRNA was likely to be processed at 
polyadenylation signals AATAAA I523 and ATTAAA4063. Importantly, long range 
RT-PCR and 5'-RACE analysis has shown that the 5'UTR sequence of the 2.1kb 
and 4.6kb mRNAs are identical (Westaway etal., 1994) confirming that during 
transcription of the ovine PrP gene, two mRNAs are the product of alternative 
polyadenylation and not alternative splicing. 
Post-transcriptional control of PrP mRNA may be directed through the 3'UTR. In 
the first instance, Denman et a! (199 1) showed that 30% of PrP mRNA was 
prevented from undergoing translation by the association of the 3 'UTR with 
ribnucleoprotein particles in the cytoplasm. The sequestered mRNA shows the 
potential for increasing cellular PrP protein concentration in a short period. Also, in 
vitro expression of constructs with the chloramphenicol acetyl transferase (CAT) 
gene linked to various regions in the PrP 3 'UTR was analysed by RT-PCR and CAT 
protein activity and showed that sequences within the 3 'UTR were capable of 
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altering the levels of protein synthesis but not the level of mRNA (discussed in depth 
in chapter four). Taken together, these results suggest that the 3 'UTR may be acting 
to control gene expression. 
The ovine PrP gene structure is similar to that in other species i.e. mouse, bovine and 
hamster, for introns I and II, and exons II and I (section 1.8.1). However, the sheep 
3 'UTR region within exon III contains two ruminant specific regions, disease 
associated polymorphisms and two known polyadenylation sites which are both used 
in peripheral tissues (section 1.8.4). Considering these features of the sheep PrP 
gene 3'UTR, questions relating to the contribution of the untranslated region in 
controlling the level of normal PrP protein and scrapie susceptibility. As 
susceptibility to scrapie is associated to the level of PrP protein expression, a link 
between translational control of PrP expression and incidence of scrapie in sheep 
may also exist. 
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1.11 Aims and Objectives. 
The aim of this thesis was to further investigate the role of the ovine PrP gene 3'UTR 
in its capacity to regulate gene expression in an ovine in vitro system. Previous work 
at the NPU (Cheung, 1996) had shown that a construct with the in vivo 4.6kb PrP 
gene 3 'UTR was capable of repressing in vitro protein levels equivalent to a 
construct with the in vivo 2.6kb PrP 3'UTR. Deleting sequence within the 3'UTR 
led to an increase in protein levels but crucially, RT-PCR analysis showed no 
alteration in mRNA levels expressed from the constructs. This result would suggest 
that a mechanism exists for controlling the amount of protein synthesised from the 
PrP mRNA through sequence present in the mRNA. The ability to selectively 
control PrP expression in this way may also account for apparently low levels of PrP 
protein detectable in peripheral tissue compared to brain. 
The hypothesis to test was whether the repressor element, associated with the PrP 
gene 3 'UTR, functioned in ovine cells and, if so, could it differentially mediate 
levels of PrP protein in brain and peripheral tissue in vitro. Additionally, any 
association between the repressor element of the UTR with scrapie susceptibility (i.e. 
PrP genotype) was to be examined. To study the role of the PrP gene 3'UTR in 
controlling in vitro expression of the PrP protein, PrP constructs resembling the in 
vivo observed 2.1kb and 4.6kb PrP mRNAs were designed and mutated to express 
ovine PrP protein with the hamster 3F4 epitope. The altered ovine PrP protein 
should allow for analyse by immunological detection of expression from the 
constructs in sheep cell lines derived from different PrP genotypes and tissue origin. 
To achieve these aims it was essential to establish and optimise a reliable method for 
transfection of various ovine primary and immortal cell lines available at the NPU. 
During the time necessary for cloning the ovine PrP constructs and developing the 
transfection methods, confirmation of the CAT expression studies by Cheung (1996) 
in ovine cell lines were completed to further identify expression control regions 
within the ovine PrP gene 3 'UTR. 
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Chapter 2: Materials and Methods. 
2.1 General Chemicals, Solutions and Centrifugation. 
The chemicals and enzymes used with in this study were purchased from Sigma 
(Dorest, UK), Gibco-BRL (Paisley, UK), DBH (DORSET, UK), Roche Diagnostics 
(East Sussex, UK), Qiagen Ltd. (West Sussex, UK) or Promega (Southampton, UK). 
All solutions were prepared with high quality chemicals, "e.g. Electran grade" (BDH, 
DORSET, UK) and when necessary were sterilised by autoclaving or filtering. Water 
used in the making of the solutions was obtained from a Millipore milli-QUF system 
and further autoclaved when required. Recipes for all solutions used in this thesis are 
listed in Appendix A. Unless otherwise stated, procedures for general methodology 
were adapted from Sambrook et a!, 1989. 
Centrifugation of solutions up to 30ml was performed in a Beckman J2-21 using 
rotor JA-14 at relative centrifugal fields (RCF) of 30,000 xg. For maximum 
centrifugal fields of 44,000 xg, 1 5m1 solutions were centrifuged using the Beckman 
J2-21, JA-20 rotor. For RCFs up to 3,750 xg, 30ml volumes were centrifuged in a 
refrigerated GS-6R, rotor GHS 3.8 (Beckman Ltd, Buckinghamshire, UK). For ultra-
centrifugation, maximum a RCF of 541,000 xg was achieved using an Optima TL 
Ultra-centrifugation 100,000 6R (Beckman Ltd, Buckinghamshire, UK) with rotor 
TLA 100.4. Micro-centrifugation for spins up to 13,400 xg in 0.5-1.5ml Eppendorf 
tubes was carried out in a bench top centrifuge (MSE Micro Centaur, Sanyo). 
2.2 General Methods for DNA Cloning 
2.2.1 Restriction enzymes. 
Restriction enzymes recognise and cut at defined sites in DNA sequences depending 
on base composition and length. The number and size of fragments generated by a 
restriction enzyme depend on the frequency of occurrence of the restriction site in the 
DNA to be cut. DNA substrates generated by restriction digestion are either 
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analysed for cleavage patterns or used in subsequent experiments such as cloning, 
sequencing, labelling or hybridisation. 
Single digestion or multiple digestion 
Single restriction digests or multiple digestions were performed to a standard 
method; 1 6.tl sterile water, 2tl restriction enzyme lOx buffer, 1 j.tl DNA sample 
(0.2-1.tg in water), and 1.tl enzyme (2-10 units) or 0.5il restriction enzyme 1 
(1 Ounits/ml), plus 0.5 .tl restriction enzyme 2 (1 Ounits/mi) for multiple digestion. 
Components were mixed gently then centrifuged briefly at 1 3,400xg in a micro-
centrifuge. The digestion reaction was then incubated at the appropriate temperature 
(usually 37'Q for one hour. The reaction was stopped by adding 4il of 
bromophenol blue loading dye, and the results were visualised by agarose gel 
electrophoresis. 
2.2.2 Modifying enzymes. 
Modifying enzymes can be used to synthesis, degrade or modify portions of nucleic 
acids in a defined manner. Modifying enzymes are most commonly used in cloning 
experiments. 
2.2.2.1 14 DNA ligase. 
T4 DNA ligase was used to catalyse the formation of a phosphodiester bond between 
adjacent 5'-phosphate and 3'-hydroxyl in cloning double stranded DNA molecules 
with cohesive or blunt ends. Using an appropriate vector:insert ratio the typical 
ligation reaction was as follows; 1 pl T4 DNA ligase (Roche Diagnostics, East 
Sussex, UK), 1.tl ligase lOx buffer and nuclease-free water to a final volume of lOj.tl. 
Components were mixed gently then centrifuged briefly at 13 ,400xg in a 
microcentrifuge. For the ligation of cohesive ends the ligation reaction was 
incubated at 14°C for 16 hours; for blunt ends the ligation reaction was incubated at 
25°C for 16 hours. 
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2.2.2.2 T4 Polynucleotide Kinase (T4 PNK) 
T4 PNK catalyses the transfer of the y—phosphate from ATP to the 5'-terminus of 
polynucleotides or mononucleotides and was used in the radiolabelling of probes 
used in differential hybridisation experiments. To label an oligonucleotide probe the 
following method was used: 5tl [32P]-ATP (10 mCi/mI) was added to I tl 
oligonucleotide (25pmol), 2pJ lOx kinase buffer, 1tl T4 PNK (Roche Diagnostics, 
East Sussex, UK) and nuclease free water to a final volume of 20tl. The reaction 
was mixed and incubated at 37 °C for 1 hour in a lead-shielded vessel. 
2.2.2.3 Shrimp Alkaline Phosphotase (SAP). 
SAP catalyses the dephosphorylation of 5'phosphates from DNA and is used to 
dephosphorylate restricted cloning vectors to prevent religation.. For cohesive-end 
cloning, SAP (Roche Diagnostics, East Sussex, UK) was added directly to the 
restriction digestion after one hour incubation at 37°C (bromophenol blue loading 
dye was not added at this stage): 1 tl 1 Ox dephosphorylation buffer and 1 il SAP. 
The reaction was incubated at 37°C for a further 10 minutes. To dephosphorylate 
blunt-ended DNA fragments, SAP was added to the completed digestion and 
incubated for 60 minutes at 37°C. SAP was inactivated by 15 minutes at 65°C. 
2.2.2.4 DNA polymerase I large fragment (Kienow). 
Kienow enzyme is the large fragment of DNA polymerase I. The enzyme catalyses 
the addition of mononucleotides from deoxynucleosides-5'phosphates to the 3'-
hydroxyl terminus of a template DNA and was used for 5'-overhang fill-in for 
cloning. Kienow also catalyses the removal of 3'- overhangs. To fill in 5'-overhang 
ends: 40mM of each dNTP and lunit of Kienow per Vg of DNA was added directly 
to the restriction buffer after one hour digestion incubated at 37'C. The reaction was 
incubated at 25°C for 10 minutes. For the removal of 3' -overhangs lunit of Klenow 
(Roche Diagnostics, East Sussex, UK) per ug of DNA was added to the digest and 
incubated at 25°C for a further 20 minutes. Klenow is inactivated by heating at 75°C 
for 10 minutes. 
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2.2.3 Agarose gel electrophoresis. 
The results of restriction digestion or PCR can be analysed using agarose gel 
electrophoresis following staining of the DNA with ethidium bromide and 
visualisation by UV light. For agarose gel electrophoresis the following method was 
used (Helling et a!, 1974, Fischer eta!, 1971). To prepare the gel, I  Agarose was 
dissolved in 1xTBE buffer, and heated in a microwave for 4 minutes on medium high 
heat. The volume of the agarose mixture was made up to lOOmI with dH 20 and 
ethidium bromide added to final concentration of 0.5ig/ml and the gel (14cm x 10cm 
x 1cm) poured and allowed to set for 2 hours. The DNA samples were prepared in 
1110th volume of bromophenol blue loading dye, mixed, then loaded on to the gel. 
The gel was run at lOOvolts, 25mA until satisfactory separation of the DNA samples 
was achieved. The DNA was visualised under UV light. 
2.2.3.1 Isolating DNA fragments from agarose gels. 
To isolate bands from a gel, the gel was run as normal and DNA visualised under UV 
light and the band isolated using Qiagen Gel extraction kit (Qiagen Ltd., West 
Sussex, UK) according to the manufacture's protocol. 
Following visualisation under UV light, the DNA band of interest was cut out from 
the agarose gel with a clean scalpel and placed in a centrifuge tube. The gel 
fragment (1 volume) was incubated in Buffer QG (3 volumes, where 100tg 100il) 
at 50°C for 10 minutes until the gel slice had completely dissolved, after which 1 
volume iso-propanol was added to the sample and mixed. To bind DNA to the 
Qiaquick spin column, the agarose-DNA solution was spun through the column for 1 
minute at 10,000 xg in bench centrifuge. The column was then washed with 0.75ml 
of Buffer PE and spun as before. The flow-through was discarded and the column 
spun dry for an additional Iminute at 10,000 xg. To elute the DNA 30tl of sterile 
water was added to the column and centrifuged for 1 minute at 12,000 xg in 
microcentrifuge. The DNA was then used directly or stored at —20 °C for further use. 
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2.2.4 Modified Inoue method for transformation competent E.coli cells. 
The following method was used to produce competent bacterial strains for efficient 
transformation. A starter culture, 5m1 2xYT, was inoculated with a XL-! Blue 
colony and grown over night at 37 °C in a shaking incubator, the same day 20-40 
1.5ml Eppendorf tubes were prepared by pre-freezing at -70 °C. Next day, a large 
scale inoculation (100-200m1) was prepared by diluting the starter culture 1:500 into 
2XYT —10mM MgSO4 which was incubated at 23°C, shaking (250rpm) to 
OD600=0.6. The cells were collected by centrifugation using the Beckman J2-21, 
rotor JA-14, at 1380 xg in 50m1 Corex tubes for 10 mm, 4°C and the supernatant 
discarded. The cells were gently resuspended in ice-cold Buffer TB in 1/3 rd the 
original culture volume and incubated on ice for 10 minutes. After repeating the 
centrifugation step, the cells were resuspended in ice-cold Buffer TB in 1110th  the 
original culture volume and transferred to a 1 Sml Corex centrifugation tube. DMSO 
was added to a final concentration of 7% and the cells incubated on ice for a further 
10 minutes. Aliquots, 0.5mIs were then dispensed in to the pre-frozen Eppendorf 
tubes and flash-frozen in liquid N 2 before storing at —70 °C 
2.2.5 Transformation of E.coli cells. 
In order to transform E.coli cells the following protocol was used. To 25pJ E.coli 
JM109 cells, 0.5.tg of DNA was added and the mixture incubated on ice for 30 
minutes, heat shocked at 42°C for 90 seconds and incubated on ice for 10 minutes as 
before. To the transformation mixture, 500.tl LB broth (no ampicillin) was added 
and allowed to shake for 1 hour at 37°C. The transformed culture, 200.il, was 
streaked on to an ampicillin agarose plate (1 ltl/ml). Plates were incubated at 37°C 
over night, upside down. Single colonies were then selected and grown in 3ml of 
ampicillin agar broth overnight at 37 °C, in a shaker. The following day plasmid 
DNA can be isolated. For storage of bacterial colonies on agarose plates, single 
colonies were picked to inoculate 3m1 ampicillin LB broth which was incubated at 
37°C with shaking for 16 hours. Fresh ampicillin agarose plates were then streaked 
with the culture and incubated at 37°C over night, upside down. 
Colonies obtained from cloning experiments were screened by isolating small-scale 
DNA preparations (mini-preps) for restriction digestion and gel analysis or DNA 
sequencing reactions. 
2.2.6 Small scale plasmid DNA preparation by alkaline lysis. 
In order to prepare small scale amounts of plasmid DNA the following protocol was 
used (Bimboim and Doly, 1979, Ish-Horowicz,D. eta!, 1981). An overnight culture 
(1.5m1) of transformed E.coli was spun for 15 seconds at 13,400 xg in a 
microcentrifuge. The supernatant was discarded and the pellet re-suspended in lOOil 
of TGE (25mM Tris-HC1, pH8.0, 10mM EDTA, 50mM glucose), then 2001.tl of 
0.2M NaOH, 10% SDS solution was added to lyse the cells. The samples were 
mixed briefly and incubated on ice for 5 minutes. To remove the SDS and allow for 
renaturation of the plasmid DNA 1501.l 3M potassium acetate solution was added, 
the sample was mixed and incubated on ice for 5 minutes then spun for 5 minutes, 
as before, to remove the precipitated protein and chromosomal DNA. The 
supernatant was transferred to a fresh Eppendorf tube and the plasmid DNA purified 
by ethanol precipitation. 
2..2.7 Ethanol precipitation of plasmid DNA 
To ethanol precipitate plasmid DNA, 2x volume 100% ethanol was added, mixed, 
and the sample incubated -20°C for 30 minutes then spun for 10 minutes at 13,400 
xg. The pellet was resuspended in 30-50iil dH20 or alternatively in RNaseA/ dH 20 
mixture (10tg/ml) to digest residual RNA. For solutions up to 15m1, ethanol 
precipitation was preformed in Cortex tubes and centrifuged (Beckman J2-2 1, rotor 
JA-20) at 29,000 xg. 
2.2.8 Large scale DNA preparation by alkaline lysis. 
To obtain large scale amounts of plasmid DNA the following protocol was used 
(Birnboim and Doly, 1979, Ish-Horowicz,D. et al, 1981). A starter culture of lOml 
ampicillin agar broth with transformed E.coli was prepared and incubated at 37 °C for 
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8 hours with shaking, then added to 300m1 ampicillin agar broth and incubated as 
before. Next day, the culture was split into 2x 250ml GSA bottles and centrifuged 
(Beckman, JA-14) for 10 minutes, 5520 xg at 4°C. The supernatant was discarded. 
The cells were resuspended in 25m1 of TGE (25mM Tris-HC1, pH8.0, 10mM EDTA, 
50mM glucose) and 5j.tl (1 0tg!ml) of lysozyme added and the cells left at room 
temperature for 10 minutes. To lyse the cells 60ml of a 0.2M NaOH, 10% SDS 
solution was added, mixed well and the bottles left on ice for 5 minutes. The lysate 
was neutralised by adding 30m1 3M potassium acetate, mixed, and the bottles left on 
ice for 15 minutes then spun as before to pellet the chromosomal DNA and cell 
debris. 
The supernatants were pooled, filtered through gauze into a 500ml cylinder and 0.6 
volume iso-propanol added then spun for 10 minutes in a fresh 250ml GSA bottle, 
9820 xg at 4°C, as before. The supernatant was discarded and the pellet air dried for 
approximately one hour. The DNA pellet was resuspended in 4m1 of TE buffer, pH 
7.4,transferrd to an autoclaved Cortex tube and the volume made up to 12m1 with 
sterile distilled water. The plasmid DNA was recovered by ethanol precipitation as 
previously described. The pellet was air dried then resuspended in 2ml TE buffer, 
pH 7.4. 
To prepare a caesium chloride gradient in Beckman Quickseal tubes, 4g CsC1 was 
added to a Corex tube and the DNA! TE buffer mixture added, TE buffer was 
added to a final volume of 5m1. Once the caesium chloride had dissolved, 1 00.tl 
ethidium bromide (5tg!ml) was added before preparing the DNA solution in a 
Beckman 5m1 Quickseal tube. Ultra-centrifugation was carried out in the Optima IL 
Ultra-centrifugation 100,000 6R, rotor TLA-lOO.3 (Beckman, Ltd) for 16 hours, at 
160,000 xg, 20°C. The plasmid band (lower) of the CsC1 preparation was removed 
using a wide bore needle syringe and the volume made up to 5m1 with autoclaved 
distilled water. The ethidium bromide was removed using 5m1 of water saturated 
butan- 1 -ol and the DNA layer (top) extracted three times. Ethanol precipitation was 
used to recover the DNA followed by centrifugation at 8K for 10 minutes then the 
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pellet air dry and resuspended in distilled water or TE, pH 7.4. Alternatively the 
pellet was dissolved in RNaseA/ dH20 mixture (1 0ig/ml) to digest residual RNA. 
2.3 General Methods for DNA Mutagenesis and Sequencing. 
Purified plasmid single stranded DNA (ssDNA) can be used in sequencing reactions 
and as a template upon which mutagenesis can be performed. Two methods were 
used to isolated ssDNA. 
2.3.1 Preparation of single strand plasmid DNA (ssDNA) using M13K07 
Helper Phage. 
To prepare ssDNA for DNA sequencing reactions the following procedure was used. 
Ampicillin LB broth (3m1) was inoculated with transfected bacteria and 100tl of 
Ml 3K07 helper phage added, and incubated for 90 minutes in a shaking incubator at 
37'C, and kanamycin added to a final concentration of 70.tg/ml. The bacteria were 
incubated overnight at 37°C, with shaking. Approximately lml of an overnight 
culture was spun in microcentrifuge, 13,400xg for 60 seconds then 800tl of the 
supernatant transferred to fresh tube. A solution of PEG6000 and NaCl was added 
to a final concentration of 4% PEG, 500mM NaCl and left at room temperature for 
30 minutes, then spun for 10 minutes as before. The pellet was dissolved in 200tl 
TE pH 7.4, mixed with 200 p.1 phenol, incubated at 60 °C for 5 minutes, then 
incubated on ice for 10 minutes. The tubes were spun for 10 minutes, 13000 xg, the 
DNA/buffer phase (top) removed to a fresh tube and mixed with 150p.l 
phenol/chloroform( 1:1). The extraction procedure was repeated and 10th volume 3M 
sodium acetate and 2x volume 100% ethanol was added to the top layer. This was 
stored at -20 0C overnight, and the precipitate was pelleted by centrifugation for 10 
minutes, 13000 xg. The pellet was air dried and dissolved in 15 PI dH 20 for a DNA 
concentration of 0.5-1 [tg/pl. 
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2.3.2 Preparation of single stranded plasmid DNA by denaturation. 
An alternative method to using helper phage in the production of single stranded 
DNA is to denature the double stranded DNA chemically. To one volume of dsDNA 
sample 1110th  volume 2M sodium hydroxide and 1110th  volume 2mM EDTA was 
added. The DNA solution was incubated at 37 °C for thirty minutes then ethanol 
precipitated at —20°C for a further thirty minutes. The DNA pellet was washed with 
70% ethanol then left to dry at room temperature for 15 minutes. Thereafter the 
pellet was dissolved in 20-30tl dH20 for a DNA concentration of 0.5-1.tg4.Ll. 
2.3.3 Mutagenesis by single oligonucleotide hybridisation. 
To create the hamster-specific anti-PrP epitope (designated 3F4, Kasack et al., 1987) 
in the sheep PrP protein coding region (Chapter Five, section 5.3) the following 
method was used (Gillam, etal., 1997). To denature 10.tg pPSHPrP, the following 
components were added: 10th volume 0.2M NaOH and 10th volume 0.25M EDTA. 
To phosphorylate 10tI (lOpmol/ml) oligonucleotide primer the following mix was 
prepared: 1 .il bacteriophage T4 polynucleotide kinase (1 OU/ml) in the presence of 
1tl lOOM DTT, 2.il 10mM ATP and 4il distilled water, the mixture was incubated 
for 30 minutes at 37°C, placed at -70°C for 10 minutes then stored at -20°C. To 2j.tl 
of phosphorylated primer 1 .tl single stranded DNA template with I tl 1 Ox TM 
buffer, and 6tl water was added. The annealing reaction was incubated at 80 °C and 
then cooled to room temperature for approximately 30 minutes. To the lO&l 
template-primer complex, 0.5pJ Kienow fragment of DNA polymerase (5U/ml), 1il 
T4 DNA ligase (1OU/ml), ltl 5mM ATP, 1tl 5mM dNTPs, ipi 100mM DTT and 
4il water were added and mixed. The reaction was incubated for 12-20 hours at 
12°C. After extension/ligation, E.coli cells were transfected and colonies screened 
for positive clones by restriction enzyme digest or hybridisation. For summary of 
oligonucleotides used see Table 2.1 and Appendix A. 
2.3.3.1 Screening for successful mutagenesis- restriction enzyme digestion. 
To screen for positive colonies restriction enzyme digestion was used. Individual 
colonies were grown in 3m1 ampicillin agar broth for 16 hours and plasmid DNA 
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obtained by alkaline lysis. Ethanol precipitated DNA was digested with HindIll and 
XbaI as described in Appendix A. The DNA fragments were separated and visualised 
by agarose gel electrophoresis. 
2.3.3.2 Differential colony hybridisation. 
An alternative method to screen for positive colonies is differential colony hybridisation 
(Grunstein et al., 1975). Colonies were lifted onto duplicate nitrocellulose membranes 
and the membranes washed in denaturing buffer for two minutes, then soaked in 
neutralising buffer for five minutes and debris removed in washing buffer. The DNA 
was fixed to the membranes by UV irradiation. The membranes were incubated with 
oligonucleotides, 20pmollml, homologous to the mutated and wild-type sequence, with 
2tl lOx kinase buffer, l.tl T4 polynucleotide kinase, 5 P 32P ATP (370MBq/ml) and 
sterile water to final volume of 20il for 1-1.5 hours at 37°C. The radiolabelled probes 
were precipitated with 5 tl E. coli tRNA(Smg), 20pl 4M ammonium acetate and 1 20il 
100% ethanol, placed at -20°C for one hour, then spun for 15 minutes at 13,400 xg, and 
the pellet dissolved in 1 00jl sterile water. The radiolabelled probe was added to the 
pre-hybridisation mix and washed over the membranes for four hours at 37'C. The 
filters were washed twice with 2xSSPE /0.05% SDS at room temperature for ten 
minutes, followed by one or two more stringent washes at higher temperature. After 
exposure to Kodak XAR-5 film at -70°C for six hours or over night with a Lightning 
Plus intensifier screen, positive colonies were identified if only present on the filters 
hybridised with the mutated oligomer probe and not the on those hybridised with the 
wild type oligomer. 
2.3.4 DNA Sequencing: Chain-termination sequencing of DNA. 
Using ssDNA as a template, the chain termination sequencing reaction involves the 
synthesis of a DNA strand (initiated by an oligonucleotide primer) by DNA 
polymerase. In four separate reactions, one for each deoxynucleotide (dNTP), a 
nucleotide analogue is added which can not support chain elongation (a 
dideoxynucylotide,ddNTP). This results in a population of chains of various lengths. 
A radioactive nucleotide is also included in the synthesis so that the chains may be 
visualised by autoradiography after separation by electrophoresis. Sequencing of 
ssDNA was completed using the Sequenase Version 2.0 DNA Sequencing Kit 
(Amersham Life Sciences, Buckinghamsire, UK) according to the manufacturer's 
protocol. Oligonucleotides used as primers for DNA polymerase are described in 
Table 2.1. 
2.3.4.1 Sequencing reaction 
To anneal the oligonucleotide primer to the ssDNA the following method was used. 
In a 0.5ml centrifuge tube ipi primer (lpmol/reaction) was added to 7.xl DNA (5-
7tg) and 2pl Reaction Buffer. The annealing reaction was incubated at 65°C for 2 
minutes in a hot water bath which was then allowed to cool to below 35°C over 30 
minutes to complete the annealing process. To label the template-primer complex 
the following was added to the completed annealing reaction on ice: ltl 0.1MDTF, 
2tI diluter labelling mix (1:5 dGTP labelling mix), 0.5.tl [35 S] —dATP, l.tl Mn 
buffer and 2.tl diluted Sequenase Version 2.0. The labelling reaction was mixed and 
incubated at room temperature for 2-5 minutes. 
For the chain termination reaction 2.5.d of each ddNTP (A, C, G and T) was 
aliquoted into a capped centrifuge tube and warmed to 37 °C for at least 1 minute. 
Labelling reaction, 3.5tl was added to each of the four prepared ddNTPs, and 
incubation at 37°C continued for 3-5 minutes. After which 4m1 Stop solution was 
added to the Termination reaction, mixed and the samples stored on ice until 
required. Prior to loading onto the prepare polyacrylamide gel, the samples were 
heated to 75-80°C for 2 minutes, then 2-3tl loaded on the gel immediately. 
2.3.4.2 Denaturing gel electrophoresis for sequencing. 
The result of sequencing reactions can be resolved by polyacrylamide gel 
electrophoresis. The gel is prepared as follows. For a 7% polyacrylamide gel, 5.7m1 
40% acrylamide/bis-acrylamide solution was mixed gently at 35°C with 17.5g urea, 
4m1 lOx TBE buffer, lOml distilled water and 80tl 10% APS. Once the urea had 
completely dissolved the volume of the polyacrylamide gel solution was adjusted to 
40m1 with distilled water and 30.tl undiluted TEMED added. The gel was then 
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poured (34cm x 17cm x 0.4mm) and allowed to polymerise for 2 hours at room 
temperature. 
Before loading the samples, the gel was pre-run for 15 minutes at 1 800V, 45 W to 
warm the gel. Conditions used to run the sequencing reaction were I 800V, 35W for 
a required time. After which the gel was soaked in a solution of 5% acetic acid, 
15% methanol for 15 minutes to remove the urea, covered with plastic-wrap and 
dried in a gel drier for ihour at 80 °C. The gel was then exposed to Kodak BioMax 
MR-i film (emulsion side in direct contact with gel) in a Lightning Plus Intensifier 
screen. In general, overnight to 36 hour exposures were sufficient to develop 
autoradiography. 
2.3.5 Polymerase Chain Reaction (PCR). 
Polymerase Chain Reaction (PCR) was used to amplify DNA sequences of interest. 
For PCR the concentration of the primers should be approximately 20pmol/1, and the 
final concentration 200mM of dNTPs. The following standard reaction was used; 
1 jtl Taq Poymerase (Roche Diagnostics, East Sussex, UK), 0.4p1 25mM dNTP, 5 P 
1 Ox buffer (Roche Diagnostics, East Sussex, UK), 1 tl oligo 1 (20pmol), I .tl oligo 
2 (20pmoI), 3tl DNA (10.tg) and sterile water to 50.tl. Controls were setup to 
check primers i.e positive control PCR reactions with both primers and a template 
known to work, and a negative control with no DNA template. Standard PCRs were 
run on a Biometra Personal Cycler (Biorad Laboratories Ltd, Hertfordshire, UK), 35 
cycles of: step 1; 95°C for 1 minute, 15 seconds: step 2; 62°C for 1 minute, 15 
seconds: step 3; 72°C 1 minute, 15 seconds. 
2.3.6 Reverse Transcription —PCR. 
Reverse transcription —PCR (RT-PCR) was used to synthesis cDNA from total RNA 
extracts prepared from mouse and ovine cell lines using The RNAzol Tm B method 
(AMS Biotechnology, Oxon,UK). Media was removed, and the cells washed twice 
in PBS before lml RNAz01TM  B was added to each 6-well plate at 4 °C. To disrupt 
the cells the plate was rocked gently and the RNA solublised by pipetting. The RNA 
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solution was transferred to a fresh Eppendorf and 0.1 ml chloroform added, the 
solution mixed then incubated on ice for 15 minutes. After centrifugation at 13,400 
xg for 15 minutes the upper aqueous layer was removed to a fresh tube and the 
RNA precipitated by adding an equal volume iso-propanol and incubating on ice for 
a further 15 minutes. The RNA pellet was washed with 75% ethanol and stored in 
75% ethanol at -20 0C until required. 
RT-PCR using Superscript II was carried out according to manufacturer's protocol 
Gibco-BRL (Paisley, UK). Total RNA, 1-5tg, and lpJ oligo dT (500ig/ml) were 
added to 12m1 sterile water and heated to 70°C for 10 minutes then chilled on ice 
briefly. The following components were added to the total RNA and mixed gently: 
41.il 5x First Strand buffer, 2tl 0.1 M DTT and 1 jiJ 10mM dNTP. This was incubated 
at 42°C for two minutes then 1 JAl of Superscript II added and mixed gently by 
pipetting, the reaction was incubated for a further 50 minutes at 42°C. The reverse 
transcriptase reaction was stopped by heating to 70 °C for 15 minutes. cDNA can 
now be used for PCR as described in section 2.3.5. 
Table 2.1 :Summary of oligonucleotides used during PCR and mutagenesis. 
Name Oligonucleotide sequence Target 
A023  CTGACAGCCGCAGAGCTGAGAG PrP promoter, 5' 
sequence 
A025  CTCATTCCCTAATCTTCA PrP promoter, 5' 
sequence 
A045" CCGTGCAGAGGAGGAGCTG PrP promoter, 3' 
sequence 
13741N GAGGCCTGAGGTGGATAGCGGTTGC PrP ORE, nt 2173' 
sequence 
Sa IPMC GCAGGTGTCGACTAATATCC 5' end of ovine PrP 
promoter region with 
Sail site added 
(underlined). 
SStPMC GGTCTGCAGTTTAAAGAGCTCCGCGGCTATT 3' end of ovine PrP 
promoter region with 
Ssti site added 
(underlined) 
Swildc CCTGCCACATGCfl'C Ovine PrP ORF, nt 337- 
351, anti-sense strand 
E439m GCTCCAGCTGCAGCAGCTCCTGCCAIATGC 3F4 epitope sequence! 
Ndei site in ovine PrP 
ORF, nt 337-351, anti- 
sense strand (mutation 
underlined) 
H3F4c CCTGCCATATGCTTC 3E4 epitope sequence! 
Ndel site in ovine PrP 
ORE, anti-sense strand 
(mutation underlined) 
E337c GAAGCATATGGCAGG Introduces 3174 epitope 
sequence/ Ndel site in 
ovine PrP ORF, nt 337- 
351, sense strand 
(mutation underlined). 
p1N* CCGATACCCGGGACAGGGCAG Ovine PrP ORE, nt 188- 
208, sense strand 
Note: 
Oligonucleotides synthesised by cCmhem  Ltd.(Glasgow, UK) or MWG-Biotech Ltd (Milton Keynes, 
UK) or N  available at NPU. * Designed by Dr Gerard O'Neill. 
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2.4 General Methods for Tissue Culture. 
2.4.1 Preparation of new plates/flasks. 
All plastic wear was purchase from Costar (Buckinghamshire, UK). The cells were 
grown in 75cm2 flasks which were treated as follows. The flasks (Costar Ltd, 
Buckinghamshire, UK) were incubated with 0.1% gelatin at room temperature for 2 
hours in the hood and rinsed with sterile phosphate buffered saline (PBS,Gibco-
BRL, Paisley, UK) prior to use. 
2.4.2 Handling cells to be passaged. 
To passage the cells the following protocol was observed. The culture medium was 
removed and the cells rinsed with PBS then 3m1 trypsin/ versene solution was added to 
the 75cm2 flask (refer to Appendix A for all solutions). The flask was rocked gently 
and placed in the incubator for a few minutes and when all the cells were off the flask 
they were collected in a 1 5ml centrifuge tube. The flask was rinsed with 2m1 sterile 
PBS which was added to the collected cells. The cells were spun at 2000 xg for 5 
minutes, and the pelleted cells resuspended in 2ml of complete culture medium. The 
resuspended cells (0.2m1) were added to a new flask and placed in the incubator at 33°C 
with 5% CO2. The remaining cells were stored at -20°C. 
2.4.3 Cells for frozen storage. 
Cells for storage were prepared by the following protocol. After collection and 
pelleting the cells, the supernatant was decanted to remove all excess trypsin/ versene 
solution The pellet was resuspended in 3ml freezing down medium, and imi of 
resuspended cells pipetted into cryovials. The vials were wrapped in paper towel and 
placed directly into -70°C overnight in an upright position, then the cells were placed in 
liquid N2 until required. 
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2.4.4 Removing cells from frozen storage. 
To remove cells from storage for re-growth the following method was used. The 
vials were removed from liquid N 2 and thawed rapidly in a warm water bath, the 
outside of the vial was sprayed with 70% Methanol to clean it. The cells were added 
to flasks prepared with 0.1% gelatin, 1 Oml of culture medium added slowly, and 
the cells incubated at 33'C. Next day the medium was replaced with fresh medium 
thus removing the dimethyl sulphoxide (DMSO; Sigma, Dorset, UK). 
2.4.5 Culturing ovine cell lines. 
The NPU sheep-derived cell lines were grown at 33 °C in 5% CO2 . A change in 
morphology was observed when the cells were grown at 37°C which may be due to 
the presence of vectors chosen to produce stable cell lines (Hew John, Moredun 
Institute, Edinburgh, personal communication). The primary cells were grown at 
37°C in 5% CO2. The cells were fed every three to four days with complete media 
(Appendix A) as required. The tops of the flasks were unscrewed loose while in the 
incubator. 
2.4.6 Culturing Neuroblastoma cells Ma) 
Neuroblastoma cells (N2a) were available at the NPU. The cell requirements for 
N2a cells are different from the sheep cells in that the N2a cells are kept at 37°C 
instead of 33 °C as for the ovine cells. Plates and media were prepared as for ovine 
cells, N2a cells are grown in the presence of complete culture medium. The cells 
were fed every three to four days with complete media (Appendix A) as required. 
The tops of the flasks were unscrewed loose while in the incubator. 
2.4.7 Immunostaining for ovine brain-derived cell type identification. 
For classification of brain cell lines specific neuronal antibodies (Table 3.1) were 
used to test for several neuronal markers and were detected by fluorescein 
isothiocyanate (FITC) labelled secondary antibodies. 
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2.4.7.1 Fixing brain-derived cell lines for immunostaining. 
The cells were passaged (Section 2.4.2) as usual and a 500.11 aliquot added to a 
60mm culture dish containing a 10-well glass slide which had been treated with 
gelatin as described for the preparation of plates and flasks (Section 24.1). Complete 
media, 5m1, was added to the dish and the cells were incubated at 33 °C for 16 hours. 
Before fixing, the cells were washed twice in warm PBS for 5 minutes, shaking. The 
cultures were fixed with methanol/acetone solution (1:1) for 5-10 minutes at 4°C. 
The cells were then washed with PBS as before and then stored at 4 °C for up to 1 
week prior to immunostaining. 
2.4.7.2 FITC-immunostaining of in vitro ovine brain-derived cultured cells. 
Using a wax pen (PAP pen supplied by Agar Scientific Ltd, UK, product number 
L4197), circles were drawn around the inner rim of each well on the glass slide. The 
cells were washed three times with warm PBS (37'C) for 5 minutes then incubated 
with 30j.tl FITC Blocking solution (refer to Appendix A) for 15 minutes at room 
temperature. The primary antibody, pre-diluted in 5% Blocking solution (if 
necessary), was added as 25jtl aliquots to the wells (Table 3.1). This was incubated 
at room temperature for 1 hour, taking care to ensure the solution remained within 
the PAP circle. Control wells were incubated with 5% Blocking solution only. The 
cells were then washed as before with warm PBS. The secondary antibody, 25.tl 
(Table 3.1; FITC-conjugated Affinipure goat anti-mouse, Jacksons JmmunoResearch 
Lab. Inc. Luton, UK) was prepared in 5% Blocking solution according to the 
supplier's protocol and incubated on the cells in the dark for 1 hour while gently 
shaking at room temperature. The cells were then washed as before with warm PBS 
in the dark and the slide mounted with a water-based mounting solution. The stained 
slides were then observed using fluorescent microscopy (Nikon eclipse E800) and 
results recorded on film. 
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2.5 Methods for Transient Transfection. 
2.5.1 Preparation of DNA for transfection. 
Quality of DNA for transfection is crucial as contaminating protein, RNA and 
chemicals can adversely affect transfection efficiency. DNA for transfection was 
purified using CsCl gradients (2.2.8) or endotoxin-free kits (Qiagen Ltd., West 
Sussex, UK). For transfection a 0D 260:0D280 ratio at or about 1.8 was obtained with 
the final DNA concentration approximately lmg/ml. 
2.5.2 Control vectors. 
The control vector pCAT3-Promoter (Promega, Southampton, UK) was used to 
optimise transfection methods by analysing reporter activity in cell lysates. To 
control for transfection efficiency or cell lysate recovery from transfection 
experiments the vector pSV--Galactosidase (Promega, Southampton, UK) was 
used. 3-galactosidase (n-gal) is a commonly used reporter molecule for co-
transfection. It is assumed that both reporter vectors are transfected with the same 
efficiency in a single transfection reaction but that different cell populations may be 
transfected at varying efficiencies. Measuring the activity of n-gal allows cell 
extracts to be measured for transfection efficiency and lysates adjusted accordingly 
for further CAT assays. 
2.5.3 Calcium phosphate precipitation. 
To transfect ovine and N2a cells by calcium phosphate precipitation the following 
protocol was observed (Gorman,1982). Cells were passaged (Section 2.4.2) at 50-
100% confluent and resuspended in 2ml complete culture medium, of which 0.2ml 
was seeded into a 6-well plate pre-treated with 0.1% gelatin (Section 2.4. 1) and 
incubated overnight at 33'C. For transfection, 5tg of plasmid DNA was mixed with 
2501.tl 2xRBS (Appendix A) and 220 p1 sterile water. To precipitate the DNA, 31 p1 
of 2M calcium chloride was added slowly and the mixture incubated at room 
temperature for 30 minutes. To each well, 160p1 of the calcium phosphate! DNA 
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precipitate was added and the cells incubated at 37 °C overnight. Next day the cell 
medium was replaced and cells harvested 24 hours later. 
2.5.4 Electroporation of brain-derived cell lines. 
For electroporation of stable ovine brain cells lines the method described by Li, 
1997, was used (Li et al., 1997). On the day before electroporation the cells were 
passaged and seeded into 75cm 2 culture flasks and the medium replaced 
approximately 1 hour before harvesting. The cells were trypsinized and resuspended 
in 5ml of complete culture medium, an aliqout could be removed at this stage for cell 
counting. The cells were collected by centrifugation and resuspended in 0.8ml 
1 xHBS and transferred to an electroporation cuvette in preparation for 
electroporation. A DNA solution was prepared for electroporation by dissolving a 
pellet containing 5.ig of plasmid DNA in 80tl 1xHBS, this was added to the cell 
suspension. The cells were electroporated (Biorad Gene Pulser, Biorad Laboratories 
Ltd, Hertfordshire, UK) (Table 3.3) then allowed to rest at room temperature for 10 
minutes before being plated onto a 75cm 2 flask pre-treated with gelatin (Section 
2.4. 1) and returned to 33 °C incubator. The cells were harvested 48 hours after 
electroporation. 
2.5.5 Liposome-mediated transfection. 
2.5.5.1 Liposome Reagent Dosper. 
Transfection using Dosper was carried out according to manufacturer's protocol 
(Roche Diagnostics, East Sussex, UK). The day before transfection the cells were 
passaged (as for calcium phosphate) into 6-well plates at 33°C. On the day of 
transfection the cells were 60-80% confluent for transfection. Different liposome/ 
DNA mixtures were prepared to determine the optimal proportions for transfection. 
For example; 6tl Dosper/ 1.5tg DNA. For this 1.5tg DNA was diluted in HBS to a 
final volume of 50tl (solution A) and 6j.tl Dosper was diluted with HBS to a final 
volume of 50tl (solution B). Solutions A and B were mixed together gently by 
pipetting and incubated at room temperature for 15 minutes to allow the 
DosperfDNA complex to form. Without removing culture medium, the DosperfDNA 
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solution was added drop wise to the cells, mixing gently by rocking the culture dish. 
After 6 hours incubation the transfection medium was replaced with 2m1 fresh 
complete medium and the cells incubated at 37 0C. The cells were harvested to 
determine the level of reporter gene activity 48 hours after starting transfection. 
2.5.5.2 Liposome Reagents TfXTM20 and TfXTM5O. 
Transfection using TfXTm2O  and Tfl'M50  was carried out following the 
manufacturer's protocol (Promega, Southhampton, UK). The cells were prepared in 
a 6-well plate at 33 °C as in calcium phosphate transfection method. The cells were 
60-80% confluent for transfection. Before use, the liposome reagents were dissolved 
in 400 jl nuclease-free water and stored at —20°C. On the day of transfection the 
reagent was thawed on ice and different ratios of liposome/ DNA mixtures were 
prepared to determine the optimal proportions for transfection. For example: 2:1, 3 M 1 
reagent per ig DNA; 3:1, 4.5tl per j.tg DNA; 4:1, 6.0pl per ig DNA. 
The TfrTm  reagent/ DNA solution was incubated at room temperature for 10-15 
minutes to allow the Tfx/DNA complex to form, after which lml of serum-free 
Iscoves Dulbeccos Modified Medium (Gibco-BRL, Paisley, UK) was added to the 
TfXTm reagent/ DNA mixture. The cells were washed twice with PBS before imi 
TflTm50/ DNA mixture was added to each well. After 1-2 hours incubation at 37 0C, 
the transfection medium was replaced with 2m1 of fresh complete culture medium 
and the cells incubated at 37°C. The cells were harvested to determine the level of 
reporter gene activity 48hours after starting the transfection. 
2.5.6 Dendrimer Technology: Superfect Transfection Reagent. 
Transfection using Superfect was carried out according to he manufacturer's protocol 
(Qiagen Ltd., West Sussex, UK). The cells were passaged 24 hours prior to 
transfection into 6-well plates, seeding 2-8x 10 5 cells per well and incubated at 33 °C. 
The cells were 60-80% confluent on the day of transfection. Plasmid DNA was 
prepared by diluting 2p.g of DNA in TE, pH7.4, to a concentration of 0.1 tg/jtl and 
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added to lOOp! cell growth medium containing no serum or antibiotics. To the 
plasmid DNA solution, 9.tl of Superfect transfection reagent was added. To allow 
the DNA-dendrimer complex to form, the sample was mixed by vortexing for 10 
seconds then left at room temperature for 10-15 minutes. 
While the complex was forming the growth medium on the cells was removed and 
the cells washed twice with imi PBS. To the reaction tube containing the 
transfection complexes 2m1 complete culture media was added, mixed by pipetting 
then added immediately to the cells. The cells were then incubated at 37°C in 5% 
CO2 for 2-3 hours, after which the medium containing any remaining complexes was 
removed from the cells. The cells were washed twice with lml PBS and 2ml 
complete culture media added to the cells and incubated at 33 °C, 5% CO2. After 48 
hours, the cells were harvested and evaluated in the appropriate way. 
2.5.7 Effectene Transfection Reagent. 
Effectene reagent was used according to the manufacturer's protocol (Qiagen Ltd., 
West Sussex, UK). The cells were 60-80% confluent for transfection. Different 
ratios of Effectene/ DNA-Enhancer mixtures were prepared to determine the optimal 
proportions for transfection (Table 2.2). A solution was prepared containing 0.5pg 
DNA, with Enhancer and Enhancer buffer to a final volume of 1 50i.tl. Effectene 
reagent was added to the DNA-Enhancer mixture as required, mixed and incubated at 
room temperature for 5 to 10 minutes. While the Effectene complexes formed, the 
growth medium was removed from the cells to be transfected, the cells washed with 
PBS and lml fresh culture medium overlaid on to the cells. For transfection, 0.5m1 
complete culture media was added to the transfection reaction, mixed by pipetting 
and immediately applied drop wise to the cells. The plate was gently rocked to 
ensure uniform distribution. After 16 hours incubation with the complexes at 
370Cand 5% CO2,  the transfection medium was replaced with 2ml fresh complete 
culture medium and the cells incubated as before. The cells were harvested to 
determine the level of reporter gene 48 hours after transfection. 
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Table 2.2: Pippetting scheme for optimising transfection with Effectene reagent 
(Qiagen Ltd, West Sussex, UK) 0.5tg pCAT3-Promoter to primary cell lines in 6-
well plates. 
Component Ratio of DNA to Effectene Reagent 
1:10 	 1:25 	 1:50 
DNA (.tg) 0.5 0.5 0.5 
Enhancer buffer 100.0 100.0 100.0 
(Buffer EC, p1) 
Enhancer (al) 3.2 3.2 3.2 
Effectene (i.tl) 4.0 10.0 20.0 
2.5.8 Cell extract preparation. 
2.5.8.1 Freeze/thaw method 
The transfected cells were harvested by freeze/thawing for CAT assay in the 
following way. The medium was removed and the cells washed in lx PBS before 
1 ml TENS buffer (Appendix A) was added directly to the cells and left at room 
temperature for ten minutes. Using a cell scraper, the cells were collected and 
transferred to a micro-centrifuge tube and centrifuged at 13,400 xg for 1 minute. The 
pellet was dissolved in 100t1 0.25M Tris-HC1, pH 8.0 and subjected to three freeze-
thaw cycles, vortexing after each cycle. Cell debris was removed by centrifugation 
as before and the supernatant transferred into a fresh tube to be assayed directly or 
stored at —70°C. 
2.5.8.2 Reporter Cell Lysis buffer. 
The transfected cells were harvested lysis by Reporter Cell Lysis Buffer (RCLB; 
Promega, Southampton, UK) in the following way. The medium was removed and 
the cells washed twice in 1xPBS. Sufficient volume of 1X RCLB was added to 
cover the cells (400p1 for 60mm dish) and the dish rocked gently at room 
temperature for 15 minutes. All areas of the plate were scraped to ensure all visible 
cell debris was collected, and using a pipette the cell lysate was transferred to an 
1.5ml Eppendorf tube and incubated on ice briefly. The cell debris was removed by 
77 
centrifugation at full speed in a microcentrifuge for two minutes. The cell lysate 
(supernatant) was transferred to a fresh tube and used directly or stored at —70 °C. 
2.5.9 Chloramphenicol Acetyltransferase (CAT) enzyme assay. 
To assay for CAT activity the standard method used is as follows (Seed, etal., 1988). 
To 100.tl cell extract, 3.tl [ 14C]chloramphenicol (0.05mCi/ml), 5.tl n-butyryl 
Coenzyme A (5mg/mI) (Promega, Southampton, UK) and sterile water to 125 PI was 
added. The reaction was incubated at 37 °C for one hour. To carry out both liquid 
scintillation (LSC) and thin layer chromatography (TLC) assays the sample was 
divided in two 75.tl aliquots. To terminate the reaction: for LSC 300tl mixed 
xylenes was added; for TLC 500tl ethyl acetate was added. From LSC the amount 
of acetylated products were measured on a scintillation counter. From TLC the 
acetylated products were either isolated for LSC or the measured directly by 
densometric reading using a Kodak Imagine Station 440 and 1D image analysis 
software (section 2.5.12). 
2.5.10 Liquid Scintillation Count (LSC) assay. 
The sample in xylene was vortexed for 30 seconds, spun in a microcentrifuge for 
three minutes at 13,400 xg and the upper layer removed to a fresh tube. Fresh 
0.25mM Tris-HC1, pH 8.0, 1001.il, was added and the spin repeated, extracting the 
upper layer again. A known volume, or 200tl, was added to a scintillation vial with 
2ml scintillation fluid and the counts per minute (cpm) measured. 
2.5.11 Thin Layer Chromatography (TLC) assay. 
The sample in ethyl acetate was vortexed for 1 minute, spun in microcentrifitge at 
13,400 xg for three minutes, the top layer was transferred to a fresh tube and dried 
under vacuum. The residue was dissolved in 1 0I.tl  ethyl acetate and spotted on to a 
silica gel plate. The plate was run in a pre-equilibrated tank with 
chloroform:methanol (97:3) for 30 minutes then allowed to dry at room temperature. 
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The plate was covered with plastic wrap and exposed to Kodak XAR-5 film 
overnight with a Lightning Plus Intensifier screen. 
2.5.12 Densometric reading of autoradioqraphs. 
Following TLC and development of autoradiographs, it was possible to measure 
directly the density of the acetylated products using a Kodak Image Station and 
processing the results using the Kodak 1D Image Analysis software. The 
measurement recorded is the "net" figure that is calculated by the sum intensity of 
the pixels within a selected area minus the background. 
2.5.13 13-Galactosidase enzyme assay. 
To assay for the level of transient 3-gal activity the method used was the - 
Galactosidase enzyme assay System (Promega, Southampton, UK). Cell extract was 
prepared by the freeze thaw method (Section 2.5.8.1) and 50tI cell extract added to 
100.tl of Assay 2x Buffer and mixed vigorously. The 3-gal assay was incubated at 
37°C for 30 minutes or until faint yellow colour had developed. The reaction was 
stopped by adding 500 j.tl of 1M NaCO 3 and the colour reaction measured by reading 
the absorbance at 420nm. 
2.6 General Methods for Protein Analysis. 
2.6.1 PrP extraction from adherent cells using Triton X-1 14 
For transient expression assays, cell extracts were prepared 48 hours after 
transfection. Cells extracts from non-transfected cells were also prepared to measure 
endogenous levels of cellular protein levels. Approximately 2x1 07  cells were 
collected from 100mm petri dishes for PrP protein extraction by harvesting the cells 
in TENS buffer (Section 2.5.8.2, Appendix A). Using a cell scraper the cells were 
collected and transferred to a microcentrifuge tube and spun at top speed for 1 
minute. The supernatant was removed and the cells stored dry at —20 °C. Prior to 
extraction all rotors and tubes used were pre-cooled to 4 °C. Also, the TL100 and the 
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GS-6R centrifuges were cooled to 2°C and 0 °C respectively at least 30 minutes 
before use. Both centrifuges have temperature controls allowing the rotors (TLA-
100.3) to be cooled to at least 0 °C. 
The cells were resuspended in 2m1 Extraction buffer (Appendix A), 2tl of 10mM 
PMSF protease inhibitor was added and the cells sonicated for 30 seconds at power 
level 8, tune 3 (Micro-ultrasonic cell disrupter, Konics). The extract was transferred 
to a pre-cooled 1 5m1 screw top tube and incubated on ice for 30 minutes. After 
centrifugation for 10 minutes at 900 xg, 0 °C in the GS-6R the supernatant was 
removed using a pasteur pipette and transferred to a thick walled TLA-100.3 tube. 
The supernatant (SP I ) was left to cool on ice for approximately 10 minutes then spun 
in the ultracentrifuge for 1 hour at 164,000 xg, 2°C. The pellet was discarded and the 
supernatant (SP2) overlaid onto 3m1 Sucrose buffer (Appendix A) then incubated at 
30°C for 15 minutes. 
The GS-6R rotor was pre-warmed to 30°C for the next stage of extraction. SP2 was 
spun in the GS-6R for 10 minutes at 380 xg at 30T. With a pasteur pipette, 2.5ml 
was removed from the aqueous layer (SD I ) and cooled on ice. The remaining 
sucrose bed was removed and discarded, the detergent layer(D i ) was transferred to a 
screw-top Eppendorf tube and stored at 4 °C. To SD I , 220tl Triton X-114 was 
added and vortexed then incubated on ice for 1 hour. SDI was overlaid onto 3ml 
Sucrose buffer, incubated at 30°C for 15 minutes then spun as before in the GS-6R 
for 10 minutes at 380 xg, 30°C. With a pasteur pipette, 2ml was removed from the 
aqueous layer (SD 2), the remaining sucrose bed discarded and the detergent layer 
(132) was transferred to a screw top Eppendorf tube and stored at 4°C. D1 and D 2 
were pooled then split into two aliquots. The protein was then precipitated by 
chloroform/methanol extraction and stored at —20°C in methanol. 
2.6.2 Chloroform/methanol extraction 
This method was used to precipitate protein from cell extracts following Triton X-
114 treatment. For a 20011l extract: 800 .tl methanol, 400 .tl chloroform and 600 tl 
H20 was added, vortexed and spun in a micro-centrifuge for 10 minutes at 2000rpm. 
The aqueous layer was removed and 800tl methanol added, the sample was mixed 
and centrifuged as before. The pellet was stored in methanol at —20°C until required 
for SDS-PAGE and Western blotting (Section 2.6.4). 
2.6.3 Immunoprecipitation 
For immunoprecipitation the following method was adapted from Firestone and 
Winguth (1990) and used to detect transient and endogenous PrPC  expression 
(Chapter 5, Section 5.5). Cell extracts were prepared from approximately 2x10 7 cells, 
48 hours after transfection using Reporter Cell Lysis Buffer (RCLB, Section 2.5.6.2). 
Cell extract from non-transfected cells was also prepared to measure endogenous 
levels of PrPC  protein levels. Cell lysate was spun briefly at 2,000 xg and the 
supernatant transferred to a fresh tube. The primary antibody (Table 2.3) was diluted 
in TBST (2x volume of the supernatant, Appendix A) and added to the lysate 
supernatant and incubated for 16 hours at 4 °C while gently mixed. To precipitate the 
PrP immunocomplex, 100.tl protein-A Sepharose solution (10% in TBST) was added 
to the lysate solution and incubated for a further hour at room temperature, gently 
mixing. The sepharose beads were collected by centrifugation at 3,000rpm, 10 
minutes, and washed in 100.tl 5x TBST. This procedure was repeated three times. 
After the third wash the beads were resuspended in SOjtl lx sample buffer to elute 
the bound PrP complex which was then denatured at 90 °C for 10 minutes and 
processed by SDS-PAGE and Western blotting (section 2.6.4) 
2.6.4 Chemiluminescence blotting. 
To detect in vitro PrPC  protein, Western blots were carried out as follows (Towbin, et 
al., 1979). All equipment and solutions described in Appendix A. After 
methanol/chloroform precipitation the protein pellet collected by micro-centrifugation 
for 10 minutes at 13,400 xg. The pellet was dissolved in 30tl lx sample buffer and 
incubated at 90°C for 10 minutes before being loaded onto a 12% acrylamide gradient 
gel. The gel was run at 200V, 75mA for 1 hour. 
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In preparation for protein transfer onto a PVDF membrane, 2x 6 pre-cut pieces of IF 
filter paper (6cm x 8.5cm) were soaked in Transfer buffer for 10 minutes. A sheet of 
pre-cut PVDF membrane (6cm x 8.5cm) was soaked in methanol for 5-10 seconds, 
washed in water for 1 minute then soaked in Transfer buffer for five minutes. For 
blotting the following was assembled on the semi-dry blotter: 6 pieces of filter paper, 
PVDF membrane, gel and 6 pieces of filter paper. A current of 2mA/sq cm was applied 
for 1 hour. 
After blotting, the PVDF membrane was washed with methanol for five seconds and 
left to dry at room temperature for 15 minutes. The membrane was re-wet with 
methanol, rinsed with sterile water then washed twice with TBS before incubating 
with 1% Western Blocking Reagent Solution (Roche Diagnostics, East Sussex, UK: 
Appendix A) at room temperature for one hour while rocking gently. The primary 
antibody was prepared in 0.5% Western Blocking Reagent Solution (Table 2.3) and 
incubated with the membrane for 2 hours at room temperature while being gently 
rocked. The membrane was washed twice for 10 minutes with 20ml TBST, then 
washed twice for 10 minutes with 0.5% blocking solution. The secondary antibody 
was prepared in 0.5% blocking buffer (Table 2.4) and added to the membrane and 
incubated at room temperature for 30 minutes while being gently rocked. The 
membrane was then washed for 15 minutes with 20ml TBST, this was repeated a 
further thtee times before rinsing the membrane with water for 90 seconds. Pre-mixed 
detection reagent (Appendix A) was added to cover the membrane and left to incubate 
for 60 seconds, the blot was wrapped in transparent film and exposed to Kodak XAR-5 
film for 30 seconds, 3 minutes and 10 minutes. 
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2.6.5 Primary antibodies 
To date, no antibody can reliably distinguish between PrPC  and PrP&.  Furthermore 
most antibodies will cross-react with PrP protein purified from two or more species 
as a result of the highly conserved PrP gene. For the purposes of this investigation 
the antibodies chosen for PrP protein analysis are shown in Table 2.2. As discussed 
in Chapter One the polyclonal antibody 1B3 recognises PrP purified from many 
species and was used as a control for PrP expression between the mouse and sheep 
cell lines. However 1133 also cross-reacts with several other cellular protein s and 
can give high background during Western blotting. Recently the monoclonal 
antibody 6H4 became commercially available (Prionics, Zurich). 6H4 shows 
specificity to PrP from several species and was used as a control between the mouse 
and sheep cell lines. The monoclonal antibody FH1 1 had been shown to be ruminant 
specific and was chosen to detect ovine PrP expression from the transiently 
expressed constructs in the mouse N2a cell line. To detect transiently expressed 
ovine PrP from the plasmids pNPU3F4.2 and pNPU3F4.4 in the sheep cell lines the 
monoclonal antibody 3F4 was used. 
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Table 2.3: Primary antibodies used for immunodetection of ovine and mouse PrP. 
Antibody 	PrP motif 
(amino acids) 
Specificity Conditions for use (dilution) Supplier 
1133 	 14-36; 83-102; Mouse, Sheep, 101.11 in 12m1 0.5% blocking solution, incubate C. Farquarson, 
Rabbit polyclonal 	119-139; Goat room temperature for 	hours, shaking (1:1200) NPU, Edinburgh 
188-212 
FHI I 	 PQGGG Goat, Sheep 51.d in 25ml 0.5% blocking solution, incubate at C. Birkett, IAH 
Mouse monoclonal 	(51-55 hu) room temperature for 2 hours, shaking (1:5000) Compton 
3F4 KHMA 	Hamster 1 1 11  in 12ml 0.5% blocking solution, incubate at R.Kascsak, MRDD, 
Mouse monoclonal (109-112 hu) room temperature for 16 hours, shaking New York 
(1:12000) (Kascsak etal., 1987) 
6H4 DYEDRYYRE 	Mouse, Sheep, 5 1.11  in 15m1 0.5% blocking solution, incubate at Prionics AG, Zurich 
Mouse monoclonal (aa 144-152 hu) 	Goat room temperature for 16 hours shaking (1:3000), (Korth etal., 1997) 
00 
2.6.6 Secondary antibodies 
Table 2.4: Peroxidase-conjugated secondary antibodies used for detection PrP after 
Chemilurninescence blotting. Supplied by Jacksons lmmunoResearch Laboratories 
Inc., Luton, UK. 
Antibody 	 Primary 	Conditions for use 
antibodies 
Goat-anti-rabbit-POD 	1133 	 ltI in 25m1 0.5% blocking solution, 
incubate at room temperature for 30 
minutes, shaking 
Rabbit-anti-mouse-POD 	FH1 1 	 5j.tI in 12m1 0.5% blocking solution, 
3F4 	 incubate at room temperature for 30 
61-14 minutes, shaking 
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Chapter 3: Development of transient transfection 
systems for in vitro expression studies in Ovine derived 
cell lines. 
3.1 Introduction 
The use of cell culture in molecular biology is an important tool for elucidating the 
functions of genes and their products. The advantage of using insect or mammalian 
cell lines, as opposed to bacterial cultures or cell free systems, is the presence of 
cellular machinery for correct post-translational modification. It can be expected 
then, that proteins expressed in vitro using mammalian cell culture will be modified 
in a similar manner to native proteins in vivo. 
The process of introducing nucleic acids into cells by non-viral methods is known as 
transfection. Two approaches exist for expression of transfected genes: stable, long-
term transfection and transient expression (Southern and Berg, 1982; Gorman et al., 
1982). Stable transfection involves the integration of the reporter gene into the host 
chromosome to produce cell lines that constitutively express the gene of interest and 
uses a selection process to screen against non-transfected cells. The alternative 
method of transient transfection was used for the work described in this thesis. This 
method involves cloning a reporter gene into an expression vector (plasmid) which is 
introduced into cultured cells in high copy number where it exists independently in 
the cell and appears to degrade slowly. The efficiency of transient transfection is 
dependent on the number of cells which take up the transfected DNA. The products 
from reporter genes following transient transfection can be analysed 48-72 hours post 
transfection. 
Several methods exist for the development of stable or transient transfection, based 
on the utilisation of different physical and chemical principles; calcium phosphate 
precipitatiow(Graham and van der Eb, 1973), electroporation (Wong and Neumann, 
1982), liposome-mediated transfection (Fraley et al., 1980; Felgner et al., 1987), and 
dendrimer-mediated transfection (Tang et al., 1996). The parameters for transfecting 
cells by these methods vary considerably for each cell type and therefore need to be 
optimised for efficient transfection. 
Previous in vitro studies involving the sheep PrP 3 'UTR (discussed in Chapter Four) 
were undertaken in mouse neuroblastoma cells (N2a) (Cheung, 1996; Goldmann et 
al., 1999). It is feasible that the mouse-derived cell line does not have the same 
transcription/ translation factors necessary for control of an ovine gene as would be 
found in sheep cells. The aim of this Chapter is to outline the methods tested for 
efficient transient transfection of various ovine cell lines. As sheep cells lines are not 
commonly used, with only limited lines available commercially, it was necessary to 
obtain suitable ovine cells lines. With this in mind, stable sheep cell lines were 
obtained from Dr Huw John, Moredun, derived from NPU Cheviot sheep (Section 
3.2) and primary cell lines (Section 3.3) were created by Dr Gerard O'Neill, NPU, 
from an Icelandic sheep breed. It was also important to identify the cell types 
present in the brain cell lines, as it is known that the level of PrP expression in 
different brain areas can vary. This may have implications for the reporter gene 
activity as discussed in Section 3.4. 
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3.2 Generation of Stable Ovine Cell Lines for Transient 
Transfection Studies. 
Immortilised cell lines were derived from brain and skin from VV 1 36RR141 QQ 171 
(scrapie susceptible) and AA136RR141QR171 (scrapie resistant) NPU Cheviot sheep by Dr 
Huw John, Moredun Institute, Edinburgh. The cell lines were kindly given to the NPU 
for the studies in this thesis. The method used to create stable cell lines from NPU 
cheviot sheep (Figure 3.A) by Dr Huw John, Moredun Institute, Edinburgh was 
modified from published methods (John eta!, 1994; John, 1994). Foetuses from these 
sheep were removed by caesarean Section at 80 days into gestation and tissue cells 
extracted from neural (brain, spinal cord) and peripheral tissues (spleen, lungs, skin). 
Briefly, the extracted tissue was washed and treated with a 0.25% trypsin solution and 
the tissue digested for 10 minutes at 37 °C. The supernatant was discarded and 
trypsin digestion repeated three times. The separated cells were recovered by 
sedimentation and resuspended in Iscove's modified Dulbecco's Medium (JMDM, 
Gibco), 10% foetal calf serum, (FCS, Gibco). The Moloney murine leukaemia virus 
(MoMLV) based vector, pZIPNeo, containing the marker neomycin was transfected to 
generate continuous proliferation in cultured cells. Monolayer cells (lxi 06)  for 
retroviral transfection were cultured at 37 °C overnight then exposed to retroviral-
containing medium for 24 hours. Successfully transfected cells were selected by 
treating the cultures with medium containing the antibiotic neomycin, G418, 2mg/mi. 
The established cell lines were sustained at 33 °C instead of 37 °C as it was observed 
that at the higher temperature they underwent morphological changes (John, personal 
communication). It was unclear whether this was a result of the vector used for 
stable transformation of the cells. The brain cell lines (Figures 3.2-3.3) derived from 
each genotype (sA80BR from  VV 136RR141 QQ 171 ; pA80BR from AA 136RR141 QR171 ) 
grew successfully at the NPU and were used in transient expression studies. The skin 
cells (Figure 3.4) derived from AA 136RR 141 QR 171 NPU Cheviot sheep also grew well. 
Unfortunately the skin cell line derived from sheep of susceptible genotype suffered 
several fungal infections, failed to grow at a satisfactory rate, and was discounted 











Fiaure 3.1: SheeD breeds used in DreDaration of cell lines. 
(A) Example of Cheviot sheep breed as used by Dr Huw John to create the 
stable cell lines sA80BR and pA80BR as described in Section 3.2. (b) 
Example of the Icelandic breed, Ovis branchura borealis pall, used by Dr 
Gerard O'Neill to establish primary cell lines from various tissues as 
described in Section 3.3. 
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Figure 3.2: NPU Cheviot sheep brain-derived cell line sA80BR 
Brain cell line, sA80BR, derived from a scrapie susceptible Cheviot sheep 
(VV136RR1QQ 171 ), passage number 13. (A) x25 magnification (B) x50 
magnification. 
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Figure 3.3: NPU Cheviot sheep brain-derived cell line pA80BR 
Brain cell line, pA80BR, derived from a scrapie resistant Cheviot sheep 
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Figure 3.4: NPU Cheviot sheeD skin-derived cell line DA80SK 
Skin cell line, pA80SK, derived from a scrapie resistant Cheviot sheep 




3.3 Generation of Primary Ovine Cell lines for Transient 
Transfection Studies 
Primary cell lines were derived from a male sheep of the Icelandic breed (Figure 
3.1B), Ovis brachyura borealis pall, by Dr Gerard O'Neill by standard cell culture 
methods (Freshney, 1987). The animal was 1.5 years of age and had a PrP genotype 
Of AA 136RR154QQ 171 which is scrapie susceptible in the Icelandic sheep breed. 
Tissue was recovered, in 2cm2 segments, from brain and other tissues and macerated 
into smaller fragments with scalpel blades. The tissue fragments were treated with a 
0.25% trypsin solution and the tissue digested for 30 minutes at 37 °C. The digested 
tissue was allowed to settle, the lysate was removed and the cell debris pelleted. 
Fresh trypsin solution was added to the cell debris and the process repeated three 
times. The cell lysate and debris fractions were re-suspended in lOml Dulbecco's 
Modified Eagle Medium (DMEM, Gibco) containing 10% foetal calf serum (FCS, 
Gibco). 
Aliquots, 2mls, of the cell lysates were added to pre-gelatinised (0.1%) 25cm 2 flasks 
and incubated at 37 °C, 5% CO2 . Fresh medium was applied to the cells after 16 
hours. When explants were observed to be growing from the cell colonies, the flasks 
were agitated to dislodge the growths and the cells washed in fresh DMEM 
containing 10% FCS. The primary cell cultures were passaged when they reached 
confluency or frozen for storage. 
Cells lines created by Dr O'Neill from cerebellum tissue (1S120.Cer), liver tissue 
(IS 1 20.Cer) and kidney tissue (IS 1 20.Kid) were intended for use within this present 
study (Figures 3.5-3.7). Both 1S120.Cer and 1S120.Liv grew well atNPU as 
adherent cultures with distinct cellular morphology. Unfortunately, the cell line 
IS 1 20.Kid grew at a slow rate, unsuitable for transfection analysis and so were not 
used in the transient expression studies, but were used for PrP analysis in Chapter 
Five. General cell requirements and recipes for the solutions used in tissue culture 
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Ficiure 3.5: Icelandic sheeD brain-derived cell line 1S120.Cer 
Cell line, 1S120.Cer, was derived from the cerebellum of an Icelandic sheep 
breed, Ovis brachyura borealis pall, scrapie susceptible genotype 
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Figure 3.6: Icelandic sheep liver-derived cell line 1S120.Liv. 
Liver cell line, 1S120.Liv, derived from liver tissue of an Icelandic sheep 
breed, Ovis brachyura borealis pall, PrP genotype AA1RR1QQ171, 
passage number 10. (A) x25 magnification (B) x50 magnification. 
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Figure 3.7: Icelandic sheep kidney-derived cell line Liv: lS12O.Kid 
Kidney cell line, 1S120.Kid, derived from kidney tissue of the Icelandic breed, Ovis 
brachyura borealis pall (scrapie susceptible genotype), passage number 6. (a) x25 
magnification. 
3.4 Classification of Ovine Brain-derived Cell Lines. 
The PrP gene has been shown to be expressed in vivo in brain fractions (Rubenstein 
etal., 1986; Kascsaket al., 1986; Manson etal., 1992a; Harris et al., 1993), a wide 
variety of non-neuronal tissues (Rubenstein et al., 1986 Bendheim etal., 1992;; 
Horiuchi etal., 1995; Fournier etal., 1998; Goldmann etal., 1999) and in vitro by 
numerous cell lines of different origin (Wion etal., 1988; Satoh etal., 1998; Dodelet 
etal., 1998; Lazarini, etal. 1994; Atoufet al., 1994; Kniazeva etal., 1997; Ikeda et 
al., 1998). In sheep it is known that the level of PrP mRNA expression varies 
between tissues with the highest level detectable in the brain (Goldmann et al., 
1999). 
Within the brain, although neuronal PrP mRNA expression has been documented by 
in situ hybridisation, PrP mRNA is also readily detectable in astrocytes and 
oligodendrocytes (Raeber et al., 1997; Moser etal., 1995). In the developing 
hamster brain the level of PrP mRNA expression in astrocytes is initially comparable 
to that of the neurones, increasing two-fold during postnatal development (Moser et 
al., 1995). A significant proportion of brain PrPC  is the result of glial cell expression. 
It has been shown that the level of PrP mRNA expressed within individual brain 
regions and cell types can vary. Regional differences in the expression level of PrP 
mRNA seen through the developing hamster brain persists within the adult (Mobley 
et al., 1988). Furthermore, the constitutive expression of PrP mRNA observed in 
numerous human neuronal cell lines alters in specific cell lines in response to 
cytokine treatments (Satoh et a!, 1998), which suggests cell type specific regulatory 
mechanisms. 
It was necessary to establish the cell types present in the brain cell cultures used in 
this study as this may have implications for the level of transient expression from the 
PrP constructs (discussed in Chapter Five).. 
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3.4.1 Experimental approach: FITC-immunostaining of in vitro ovine brain-
derived cultured cells. 
Several specific neuronal antibodies were used for classification of cell types present 
in the sheep brain cell lines. The brain cell lines were prepared for immunostaining 
by fixing with methanol: acetone (1:1) and bound antigens were detected by 
fluorescein isothiocyanate (FITC) labelled secondary antibodies in the method 
described briefly below and in detail in Section 2.4.7.2. Classification of the brain 
cell line sA80BR was repeated twice, results shown in Figure 3.8. FITC-staining of 
the cell lines pA80BR (results not shown) and 1S120.Cer (Figure 3.9) was completed 
once. 
Pre-fixed and blocked cells were incubated with the primary antibody (Table 3. 1), 
pre-diluted in 5% Blocking solution at room temperature for 1 hour. Control cells 
were incubated with 5% Blocking solution only. The secondary antibody, labelled 
with fluorescein isothiocyanate (FITC), was diluted according to the suppliers' 
protocol (Jacksons, UK) in 5% Blocking solution (Table 3.1) and incubated on the 
cells in the dark for 1 hour, gently shaking at room temperature. The cells were then 
washed with warm PBS (37'C) in the dark and the slide mounted with Aquamount 
solution (BDH,TJK). The stained slides were observed using fluorescent microscopy 
and photographed using a Nikon Eclipse E800 (Figures 3.8 and 3.9). 
Table 3-1 : Antibodies used to classify cells present in ovine brain derived cell 
cultures. Secondary antibodies are FITC-conjugated Affinipure goat anti-mouse! 
rabbit, (Jacksons lmmunoResearch Lab. Inc, Luton, UK). 
Name and Specificity Detect Source Dilution 
10 	Anti-glial fibrillary acidic protein Astrocytes Mouse 1/600 
(GFAP, Sigma G-3893) Glial cells 
Monoclonal 
Neurofilament 200 Neuronal cells Mouse 1/500 
(N200, Sigma N-0142) 
Monoclonal 
Anti-fibronectin Fibroblasts Rabbit 1/100 
(Sigma F-3648) 
Polyclonal 
20 	Goat anti-mouse FITC Mouse lgG Goat 1/50 
Goat anti-rabbit FITC Rabbit lgG Goat 1/30 
3.4.2 Results: Immunohistochemical staining of ovine brain-derived cell 
lines using fluorescein isothiocyanate (FITC) labelled antibodies. 
Figure 3.8 : Classification of cell types present in Cheviot brain sA80BR cell line. 
Immunohistochemical staining of cell line sA80BR using fluorescein isothiocyanate 
(FITC) labelled secondary antibodies. (A) Positive staining of anti- N200 captured 
at x20 magnification, (B) Positive labelling of anti-GFAP captured at x40 
magnification, (C) Negative labelling for anti-fibronectin, (D) Negative control using 
goat anti-mouse FITC. 
100 
Figure 3.9: Classification of cell types present in Icelandic breed cell line, IS!20.Cer 
Immunohistochemical staining of primary Cerebral cell line using fluorescein 
isothiocyanate (FITC) labelled secondary antibodies. (A) Positive staining of anti-
N200 captured at x40 magnification, (B) Negative staining of anti-GFAP, (C) 
Negative control using goat anti-mouse FITC. 
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3.4.2 (results continued). 
The Cheviot ovine brain cell line sA80BR stained positive for anti-N200 and anti-
GFAP (Figure 3.8, Table 3. 1), suggesting the presence of neuronal and glial derived 
cells. Staining for anti-N200 was strong, abundant and easily observed at low 
magnification (x20 magnification). In contrast, staining for anti- GFAP was weaker, 
less abundant and only visible at a higher magnification (x40). The ovine brain cell 
line sA80BR did not stain with anti-fibronectin suggesting the absence of fibroblasts 
within the cell culture. The Cheviot brain cell lines pA80BR also stained positive for 
anti-N200 and anti-GFAP and negative with anti-fibronectin. The same pattern of 
staining was observed in pA80BR as the sA80BR cell line, again suggesting a 
heterogeneous culture of neuronal and glial derived cells (results not shown). 
The primary brain cell line IS 1 20.Cer prepared from Ovis brachyura borealis pall 
stained positive for anti-N200 (Figure 3.9), indicating the presence of cells derived 
from neuronal tissue within the cell culture. Staining for anti-N200 was strong and 
abundant, defining the nucleus of the cells well. The cells did not stain with anti- 
GFAP or anti-fibronectin suggesting the absence of astrocytes and fibroblasts within 
the culture. 
All the brain-derived cell lines tested by FITC were positive for the presence of 
neuronal cells. 
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3.5 Transient Transfection of Ovine Cell Lines. 
An ideal method for transfection should have the following properties: efficient in 
reporter gene transfer; low toxicity for the cells; and reproducibility. Many different 
methods exist, each has its advantages and limitations, and a method that works for 
one cell type may not work for another. Furthermore, different lines of culture cells 
can vary greatly in their ability to assimilate and express exogenously added DNA. 
Therefore choosing the method for transfection for a new cell line can be trial and error 
to begin with. 
In particular, it is believed that because of their highly differentiated state, neuronal 
cell lines are relatively resistant to conventional transfection methods. For this 
reason it was decided to concentrate to begin with on finding an efficient method for 
transfection for sheep brain cells. 
3.5.1 Experimental approach. 
The procedures used for handling cell lines are described fully in Chapter Two. 
Briefly, all DNA was prepared to ensure it was endotoxin free and cell culture work 
was carried out in an area which could be UV treated to eradicate microbial 
contaminants. The methods tested to establish transient expression in sheep brain 
cells (Section 2.5) included calcium phosphate precipitation, electroporation, 
lipofection and dendrimer technology. The control vector pCAT3-Promoter 
(Promega, UK, Appendix A) which expresses chloramphenicol acetyl transferase 
(CAT), was used to optimise transfection methods by analysing CAT activity in cell 
lysates. The vector pSV-3-Galactosidase, which expresses 13-Galactosidase, was 




3.5.2.1 Calcium phosphate precipitation. 
The method of calcium phosphate precipitation for transfection was one of the first to 
be described (Graham and van der Eb, 1973). Transfection mediated by calcium 
phosphate involves mixing DNA directly with a calcium chloride solution and 
phosphate buffer to form a fine precipitate that covers the cultured cells. The 
mechanism is not fully understood but it is thought that precipitated DNA enters the 
cytoplasm of the cell by endocytosis and is transferred to the nucleus. The factors that 
influence efficiency of calcium phosphate transfection are primarily the amount of 
DNA in the precipitate and the length of time the precipitate is left on the cells. A 
calcium phosphate optimisation scheme is shown in Table 3.2, full details of the 
protocol followed are described in Chapter Two (Section 2.5.3) and full data in 
Appendix B 1.0, Table B 1.1. 
Calcium phosphate is widely used for transient transfection and has been used in this 
laboratory for recent reporter gene studies on other cell lines (Baybutt and Manson 
1997; Cheung, 1996). The cells, sA80BR, were harvested 48 hours post-transfection 
with the vector pCAT3 -Promoter and a CAT assay was performed, the results of 
which were analysed by thin layer chromatography (TLC). A typical autoradiograph 
developed from TLC following calcium phosphate transfection is shown in Figure 
3.10. Using the developed autoradiogragh, it was possible to isolate the acetylated 
products from the silica plate and the level of CAT activity determined by measuring 
[' 4C] by liquid scintillation counting (LSC, Section 2.5.10). Relative CAT activity 
was determined (Table 3.2.) by comparing the CAT activity of the reporter construct 
to a positive CAT control reaction (100%). The positive CAT control was 1 unit of 
purified CAT enzyme (Promega, UK). The calcium phosphate transfection method 
was repeated three times (twice in duplicate) and found ineffective for transient 
transfection of the pCAT3-Promoter plasmid to ovine brain cell cultures. Little cell 
death was observed irrespective of amount of DNA or time of exposure to 
precipitate. 
104 
Table 3.2: Optimisation and results of transfection of sA80BR with pCAT3-Promoter 











10 6 nld 0.0 n/d 
ba 16 36130.82 0.0 0.00 
5a 16 36130.82 10.93 0.03 
5b 16 22744.3 345.72 1.5 
16 22744.3 294.61 1.2 
Note. Positive CAT was the measured acetlyated product (100%) when 1 unit of purified 
chloramphenicol transferase was incubated with acetyl Coenzyme A (5mg/mi) and 
[' 4C]chloramphenicol (0.05mCi/ml). Cell CAT activity was the measured acetylated product 
isolated by TLC from a CAT assay on the sA80BR cell lysate after calcium phosphate 
precipitation of pCAT3-Promoter (Promega, UK). a  signifies that the experiments were 
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Figure 3.10 :Transfection of ovine brain cell line sA80BR using the calcium 
phosphate method. (A) Positive control, 1 unit of purified CAT enzyme; (B,C) 
repeat assays from non-transfected cells; (D,E) cell lysate assays from cells 
transfected with 5jig pCAT3-Promoter (Promega). ACm: acetylated 
chloramphenicol, Cm: chloramphenicol. 
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3.5.2.2 Electroporation of brain-derived cell lines. 
The physical method of electroporation is based upon perturbation of the cell 
membrane by an electrical pulse, forming pores that allow the uptake of nucleic acids 
into the cell (Shigekawa, etal., 1989). Consequently, the concentration of DNA is 
less likely to be a factor determining transfection than are the duration and strength 
of pulse for each cell type. A balance must be found between conditions that kill 
cells and conditions that allow efficient transfer of DNA. 
The vector pCAT5 (Appendix A) was used for testing this method of transfection as 
it was shown to have higher expression in vitro than pCAT3 -Promoter and may have 
enhanced the likelihood of detectable CAT expression (Baybutt, personal 
communication and Table 3.8). The method used for electroporation is fully 
described in Chapter Two, Section 2.5.4, and full data presented in Appendix B. 
Cells were harvested 48 hours post-transfection and a CAT assay performed, the 
results of which were analysed by TLC. Relative CAT activity was determined by 
TLC and autoradiography (Figure 3.11, Table 3.3.). The amount of acetylated 
substrate produced from the transfected cell lysates was compared to a positive CAT 
control reaction (100%). Full data can be found in Appendix B 1.0, Table B 1.2-1.3. 
Significant cell death was suffered under most conditions, particularly when the 
parameters 5tg DNA, 800V and 300F were used. Cell death under other 
conditions was approximately 40-60%. Electroporation was not effective in 
transient transfection of the pCAT5 plasmid (Table 3.3). Altering the conditions for 
electroporation did not affect the efficiency of transfection. 
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Table 3.3: Result of transfection of pCAT5 into sA80BR cells following 






















5 5 800 300 100 100 0 0.0 
25 800 300 80-50 0 0.0 
50 800 300 50-40 0 0.0 
6 20 200 960 70 100 0 0.0 
20 250 960 60 0 0.0 
20 300 960 60 0 0.0 
Note. Positive CAT was the measured acetlyated product (100%) when 1 unit of purified 
chioramphenicol transferase was incubated with acetyl Coenzyme A (5mg/mi) and 
[ 14C]chloramphenicol (0.05mCi/ml). Cell CAT activity was the measured acetylated product 
anylised by TLC and LSC following CAT assay on the sA80BR cell lysate after 
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Figure 3.11:Electroporation was ineffective in transfection of ovine brain cell 
line sA80BR with the reporter vector pCAT5. (A) Positive CAT reaction, I unit 
of purified CAT enzyme (Promega) (B) Negative CAT reaction (C) 
Electroporation of 20ig pCAT5, 200V, 960p.F (D) Electroporation of 20ig 
pCAT5, 250V, 960iF (E) Electroporation of 20.tg pCAT5, 300V, 960F. 
ACm: acetylated chloramphenicol, Cm: chloramphenicol. 
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3.5.2.3 Liposome-mediated transfection. 
The use of synthetic cationic lipids for transfection offers advantages of high efficiency 
gene transfer usually to cells which are resistant to calcium phosphate transfection 
(Fraley etal., 1980; Felgner etal., 1987). Lipofection involves encapsulating DNA or 
RNA with liposomes. The cationic head of the lipid associates with the negatively 
charge phosphates on the nucleic acid. The nucleic acid/lipid complex then fuses, or 
associates, with the overall negatively charged cell membrane and results in the 
internalisation of the nucleic acid into the cell. Following endocytosis the complex 
appears in endosomes then later in the nucleus. 
Commercial cationic lipids tested on the stable ovine brain cell lines were Tfx-50 and 
TflM20 reagent (Promega, UK), Dosper (Roche Diagnostics, UK) and Effectene 
(Qiagen Ltd, UK). These reagents are preparations of polycationic lipids, each unique 
in the cationic lipid supplied. Tfl-20 and TflM50  contain the same cationic lipid 
but different molar concentration of a fusogenic lipid. It is vital to develop optimal 
transfection conditions as factors such as cell line, clonal variety within the cell line, 
culture conditions and the DNA being transfected can influence transfection efficiency. 
The following parameters are also known to alter transfection efficiency: the charge 
ratio of lipid reagent to DNA, transfection time, and the absence or presence of serum. 
The charge ratio of lipid to DNA is vital for transfection as a net neutral or positive 
charge is required to ensure successful micelle formation. In general increasing the 
amount of available lipids improves transfection efficiency but at high levels lipids can 
be toxic to cells, also the length of time cells are exposed to a liposome reagent may be 
toxic. The high concentration of proteins present in serum may prevent formation of 
micelles essential for DNA transfection. However, the absence of serum from cells for 
a considerable time is stressful to the cells and may result in poor DNA uptake or cell 
death. A full description of each of the methods followed for liposome-mediated 
transfection can be found in Chapter Two (Section 2.5.5) and data listed in Appendix B. 
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A) Liposome transfection: Dosper (Roche Diagnostics) 
Liposome transfection using the Dosper reagent (1 j.tgI.tl, Roche Diagnostics) was 
carried out as recommended by the manufacturer's protocol (Section 2.5.5.1). For 
optimisation of transfection (Table 3.4) of the pCAT3-Promoter plasmid (Promega, 
Appendix A) various ratios of Dosper (p.g/ml) and DNA (Vg/ml) were tested to give 
different charge ratios of Dosper reagent to DNA. Full data can be found in 
Appendix B. 1.0, Tables B 1.4-1.5. The Dosper reagent did not appear to be toxic to 
the cells however transfection of the ovine cell line, sA80BR, was attempted for a 
total of three times, each being negative (Table 3.4, Figure 3.12). As this was a new 
method to the laboratory, it was decided to test the procedure in mouse N2a cells, a 
cell line which has been transfected before with pCAT3-Promoter by calcium 
phosphate. This was carried out with the assistance of Dr Gerard O'Neill, but the 
results were also negative (Table 3.5). 
The cells were harvested 48 hours post-transfection and a CAT assay performed, the 
results being analysed by LSC and confirmed as before by TLC (Figure 3.12). The 
relative CAT activity from the transfected cells was calculated as a percentage of 
CAT activity (100%) determined from the positive CAT control. 
Transfection reagent, Dosper was not effective in transfecting the ovine brain derived 
cell line sA80BR. 
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Table 3.4: Results from two separate transfections of sA80BR with 3tg 














11 0 0 3763.11 69.55 1.85 
2 1:1 0.0 0.0 
4 2.5:1 0.0 0.0 
6 4:1 72.54 1.93 
13 0 0 92427.94 249.37 0.27 
2 1:1 94.74 0.1 
4 2.5:1 17.89 0.02 
6 4:1 10728 1.17 
Table 3.5: Result of transfection of murine N2a cell line (passage number 189) with 













1 2 4:1 108213.89 2444.38 2.24 
1.5 2 2.5:1 6.07 0.01 
2 2 2:1 0.0 0.0 
3 2 1.3:1 365.64 0.33 
3 0 0 0.0 0.0 
0 2 0 16.99 0.01 
Note. Positive CAT was the measured acetlyated product (100%) when 1 unit of purified 
chioramphenicol transferase was incubated with acetyl Coenzyme A (5mg/mi) and 
[ 14C]chloramphenicol (0.05mCi/ml). Cell CAT activity shown in table 3.4 refers to 
measured acetylated product anayised by TLC and LSC on the sA80BR cell lysate after 
lipofection of pCAT3-Promtoer with Dosper reagent (Roche Diagnostics, UK). Table 3.5 
shows Cell CAT activity measured from N2a cell lysates after Dosper transfection of 
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Fiaure 3.12: Transfection of the ovine brain cell line sA80BR with DCAT3-
promoter plasmid by the liposome reagent Dosper. Altering the ratio of DNA 
to lipsome reagent did not increase transfection efficiency. (A) Positive 
CAT reaction, 1 unit for purified CAT enzyme (Promega) (B) Negative CAT 
reaction (C) Liposome transfection with Otl of Dosper reagent (D) Liposome 
transfection with 2il of Dosper reagent (E) Liposome transfection with 4jtl of 
Dosper reagent (F) Liposome transfection with 6il of Dosper reagent. ACm: 
acetylated chloramphenicol, Cm: chloramphenicol. 
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B) Liposome transfection: TfX5OTm  (Promeqa) 
Liposome transfection of sA80BR with the plasmid pCAT3-Promoter (Promega) 
using the Tfr5OTm  reagent (Promega) was examined according to the manufacturer's 
protocol. The TfX50Tm  reagent was resuspended in 400 j.il nuclease-free water to 
give a final concentration of 1.75jtg4il. Various concentrations of DNA and 
transfection reagent were tested to alter the charge ratio between the DNA and lipid 
components of the transfection reaction (Table 3.6 and 3.7). Several parameters 
known to effect the efficiency of Tfx 50Tm  reagent transfection were tested: y the 
ratio of DNA to Tfl5.OTm  reagent and presence or absence of serum (Table 3.7). As 
described in Chapter Two (Section 2.5) cells were harvested 48 hours post-
transfection and a CAT assay performed, and results analysed by TLC (Figure 3.13) 
and LSC. The relative CAT activity (Table 3.7) from Tfl5OTm  transfected cells was 
calculated as a percentage of CAT activity determined from the positive CAT control 
(100%). 
The conditions for transfection with TfláOTm  were favoured in the absence of serum 
(Figure 3.13b, lanes 3-5), with a charge ratio of 2:1. CAT activity was low in these 
studies probably because of the amount of DNA used (see Figures 3.13 and 3.14) 
Optimum transfection of pCAT3-Promoter (Promega) into sA80BR gave 33% 
conversion of chloramphenicol to acetyl chloramphenicol when compared to the 
positive control with a charge ratio of 2:1 and increasing concentration of DNA 
(Figure 3.14, lanes D-F, Table 3.7, rows 10-12). Cell death was observed under 
conditions where the liposome reagent Tfx50 Tm was in contact with the cells from 
more than two hours, when high concentrations of DNA were used and when high 
DNA: TBC50Tm  ratios were tested. Liposome transfection using TfXSOTM  was tested 
on sA80BR under different experimental conditions, full data can be found in 
Appendix B. 1.0, Tables B 1.6-1.8. 
Liposome transfection using TfX50Tm  was further tested on mouse N2a cells as a 
control for transfection efficiency (Table 3.8). TfXSOTm  was a powerful transfection 
reagent on N2a cells when used at the same conditions as those optimal for the sheep 
cell line sA80BR (Figure 3.15). 
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Table 3.6: Charge ratio of TfXTm  :DNA with reference to the volume of TfXTm  in each 
reaction. 




Table 3.7: Result of three separate transfections of sA80BR with pCAT3-Promoter 













16 3 2:1 108638.48 900.67 0.83 
3 3:1 1779.91 1.64 
3 4:1 110.81 0.1 
17 3 2:1 107282.88 283.1 0.26 
3 3:1 113.35 0.11 
3 4:1 531.85 0.5 
3 2 : 1* 107282.88 7553.87 7.04 
3 3 : 1* 4851.03 4.52 
3 4:1k 1556.45 1.45 
18 3 2 : 1* 94205.49 2108.88 1.71 
6 2 : 1* 5584.09 5.4 
10 2 : 1* 15947.73 33.33 
3 3 : 1* 1586.23 1.15 
6 3 : 1* 2232.76 1.84 
10 3 : 1* 1122.0 1.85 
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Fiaure 3.13:Transfection of sA80BR with DCAT3-Promoter usina Tf X50Tm 
reagent. (A) in the presence of serum (B) in the absence of serum. On both 
plates lanes; 1, 1 unit purified CAT: 2, negative control. To optimise for the 
ratio of DNA to TfX5OTm  reagent various conditions were used: lanes 3-5, 
Tfx5OTm: DNA ratio of 2:1: lanes 6-8, Tfx5O Im :DNA ratio of 3:1; lanes 9-11, 
Tfx50Tm :  DNA ratio of 4:1. To optimise for the amount of DNA available for 
the transfection reaction various concentrations were tested: 3,6,9, 0.5tg 
pCAT3-Promoter: 4, 7,10, ljig pCAT3-Promoter: 5,8,11 3tg pCAT3-







A 	B C D 	E 	F 	G H 
Figure 3.14: Transfection of sA80BR cells with pCAT3-Promoter and 
increasing amounts of DNA at ratios of 2:1 (D-F) and 3:1 (G-I) with TfX50Tm 
reagent. Lane A, positive CAT control,1 unit purified CAT ( Promega): B, 
negative CAT control: C; non transfected cells: D and G; 3tg pCAT3-
Promoter: E and H; 6ig pCAT3-Promoter: F and I; 10ig pCAT3-Promoter. 
ACm: acetylated chloramphenicol, Cm: chloramphenicol. 
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Table 3.8: Result of transfection of mouse N2a cell line following lipofection using 
TfX50Tm according to the various conditions used. 
Vector DNA Charge ratio Positive Cell CAT Relative CAT 
(jig) (Tfx5OIm : DNA) CAT (cpm) (cpm) activity (%) 
pCAT3- 1.0 2:1 108017.1 36242.53 33.55 
Promoter 
3.0 2:1 67536.27 62.52 
pCAT5 1.0 2:1 78157.07 72.36 
3.0 2:1 92845.96 85.50 
ACmL 
db 
Cm— 40 	 * 40 4W 4W 40 go 
A 	B C 	D E F G 	H I 
Ficiure 3.15:Transfection of N2a cells with DCAT3-Promoter reoorter aene I 
using 	 50' reagent. Ratio of DNA to -50Tm  used was 3:1 Lane A, 
positive CAT control, lunit purified CAT (Promega): B and C; non 
transfected cells: D and E; 3j.tg pCATBasic: F and G; 3tg pCAT3-Promoter: 
H and I; 3g pCAT5. ACm: acetylated chloramphenicol, Cm: chioramphenicol. 
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C) Liposome transfection: TfX2OTm  (Promeqa) 
Liposome transfection was examined according to the manufacturer's protocol. The 
reagent TfX20Tm  was dissolved in 400tl nuclease-free water to a final concentration 
of 4pgIp.l. As with TfláOTm  several parameters known to effect the efficiency of Tfx 
20Tm reagent transfection were tested: primarily the ratio of DNA to Tfl5OTm  reagent 
and presence or absence of serum. Various DNA and liposome reagent 
concentrations (Table 3.6) were tested to alter the net charge ratio. Cells were grown 
in 24-well plates for transfection analysis and harvested 48 hours post-transfection. 
A CAT assay was performed, the result of which was analysed by TLC and the 
amount of acetylated chioramphenicol determined using densitrometry (Kodak 
Image Station, Section 2.5.12) as opposed to LSC. The advantage to using this 
method of analysis is that it allows the CAT assays to be read directly and avoids 
handling of radioactive products. The relative CAT activity (Table 3.9) from 
Tfl(2OTm transfected cells was calculated as a percentage of CAT activity determined 
from the positive CAT control in the normal manner. 
Cell death was observed using TfX20Tm  when the reagent was exposed to the cells for 
more than 4 hours. Optimum transfection (Table 3.9) of 1tg pCAT3-Promoter 
(Promega) into sheep sA80BR cell line gave 49% conversion of chloramphenicol 
to acetyl chioramphenicol when compared to the positive control using Tfr20Tm 
(Promega) reagent at a ratio of 3:1 to the pCAT3 -Promoter DNA in the absence of 
serum (Figure 3.16). Transfection of pCAT3-Promoter was attempted several 
times, full data can be found in Appendix B. 1.0, Tables B 1.9. However, this method 
proved to be unreliable as it was not possible to repeat the transfection to the same 
degree of success as shown in Table 3.9. 
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Table 3.9: Result of one transfection, carried out in triplicate, of sA80BR with 
pCAT3-Promoter (Promega) following lipofection using TfX2OTm  according to various 








(net intensity, 10) 
Cell CAT 
(net intensity, 10) 
Relative CAT 
activity (%) 
5 0.25 2:1 5.22 0.47 9.02 
0.5 2:1 0.36 6.91 
0.75 2:1 1.07 20.6 
1.0 2:1 1.76 33.81 
5 0.25 3:1 1.31 25.08 
0.5 3:1 1.41 27.02 
0.75 3:1 1.46 28.06 
1.0 3:1 2.56 49.01 
5 0.25 4:1 0.67 12.82 
0.5 4:1 1.25 23.91 
0.75 4:1 0.02 0.39 
1.0 4:1 1.21 23.18 
Note. Acetylated products from CAT assays were isolated by TLC and measured by 
densitometry (refer to Section 2.5). The density of staining was measured with regards to the 
background and the net intensity eg 5222458.16 which was abbreviated to 5.22x10 5 . 
Positive CAT was the measured acetylated product (100%) when 1 unit of purified 
chioramphenicol transferase was incubated with acetyl Coenzyme A (5mg/ml) and [ 14C] 
chioramphenicol (0.05mCi/ml). Cell CAT activity was the measured acetylated product 
isolated following a CAT assay and TLC on the sA80BR cell lysate after lipofection of 
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Fiaure 3.16:Transfection of sA80BR cell line with DCAT3-Dromoter usin 
TfX20Tm reagent. Lane A; positive control, 1 unit purified CAT; lane B; 
negative control; lanes C-F; TfX2OTm  :DNA ratio of 2:1; lanes G-J: TfX2OTm 
:DNA ratio of 3:1; lanes K-N: Tfx2OTm:DNA  ratio of 4:1. The amount of DNA 
in each transfection reaction was also controlled as; lanes C, G, K: 0.25p.g; 
lanes D, H, L: 0.5tg; lanes E, I, M; 0.75tg; lanes F, J, N; 1.0tg. ACm: 
acetylated chloramphenicol, Cm: chloramphenicol. 
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D) Liposome transfection: Effectene reagent. 
The Effectene reagent is a lipid based reagent which has been proven to efficiently 
transfect a wide variety of cell types, including primary cell lines. In contrast to 
other liposome reagents, the first step in Effectene transfection condenses the DNA 
into a compact structure that allows the Effectene reagent to form regular, uniform 
micelle structures around the condensed DNA. These micelles interact with the cell 
membrane and the DNA is transported into the cells as previously described. 
Effectene has also been designed for use in the presence of serum, which reduces the 
stress on the cells. Due to time constraints Effectene was the only transfection 
reagent to be tested on the primary cell lines derived from the Icelandic sheep breed. 
Transfection using the Effectene reagent was carried out according to the 
manufacturer's protocol for primary cells (Chapter Two, Section 2.5.7). As with 
other liposome based reagents it was necessary to optimise the charge ratio between 
the lipid component and DNA for each cell line (Table 2.2, Section 2.5.7). Cells were 
harvested 48 hours post-transfection and a CAT assay performed, the result of which 
was analysed by TLC and the amount of acetylated chloramphenicol determined 
using densitometry (Kodak Image Station, 2.5.12). In contrast to previously tested 
liposome-based reagents, no significant cell death was observed as the cells were 
exposed to Effectene during the transfection reaction. Furthermore, Effectene 
transfection gave consistent levels of detectable CAT activity and considerably less 
DNA was used for each transfection. For full details on Effectene transfection 
levels refer to Appendix B 1.0, Tables 1.1 1-1.14. 
Transfection of 1tg pCAT3-promoter into primary liver cell line, 1S120.Liv, was 
optimal when an Effectene:DNA ratio of 25:1 was used (Figure 3.17, Table 3.10). 
Under these conditions the relative CAT activity was 103 and 123% when compared 
to the positive control (Table 3.10). Effectene reagent was extremely effective at 
transiently transfecting ovine primary liver cells. 
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Table 3.10: Result of one transfection, carried out in triplicate, of lS120.Liv, grown in 
6-well plates, with pCAT3-Promoter (Promega) following lipofection using Effectene 







Positive CAT (net 
intensity, 10) 




6 0.2 10:1 4.01 0.0 0.0 
0.4 10:1 2.25 56.17 
1.0 10:1 1.09 27.29 
6 0.2 25:1 4.01 1.27 31.64 
0.4 25:1 4.3 107.33 
1.0 25:1 4.16 103.89 
6 0.2 50:1 4.01 0.39 9.75 
0.4 50:1 2.04 51.12 
1.0 50:1 1.36 34.13 
Note. Acetylated products from CAT assays were isolated by TLC and measured by 
densitometry (refer to Section 2.5). The density of staining was measured with regards to the 
background and the net intensity eg 4007509 abbreviated to 4.01x10 5 . Positive CAT was 
the measured acetylated product (100%) when 1 unit of purified chloramphenicol transferase 
was incubated with acetyl Coenzyme A (5mg/mI) and [ 14C] chloramphenicol (0.05mCi/ml). 
Cell CAT activity was the measured acetylated product isolated following a CAT assay and 
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Fiaure 3.17: Transfection of 1S120.Liv cell cultures with DCAT3-Dromtoer b 
Effectene reagent. Varying ratios of Effectene to DNA were tested. Lane A; 
positive control, 1 unit purified CAT; lane B; negative control; lanes C-F: 
Effectene: DNA ratio of 10:1; lanes G-L: Effectene: DNA ratio of 25:1; lanes 
M-R: Effectene:DNA ratio of 50:1. Amount of DNA tested was; 0.2j.tg (C, G, 
H, M, N); 0.4p.g (D, I, J, O,P); 1 .Ojig (E, F, K, L, Q, R) ACm: acetylated 
chloramphenicol, Cm: chloramphenicol. 
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The efficiency of Effectene in the transient transfection of primary ovine cerebral 
cells, IS 1 20.Cer, was also observed (Figure 3.18). Conditions for optimal 
transfection of 0.5ig pCAT3-Promoter into the cerebral cell line grown in 24-well 
plate were found to be an Effectene:DNA ratio of 10:1 (Table 3.11). Due to time 
limitations it was only possible to perform this experiment once, in duplicate. 
Table 3-11: Result of three separate transfections, carried out in duplicate, of 
lS12O.Cer cell line, grown in 24-well plates, with pCAT3-Promoter (Promega) 








(net intensity, 10) 
5 0.1 10:1 0.0 	0.0 
0.2 10:1 10.23 0.38 
0.5 10:1 13.41 	1.72 
5 0.1 25:1 0.0 0.0 
0.2 25:1 0.0 	7.42 
0.5 25:1 2.73 0.0 
5 0.1 50:1 0.0 	0.0 
0.2 50:1 0.0 0.0 
0.5 50:1 0.0 	0.0 
Note. Acetylated products from CAT assays were isolated by TLC and measured by 
densitometry (refer to Section 2.5). The density of staining was measured with regards to the 
background and the net intensity eg 1023404 which was abbreviated to 10.23x i0 5 . Cell 
CAT activity was the measured acetylated product isolated following a CAT assay and TLC 
on the 1S120.Cer cell lysate after lipofection of pCAT3-Promoter with Effectene (Qiagen). 
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Fiaure 3.18:Transfection of DCAT3-Promoter into 1S120.Cer cell line usin 
Effectene. Varying ratios of Effectene to DNA were tested in duplicate. A 
positive and negative control was not included on this plate. Lanes A-F: 
Effectene: DNA ratio of 10:1; lanes G-K: Effectene:DNA ratio of 25:1; lanes 
L-Q: Effectene: DNA ratio of 50:1. Concentrations of DNA used were: A-B, 
G-H,L-M with 0.1 jug; C-D, I-J N-O with 0.2tg; E-F, K, P-Q with 0.5tg. ACm: 
acetylated chloramphenicol, Cm: chloramphenicol. 
126 
3.5.2.4 Dendrimer technology: Superfect Transfection Reagent. 
Superfect Transfection Reagent is a specifically designed polycation, which at the 
molecular level is spherical in shape with branches radiating from a central core and 
terminating with charged amino groups (Tang et al., 1996; Tang and Szoka, 1997). 
It is believed that the Superfect Reagent assembles the DNA into compact structures 
similar to histones, and having a net positive charge the DNA-Superfect complex 
associates with negatively charged receptors on the cell membrane facilitating the 
entry of DNA into the cell. Once inside the cell, Superfect is thought to protect the 
DNA during transport to the nucleus. Superfect Reagent has been shown to 
efficiently transfect a variety of different cells lines and primary cells lines. 
As with liposome based transfection reagents, the amount of available dendrimer 
reagent will effect the formation of transfection complexes. For efficient transfection, 
the overall net charge of Superfect-DNA complex should be slightly positive to 
promote the interaction with negatively charged groups (e.g. sialylated 
glycoproteins) on the cell surface. Various schemes were used to optimise the 
charge ratio of Superfect reagent to DNA (Table 3.13). 
Table 3.12: Charge ratio of Superfect: DNA with reference to the volume of 
Superfect in each reaction for cell growing in 6-well plates. 
DNA (jtg) Charge ratio (Superfect:DNA) 
3:1 	 6:1 	 15:1 
1 3 6 15 
2 6 12 30 
3 9 18 45 
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Transfection of sA80BR cell line with pCAT5 and pCAT3 -Promoter using Superfect 
reagent was as described in Section 2.5.6. Cells were harvested 48 hours post-
transfection and a CAT assay performed, the results of which were analysed by TLC 
and the amount of acetylated chioramphenicol determined by LSC. The relative 
CAT activity (Figure 3.19, Table 3.13) from Superfect transfected cells was 
calculated as a percentage of CAT activity determined from the positive CAT control 
in the normal manner. Full data is presented in Appendix B 1.0, Table 1.10. 
Transfection of the vectors pCAT5 and pCAT3-Promoter into sA80BR cell line was 
optimal when a charge ratio of 3:1 (Superfect: DNA) was used to transfect 5g of 
reporter vector (Table 3.13). 
Table 3.13: Result of transfection of sA80BR with pCAT3-Promoter (Promega) 







Positive CAT (net 
intensity, 10) 
Cell CAT (net 
intensity,10 5 ) 
Relative CAT 
activity (%) 
9 2 a 15:1 30.93 0.0 0.00 
5a 6:1 11.11 35.90 
ba 3:1 36.01 116.43 
10 5 5  3:1 19.62 22.75 115.91 
3:1 24.85 126.60 
3:1 127.79 17.07 13.36 
2b 3:1 50.03 39.15 
Note. a  denotes transfection with the vector pCAT5 
b denotes transfection with the vector pCAT3-Promtoer 
Acetylated products from CAT assays were isolated by TLC and measured by densitometry 
(Section 2.5). The density of staining was estimated with regards to the background and 
gives the value as net intensity eg 3093140 which was abbreviated to 30.9x10 5 . Positive 
CAT was the measured acetylated product (100%) when I unit of purified chioramphenicol 
transferase was incubated with acetyl Coenzyme A (5mg/ml) and [ 14C] chloramphenicol 
(0.05mCi/ml). Cell CAT activity was the measured acetylated product isolated following a 
CAT assay and TLC on the sA80BR cell lysate after transfection of pCAT3-Promoter with 
Superfect (Qiagen Ltd, UK). 
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Figure 3.19: Transfection of sA80BR cell line with pCAT5 and pCAT3-Promoter (Promega) with Superfect reagent (Qiagen). 
Optimisation of transfection of sheep sA80BR brain cell line with pCAT5 (Appendix C) and pCAT3-Promoter (Promega) using 
Superfect reagent (Qiagen). (A): lane 1: positive control, 1 unit CAT; lane 2; 2.tg pCAT5, charge ratio of Superfect: DNA of 
15:1: lane 3; 5.tg pCAT5, charge ratio of 6:1: lane 4; 1O.tg of pCAT5, charge ratio of 3:1. (B) lane 1: positive control CAT: lane 
2; 5.tg pCAT3-Promoter, charge ratio of 3:1: lane 3: 5tg pCAT5, charge ratio of 3:1. (C) lane 1: positive control CAT; lane 2: 
1 tg pCAT3-Promoter, charge ratio of 3:1; lane 3: 2tg pCAT3-Promoter, charge ratio 3:1. ACm: acetylated chioramphenicol, 
Cm: chioramphenicol. 
3.6 Discussion. 
3.6.1 Classification of cell types present in brain-derived cell cultures. 
The ovine cell lines intended for transfection experiments were stable (sA80BR, 
pA80BR and pS8OSK) and primary cell lines (1S120.Cer and 1S120.Liv) as described in 
Sections 3.2 and 3.3. The morphology of the cells present in the stable brain cultures 
was not typically neuronal or astrocyte like (Figures 3.2 and 3.3). This is probably an 
artefact of the retroviral transformation method used to create the stable cell lines. 
Although one advantage of stable cell lines is their immortality, however it is known that 
the introduction of an oncogenic gene can alter the phenotype and/or the growth pattern 
of the transformed cell (Rous, 1970; Bishop, 1985). For example, the mouse mammary 
tumour virus (a RNA tumour virus/ retrovirus) carries an oncogenic gene within its 
genome which causes uncharacteristic growth patterns and appearance (neoplastic 
transformation) of infected mammary gland cells (Butel et al., 1977). The morphology 
of cells present in the primary brain culture 1S120.Cer (Figure 3.5) was more typical of 
neurones with long, thin processes extending from the main cell body. These cells also 
appeared to grow as a network of colonies connected by the cellular extensions. 
Prior to screening transfection methods, the use of fluorescent immuno-cytochemistry 
(F-ITC) was used to identify the cell types present in the brain cell cultures. The stable 
brain cells, sA80BR and pA80BR, were a heterogeneous culture of neuronal and glial 
cells (Figure 3.8). The primary brain cell line derived from the cerebellum of the 
Icelandic breed, Ovis brachyura borealis pall, IS 1 20.Cer appeared to be a homogenous 
culture of cells derived from neuronal tissue (Figure 3 9). All brain cell lines were 
grown in the presence of NGF. When NGF was removed from the stable cell lines, 
sA80BR and pA80BR, the growth rate slowed down but did not arrest, nor was there 
any change in morphology. The lack of requirement for NGF may be an effect of stable 
transformation and heterogeneous culture. In contrast, when NGF was removed from 
the primary cerebellum cell line, 1S120.Cer, cell growth was severely inhibited, the cells 
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appeared to shrivel and the network of cell processes was withdrawn towards colonies 
which had formed. To maintain uniformity between the brain cell cultures for future 
comparison, the presence of NGF was maintained throughout this study. 
3.6.2 Optimisation of transient transfection of ovine cell lines. 
The methods investigated are discussed below and compared in figure 3.20. Various 
methods were tested in the attempt to find a reliable transfection method for the stable 
Cheviot brain cell lines. As both sA80BR and pA80BR appeared to be similar 
morphologically and showed the same staining patterns to anti-N200 and anti-GFAP, it 
was assumed that they would also react in the same manner the various transfection 
reagents. 
3.6.2.1 Calcium DhosDhate. 
Transfection using the method of calcium phosphate precipitation has been proven by 
others to be effective for producing stable and transient expressing cells. Crucial to 
transfection using this method is the formation of a DNA precipitate which is dependent 
on the pH of the phosphate buffer (2xHEBS). The optimal pH range for transfection is 
extremely narrow: typically between 7.05 and 7.12 (Graham, et al., 1973) and during 
storage the pH of the solution may change. Furthermore the pH of the medium may 
alter to become too acidic reducing transfection efficiency by causing protein 
precipitation, noted by a colour change in the cell medium from red to orange. On 
occasion, even when conditions would appear to be optimal (i.e. DNA concentration, 
solution pH, and cell density) transfection by calcium phosphate simply does not work. 
Calcium phosphate precipitation was ineffective at transfecting sheep brain cell line 
sA80BR with pCAT3-Promoter. Both the phosphate buffer and calcium solution were 
freshly made and the pH checked to be pH 7.05. On every transfection attempt, a DNA 
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precipitate was observed to have formed confirming that the pH of the phosphate buffer 
was within the optimal range. Furthermore no cell death or colour change in the 
medium was apparent suggesting the cell medium pH was suitable for transfection by 
calcium phosphate. Calcium phosphate was therefore not used in further studies. 
3.6.2.2 Electroporation. 
The use of high voltage electric shocks for transfection of fibroblasts was first described 
by Wong and Neuman (Wong and Neumann, 1982; Neumann et al., 1982) and later 
proven to be effective for other cell types known to be resistant to calcium phosphate 
precipitation (e.g. lymphocytes, Potter et al., 1984). Disadvantages of electroporation 
include the need for specialised equipment, almost five-fold more cells and DNA than 
the calcium phosphate method and the high rate of cell death. The critical parameters 
for electroporation are maximum voltage of the shock and the duration of the current 
pulse (capacitance) which must be optimised for each cell type. The electroporation 
buffer may also affect transfection efficiency. Low-resistance buffers (high salt, e.g. 
HeBS) may require high voltages and sensitive cells may prefer electroporation in tissue 
culture medium though it has been shown that magnesium and calcium ions in the 
medium lower electroporation efficiency (Neumann et al., 1982). It is known, however, 
that some cell lines will transfect poorly under standard conditions. 
Under the conditions used (Table 3.3) electroporation was ineffective for transient 
transfection of the CAT reporter gene, pCAT5, into the sheep cell line sA80BR. There 
was no difference in the efficiency of transfection when either PBS or HeBS was used as 
the electroporation buffer. Electroporation of cells resuspended in culture medium was 
not tested. Significant cell death was recorded with all conditions tested. 
Electroporation of sA80BR cell line may have been possible using further combinations 
of high voltage/ low capacitance or low voltage/ high capacitance however the 
procedure was lengthy and expensive in term of resources used. A decision was 
therefore taken to discontinue testing this method of transfection. 
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3.6.2.3 Lipofection. 
The commercially available Dosper (Roche Diagnostics, UK), TfX20Tm and TfX5OTm 
(Promega, UK) and Effectene (Qiagen, UK) liposome-based transfection reagents were 
tested for their ability to transfect pCAT3-Promoter into sheep brain cell line sA80BR 
(Section 3.5.2.3). Dopser reagent did not efficiently transfect sheep sA80BR or mouse 
N2a cell lines with pCAT3-promoter. The active lipid in Dosper is 1 ,3-Di-Oleoyloxy-
2-(6-Carboxy-spermyl)-propylamid which may have been unable to form functional 
micelles with the pCAT3-Promter or the micelles which were formed were not 
efficiently absorbed by the cells. Alternatively proteins present in the cell medium may 
have been competing with the DNA for the positively charged chain on the lipids and 
thus reducing transfection efficiency. Liposome reagents TfX50Tm and Tfx20Tm 
(Promega, UK) showed limited efficiency for the transfection of pCAT3-Promoter to 
ovine brain cell line sA80BR in the absence of serum and were toxic to the cells, 3-30% 
and 10-50% respectively (Figure 3.20). However the Tfx reagents (a mixture of the 
synthetic lipid N,N,N' ,N' -tetramethly-N,N ' -bis(2-hydroxyethyl)-2,3 -di(oleoyloxy)- 1,4-
butanediammonium iodide and DOPE) had poor reproducibility between transfection 
experiments. This may be primarily due to the fact that the shape and size of the 
micelles which form in each reaction will vary slightly and so alter the rate and 
efficiency of DNA uptake into the cell. 
In contrast to other liposome based reagents, Effectene (Qiagene, UK) uses a DNA 
enhancer to improve transfection efficiency. The enhancer functions to condense the 
transfected DNA into a compact structure with which the lipids freely interact to form 
regular micelles. Thus eliminating the possibility of size, charge and shape irregularities 
between transfection reaction. Effectene reagent was efficient in transfecting primary 
liver (IS 120.Liv) and brain cell lines (Is 120.Cer) derived from the Icelandic sheep 
(Tables 3.10 and 3.11, Figure 3.20). Effectene reagent was also not toxic to the cells in 
the presence of serum or antibiotic, and significantly less DNA was required to transfect 
with cell lines to achieve high levels of CAT expression. 
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With all liposome based transfection reagents the health of the cells is vital to 
transfection. A reduced transfection efficiency was observed with cells of high passage 
number. Cell lines of low passage number were therefore used in later transient 
expression studies. 
3.6.2.4 Dendrimer technology. 
Superfect transfection reagent (Qiagen, UK) has only been commercially available 
since 1997 but is similar to Effectene in that it functions to condense the transfected 
DNA into regular sized vessels which are easily and efficiently adsorbed into the cell. 
As with liposmes the charge ration of the polycation dendrimer and DNA must be 
optimised for efficient transfection (Tang etal., 1996; Tang and Szoka, 1997). However 
the advantages of Superfect over liposome reagents include: the presence of serum 
actually increases transfection efficiency, antibiotics do not effect Superfect function, 
and reproducibility is good if cell density at time of transfection is consistent. Superfect 
reagent was efficient in transfecting pCAT3-Promoter into sheep brain cell line sA80BR 
with 40-80% efficiency (Section 3.5.2.4 and Figure 3.20). Optimal transfection was 
observed with increased DNA amount (5 pjg) and a charge ratio of 3:1 (Table 3.14). 
During use of Superfect reagent, no cell death was observed. Superfect reagent was 
proven to be the most efficient transfection reagent for ovine brain cell line sA80BR and 
as such was used for further transient expression studies of the CAT-PrP 3 'UTR vectors 
(Chapter Four) and PrP mini-gene vectors (Chapter Five). 
A comparison of all the method used to develop a transfection method for the immortal 
sheep cell lines is shown in Figure 3.20. 
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Transient expression of CAT reporter gene in cell line 













Calcium 	Electro- 	Dosper 	Tfx50 	Tfx50 	Tfx2O 	Superfect 
Phosphate 	poration (+serum) (- serum) (-serum) 
Transfection 
I Calcium phosphate 	 El Electroporation 
Dosper (Roche Diagnostics) 	0  Tfx50 (Promega), serum present 
0 Tfx5O (Promega), serum free 0 Tfx20 (Promega), serum free 
IN Superfect (Qiagen) 
Figure 3.20: Summary of transfection efficiencies of CAT reDorter aene b 
various methods in cell line sA80BR. Ovine brain cell lines sA80BR was 
optimally transfected with pCAT3-promoter by Superfect transfection reagent 
(Qiagen Ltd, UK). See Appendix B for full data. SEM shown. High variability in 
Superfect CAT activity is due to low level of expression when low amounts of 
DNA were used as part of the optimisation screening. 
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Chapter 4: Transient Expression of CAT Reporter 
Genes in Various Ovine Cell Lines and the Function of 
the PrP 3'UTR. 
4.1 Introduction. 
The term gene expression commonly refers to the entire process of DNA 
transcription, RNA processing and mRNA translation into protein. Regulation at 
any stage in this process could lead to differential gene expression. Control over 
gene expression allows for a cellular response to external stimuli or the execution of 
developmental pathways, ensuring the correct genes are activated at the correct time 
(spatial and temporal control). Maturation of 5' capped mRNA requires two primary 
steps: 1) cleavage and polyadenylation at the 3' end and 2) ligation of exons 
(splicing). In eukaryotes, RNA processing can control gene expression by on- off 
regulation, exon splicing, or alternative cleavage and polyadenylation at polyA sites 
(Chapter one, Section 1.10; Zhao et al., 1999). Such alternative processing pathways 
are often regulated in a cell type-specific manner. 
Post-transcriptional control of gene expression is mostly mediated through the 
untranslated regions. Secondary structures and protein binding motifs present in the 
5' region have been shown to influence translation initiation and efficiency (Dever, 
1999). Initially the 3'UTR was considered to function only to control 
polyadenylation of the maturing mRNA for export into the cytoplasm for translation, 
with the length of the poly (A) tail determining the stability of the mRNA. In the 
absence of efficient polyadenylation, the pre-mRNA molecule will be degraded 
before translation. For example, autoregulation of the snRNP protein U1A prevents 
wasteful synthesis of the U1A protein when the U  snRNP splicing machinery is not 
required (Gunderson et al., 1994). However, investigations have shown that further 
sequences and structures within the 3 'UTR are also capable of effecting stability, 
location and translation efficiency of mRNA and hence controlling gene expression 
(Chapter 1, Section 1.10). 
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The stability of an mRNA is a function of its synthesis and the rate of degradation 
(review Ross, 1995). The stability of an mRNA also determines how tightly the rate 
of synthesis of the encoded protein can be controlled. Many short-lived mRNA 
transcripts contain multiple, often overlapping AUUUA sequences within their 
3'UTRs (Shaw and Kamen, 1986; Fan et al., 1997). The mechanism by which these 
sequences function is not yet understood. In several cases, the rate of degradation is 
also regulated by RNA-protein interactions in the 3'UTR. Expression of the 
transferrin receptor is regulated by the intracellular iron concentration through iron-
response element (IRE) located within the 3 'UTR: a drop in iron concentration 
stabilises Tfr mRNA and promotes synthesis of the Tfr protein (Roa et al., 1986). 
In mammalian cells translational control via the 5' UTR is well documented however 
little is known of the function of the 3'UTR during translation. From studies in 
yeast, an interaction between the poly(A) tail and a cytoplasmic poly(A) binding 
protein (PABP) may influence translation efficiency (Sachs et al., 1986). 
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4.1.1 Protein levels mediated by the ovine PrP 3'UTR. 
As discussed in Chapter 1 (Section 1.10), controlling the process of cleavage/ 
polyadenylation may regulate the amount of protein synthesised. One method 
frequently used to determine DNA sequences vital to gene expression involves 
constructing reporter vectors with deletions in the flanking region of interest i.e. 
promoter regions, 5' or 3' UTRs or introns. Assaying for in vitro expression of the 
reporter gene determines if inserted DNA sequences stimulate or inhibit expression 
of the reporter vector compared to a control expressing a bacterial gene. Using this 
method of analysis the ovine PrP 3'UTR was the subject for a previous Ph.D. project 
at the NPU (Cheung, 1996). The PrP 3 'UTR fragment used for the CAT analysis 
work was originally cloned from a Suffolk sheep with the PrP allele A 1 36R154Q 171 
(Goldmann et al., 1991a). Previous analysis of the cloned PrP 3'UTR by RFLP has 
shown it to it to be from an el allele. Deletions were made in the PrP 3'UTR (Figure 
4.1) inserted downstream of the reporter gene chloramphenicol transferase (CAT) 
and used in a series of transient transfection experiments in a mouse N2a cell line 
(Cheung, 1996). As the only differences between the constructs lay in the 3'UTR, 
the assumption was made that the level of measured CAT activity was a direct result 
of the influence of PrP 3 'UTR sequence inserted into the reporter vector. If the level 
of CAT activity decreases when a region of 3' UTR has been removed, it can be 
considered that the deleted sequence was essential for expression. Conversely, if the 
CAT activity rises the deleted sequence may have an inhibitory effect. 
In the previous work by Cheung (1996) the CAT constructs included two which 
resembled the in vivo PrP mRNA 3'UTR sequences (Hunter et al., 1994; Goldmann 
et al., 1999) with a UTR of 3.2 kb (as found on 4.6 PrP mRNA) and 0.7kb (the 
2.1kb PrP mRNA). In vitro expression in mouse N2a cells of CATPrP-3 'UTR 
vectors showed that sequences within the 3 'UTR had an inhibitory effect on levels of 
CAT protein produced (Cheung, 1996; Goldmann et al., 1999). Interestingly the 
constructs pEYR and pD 17 which resemble the in vivo PrP transcripts (mRNAs 
4.6kb and 2.1kb respectively) produced amongst the lowest CAT activities. 
Mutating the sequence ATTAAA 1523 to TATAAAI523 in both pEYR and pDl7 
caused a 60% decrease in detectable CAT activity suggesting very low in vitro 
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expression of CAT in the presence of the full length PrP 3 'UTR. Further studies by 
Cheung (1996) comparing the amount of RNA transcribed in vitro (cell free system 
and N2a cells) from the constructs pEYR, pD36(Figure 4. 1), and the CAT control 
(pCAT3-Promoter, Promega Ltd, UK) judged by semi-quantitative RT-PCR 
analysis, showed no significant difference in the level of mRNA produced from the 
vectors over the 48 hour transfection period. In contrast, the level of CAT activity 
detected for constructs pEYR, pD36 and the CAT control was 12.4%, 44.9% and 
100% respectively. Taken together, Cheung's results suggested that the 3'UTR may 
be acting to control PrP gene expression. 
The aim of this chapter was to investigate the role of the ovine PrP 3' UTR in 
controlling expression of the CAT gene with regards to sheep tissue specificity and 
PrP genotype. The chimeric CAT-PrP 3'UTR vectors were transiently expressed in 
transformed Cheviot foetal brain cell lines with PrP genotypes VV 136RR154QQ 171 
(susceptible) and AA 136RR154RQ 171 (resistant). The level of expression from the 
CAT-PrP 3'UTR vectors was also assayed in cerebellum and liver cell line from the 
Icelandic sheep breed, Ovis brachyura borealis pall, which had a susceptible 
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Figure 4.1: Chimeric CAT/PrP-3'UTR constructs. A series of CAT reporter vectors were created by Cheung 
(1996) containing the sheep PrP 3'UTR cloned downstream of the CAT ORF. Deletions were made within the 
3'UTR region and CAT expression studied in mouse N2a cells (Cheung, 1996, Goldmann, 1999). These vectors 
have now been transiently expressed in sheep cell lines from various tissue origins and PrP genotypes. 
SV40promoter region = CAT coding region fl Ovine PrP 3'UTR LI  Ovine PrP coding region 
Ovine specific PrP 3'UTR sequence - Conserved polyadenylation signal 	Deletion 
Table 4.1: Structural properties of the UTR in chimeric CAT/PrP-3'UTR vectors. 









pEYR 3.2 A-G 5 5 
pD17 0.7 A-C 0 1 
pD20 2.1 E-G 4 4 
pD27 1.4 F-G 3 1 
pD34 1.1 f-G 3 1 
pD36 0.5 f-G 2 1 
PCAT3- 0.9 n/a * 1 
Promoter 
Note. Refer to Figure 4.1 and Cheung (1996) Goldmann et al.(1999) 
*No ATTTA consensus sequence 
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4.2 PrP 3'UTR: Translational Control of the CAT ReDorter Gene 
in Ovine Brain-derived Cell Lines of Susceptible and Resistant 
PrP Genotvoe. 
4.2.1 Experimental approach. 
The aim of this section was to investigate whether or not sequences within the PrP 
3'UTR displayed control over expression of the CAT gene in brain cell lines derived 
from NPU Cheviot sheep of scrapie susceptible (cell line sA80BR, 
VV136RR1 54QQ171)  and resistant 1pA80BR, AA136RR145QR17 1)  PrP genotype. 
Chimeric CAT! PrP -3'UTR plasmids (Cheung, 1996, Figure 4.1) were transiently 
transfected by Superfect reagent (Qiagen) into the brain cell lines using the method. 
discussed in Chapter 3. For each experiment approximately 2x 1 07  cell were 
recovered from a single well of a 6-well plate. Transfection efficiency was 
controlled for by co-transfecting with pSV--galactosidase and the relative CAT 
activity recorded from each expression vector was proportioned to the level of CAT 
activity from pCAT3-Promoter (Promega) which was assumed to be 100%. The 
results of the CAT assays were analysed by TLC and the amount of acetylated 
product was measured by LSC directly from the TLC plate or by densometric 
reading of the autoradiograph using a Kodak Image Station (Chapter 2, Section 
2.5.12). Throughout the study, the cells appeared to remain healthy and no change in 
growth pattern was observed. A full record of data obtained can be found in 
Appendix B, Sections B 2.1-2.2. Typical autoradiographic films developed for each 
of the cell lines are shown in Figure 4.2A and 4.213. 
4.2.2 Results and analysis. Comparative transient expression studies of 
chimeric CAT-PrP 3'UTR in brain cell lines sA80BR and pA80BR. 
4.2.2.1 Results. 
The collected results from the five assays performed in cell line sA80BR are shown 
in Figure 4.3A and the seven assays performed in cell line pA80BR in Figure 4.313. 
The data presented in Table 4.2 and 4.3 shows results of statistical analysis 
completed on the transformed CAT measurements recorded for both cell lines. 
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Figure 4.2 A:Transient expression of chimeric CAT-PrP 3'UTR plasmids in cell line sA80BR. 
Products from CAT transfection experiments were separated by TLC and the acetylated product was isolated and 
quantified by scintillation counting. The assay positive control containedi unit of purified CAT enzyme (Promega), negative 
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Figure 4.2 B:Transient expression of chimeric CAT-PrP 3'UTR plasmids in cell line pA80BR. 
Products from CAT transfection experiments were separated by TLC (section 2) and the acetylated product was 
isolated and quantified by scintillation counting. The assay positive control contained I unit of purified CAT enzyme 
(Promega), negative control contained 0.25 M Tris and [ 14C]chloramphenicol only ACm: acetylated chioramphenicol, 
Cm: chioramphenicol. 
Observed CAT activity in cell line sA80BR following five separate transient transfection of 
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CAT expression vectors 
Figure 4.3 A: Relative CAT activity (%) measured in cell lines sA80BR. 
TransientCAT expression of chimeric CAT-PrP 3'UTR plasmids in ovine cell lines derived from Cheviot brain cell line 
sA80BR (PrP genotype W136RR 1 54QQ171). The amount of acetylated chloramphenicol product was measured for each 
CAT/PrP-3'UTR vector and calculated as a percentage of the vector pCAT3-Promoter (100%) for each transfection 
experiments. The results were plotted on the log e scale as the level of detectable CAT activity from separate transfection 
experiments varied in magnitude. 
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Observed CAT activity in cell line pA80BR following seven separate transient transfection of 







pEYR 	pD17 	pD20 	pD27 	pD34 	pD36 	pCAT3-Promter 
CAT expression vectors 
Figure 4.3 B: Relative CAT activity (%) measured in cell lines pA80BR. 
Transient CAT expression of chimeric CAT-PrP 3'UTR plasmids in ovine cell lines derived from Cheviot brain cell line 
pA80BR (PrP genotype AA l RRl54QR171 ). The amount of acetylated chloramphenicol product was measured for each 
CAT/PrP- 3'UTR vector and calculated as a percentage of the vector pCAT3-Promoter (100%) for each transfection 
experiments. The results were plotted on the loge  scale as the level of detectable CAT activity from separate transfection 
experiments varied in magnitude. 
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Table 4.2 Statistical analysis of expression from CAT/PrP-3'UTR constructs 
in cell lines sA80BR and pA80BR. 
Constructs for 	 Cell line 
comparison sA80BR (p =:!~ ) 	pA80BR (p:!~ ) 
p17 with pEYR 0.42 0.97 
p 20 with pEYR 0.14 0.96 
p27 with pEYR 0.1 0.37 
p34 with pEYR 0.02 0.05 
p36 with pEYR 0.52 0.55 
pEYR with pDl7 0.99 0.97 
pD17 with pD20 0.1 0.95 
pD20 with pD27 0.63 0.41 
pD27 with pD34 0.03 0.21 
pD34 with pD36 0.15 0.08 
Note. In rows 1-5, the mean CAT activity recorded for each construct was compared against 
the CAT activity from pEYR (resembling in vivo 4.6kb PrP mRNA 3'UTR). In rows 6-10 
the significance of the change in CAT expression as sequential deletions were introduced 
into the 3'UTR is considered. Analysis was completed by a t-test on the transformed data, 
please refer to Appendix B, Section B 2.2.1 . For sA80BR and pA80BR the degrees of 
freedom were 8 and 11 respectively. 
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Table 4.3 Comparison of expression from CAT/PrP-3'UTR constructs in cell 
lines sA80BR and pA8013R. 
	
Constructs for 	Between cell lines sA80BR and pA80BR 
comparison (o=<) 
PEYR 	 0.57 
pDl7 	 0.52 
pD2O 	 0.26 
pD27 	 0.54 
pD34 	 0.93 
p036 	 0.91 
PEYR with pDl7 	 0.54 
p017 with pD20 	 083 
pD20 with pD27 	 0.36 
pD27 with pD34 	 0.74 
pD34 with p036 	 0.98 
Note. In rows 1-5, the mean CAT activity recorded for each construct was compared against 
equivalent expression in each cell line. In rows 6-10 the significance of the change in CAT 
expression as sequential deletions were introduced into the 3 'UTR is considered. Analysis 
was completed by a t-test on the transformed data, please refer to Appendix B, Section B 
2.2.1. The degrees of freedom were 10. 
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4.2.2.2 Analysis. 
Independent transient transfections of ovine brain cell lines derived from scrapie 
resistant and scrapie susceptible PrP genotypes were completed with the chimeric 
CAT/PrP-3'UTR constructs (Figure 4.1). In both cell lines, the CAT activity 
recorded between experiments varied by an order of magnitude. To allow for 
statistical analysis, the value for CAT activity (% CAT) was transformed on to the 
loge scale (Snedecor and Cochran, 1967). Before Students t-test was completed on 
the transformed data, the level of variance between experiments was examined for 
significance using Analysis of Variants (ANOVA) (full explanation and working in 
Appendix B, Section B 2.5). In summary, ANOVA confirmed that variance did 
occur between transfection experiments but, importantly, that this variance was not 
significant in terms of in vitro expression of the plasmids. This means that although 
there was a great deal of variation in the overall magnitudes of the standardised CAT 
results between experiments, the pattern of relative differences in expression from 
the series of plasmids was consistent across all experiments. Further analysis was 
carried out using a t-test on the probability that the 3 'UTR sequence present in the 
CATIPrP-3 UTR constructs influenced the level of detectable CAT activity (Table 
4.3). 
As observed in mouse N2a cell line (Cheung, 1996; Goldmann et al., 1999), in vitro 
expression of constructs pEYR and pDl7 (resembling 3'UTRs of in vivo PrP 
mRNA) was lower than the other plasmids. In both cell lines, an increase in the level 
of detectable CAT activity was observed as deletions were introduced into the PrP 
3 'UTR sequence in the 5' to 3' direction. For the sA80BR cell line this increase was 
observed to begin when sequence upstream of 3'UTR nucleotide (nt) position 2000 
had been deleted (construct pD20) and continued to increase, peaking at a deletion 
up to nt 3400 (pD34) (Figure 4.2A). Although the difference in mean CAT 
expression between pEYR and pD20 was not significant (Table 4.2, p=0. 14), the 
figures do support a tendency for increased expression from constructs pD20 to 
pD34 (Table 4.2, rows 1-6). For the pA80BR cell line, an increase in CAT activity 
was observed after deletion of sequence upstream of nt position 2700 (pD27, Figure 
4.2B). However, this increase in detectable CAT activity was not significantly 
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different to the wild type construct pEYR (Table 4.2). As observed in sA80BR, CAT 
activity peaked in pA80BR with construct pD34 (p= 0.05). A direct comparison of 
expression from the CATIPrP-3'UTR constructs in the two cell lines reveals no 
significant difference (Table 4.3). 
An alternative explanation for the observed difference in CAT gene expression 
between the sA80BR and pA80BR cell line is the efficiency of the transformation 
process. As described in Chapter Three, Section 3.2, the Cheviot cell lines were 
immortalised by transformation with the Moloney murine leukaemia virus. The 
nature of retroviruses allows integration of the viral genome into the host genome by 
illegitimate recombination where the viral genome has no sequence homology with 
the insert site. Consequently the two cell lines sA80BR and pA80BR will be 
transformed differently which may give rise to differences in efficient gene 
expression and control. However, similarities in CAT expression were observed 
between the stable and primary cell lines as described in Section 4.3 which argues 
against any effect on gene expression in the Cheviot cell lines which may be 
attributed to the transformation process. 
4.3 Translational Control of the CAT Reporter Gene Constructs 
in Ovine Neuronal and Peripheral Cell Lines. 
4.3.1 Experimental approach. 
The aim of this Section was to evaluate the role of sequences within the sheep PrP 
3'UTR in controlling transient expression of CAT in ovine cell lines derived from 
neuronal and peripheral tissues. At the start of this study, the intention was to 
compare CAT expression in the stable brain cell lines to similar transfections in skin 
derived cell lines. However, as discussed in Chapter Three, several problems were 
encountered in the growing and transfection of the skin cells and they were 
discounted from this particular study. As an alternative, the primary cell lines 
(Chapter Three) derived by Dr Gerard O'Neill from cerebellum (designated 
15120.Cer) and liver (designated 15120.Liv) tissues from the Icelandic sheep 
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(genotype AA 136RR154QQ 171 which is scrapie susceptible in this breed) were used. 
Chimeric CAT! PrP -3 'UTR plasmids (Cheung, 1996, Figure 4.1) were transiently 
transfected by Effectene reagent (Qiagen) into the primary cell lines using the 
method discussed in Chapter Three and Chapter Two, Section 2.5. For each 
experiment approximately 2x1 07  cell were recovered from a single well of a 6-well 
plate. As before, transfection efficiency was controlled for by co-transfecting with 
pSV-3-galactosidase and the relative CAT activity recorded from each expression 
vector standardised against the level of CAT activity from pCAT3-Promoter 
(Promega) which was assumed to be 100%. The results of the CAT assays were as 
previously described (Chapter Two, Section 2.5.12). Throughout the study, the cells 
appeared to remain healthy and no change in growth pattern was observed. A full 
record of data obtained can be found in Appendix B, Sections B2.3 and 2.4. Typical 
autoradiographic films developed for each of the cell lines are shown in Figures 4.4A 
and 4.413. 
4.3.2 Results and analysis. Comparative transient expression studies of 
chimeric CAT-PrP 3'UTR constructs in cell lines 1S120.Cer and 1S120.Liv.. 
4.3.2.1 Results. 
The collected results from the six assays in cell line 1S120.Cer are in Figure 4.5A and 
the five assays in cell line ISl2O.Liv in Figure 4.5B. The data presented in Tables 
4.4 and 4.5 shows results of statistical analysis completed on the transformed CAT 
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Figure 4.4A: Transient expression of chimeric CAT-PrP 3'UTR plasmids in cell line 1S120.Cer. Products 
from CAT transfection experiments were separated by TLC and the acetylated product isolated and 
quantified by scintillation counting. Typical autorad from one separate transfection is shown. The assay 
positive control contained 1 unit of purified CAT enzyme (Promega), negative control contained 0.25 M Tris 
1-ICI and [ 14C]chloramphenicol only; ACm: acetylated chloramphenicol, Cm: chloramphenicol. 
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Figure 4.4 B: Transient expression of chimeric CAT-PrP 3'UTR plasm ids in cell line 1S120.Liv. Products from CAT transfection 
experiments were separated by TLC (section 2) and the acetylated product was isolated and quantified by scintillation counting. 
Typical autorad from one transfection is shown. The assay positive control contained 1 unit of purified CAT enzyme (Promega), 
negative control contained 0.25 M Tris HCI and [' 4C] chloramphenicol only. ACm: acetylated chloramphenicol, Cm: 
chloramphenicol. 
Observed CAT activity in cell line 1S120.Cer following five separate transient transfection 
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Figure 4.5 A: Relative CAT activity (%) measured in cell line 1S120.Cer Transient expression of chimeric CAT-PrP 3'UTR 
plasmids in ovine cell lines derived from cerebellum tissue (cell line lS12O.Cer) from the Icelandic sheep breed Ovis 
brachyura borealis pal! (genotype M1 RR 1 QQ171 .) Relative CAT activity was calculated by the amount of acetylated 
chioramphenicol produced in each CAT assay with regard to pCAT3-Promoter (100%) and plotted on the log e scale. 
Observed CAT activity in cell line 1S120.Liv following six separate transient transfections 
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Figure 4.5 B: Relative CAT activity (%) measured in cell line lS12O.Liv . -Transient expression of chimeric CAT-PrP 
3'UTR plasmids in ovine cell lines derived from liver tissue (cell line lS12O.Liv) from the Icelandic sheep breed Ovis 
brachyura borealis pall (genotype AA 1 RR 1 QQ171 .) Relative CAT activity was calculated by the amount of 
acetylated chloramphenicol produced in each CAT assay with regard to pCAT3-Promoter (100%) and plotted on the 
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Table 4.4: Statistical analysis of expression from CAT/PrP-3'UTR constructs 
in cell lines 1S120.Cer and 1S120.Liv. 
Constructs for 	 Cell line 
comparison lS120. Cer  (p=:!~) 	IS1 20. Liv(p=:!~-) 
p17 with pEYR 0.35. 0.73 
p 20 with pEYR 0.53 0.3 
p27 with pEYR 0.12 0.19 
p34 with pEYR 0.06 0.09 
p36 with pEYR 0.05 0.12 
PEYR with pD17 0.73 0.73 
pD17 with pD20 0.96 0.3 
pD20 with pD27 0.02 0.36 
pD27 with pD34 0.7 0.53 
pD34 with pD36 0.9 0.12 
Note. In rows 1-5, the mean CAT activity recorded for each construct was compared against 
the CAT activity from pEYR (resembling in vivo 4.6kb PrP mRNA 3'UTR). In rows 6-10 
the significance of the change in CAT expression as sequential deletions were introduced 
into the 3'UTR is considered. Analysis was completed by a t-test on the transformed data, 
please refer to Appendix B, Table B 2.4.14.6. For 1S120.Cer and 1S120.Liv the degrees of 
freedom were 5 and 4 respectively. 
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Table 4.5: Comparison of expression from CAT/PrP-3'UTR constructs in cell 
lines 1S120.Cer and 1S120.Liv. 








PEYR with pD17 0.75 
pD17 with pD20 0.55 
pD20 with pD27 0.55 
pD27 with pD34 0.56 
PD34 with pD36 0.18 
Note. In rows 1-5, the mean CAT activity recorded for each construct was compared against 
equivalent expression in each cell line. In rows 6-10 the significance of the change in CAT 
expression as sequential deletions were introduced into the 3'UTR is considered. Analysis 
was completed by a t-test on the transformed data, please refer to Appendix B, Table B 2.4.6 
The degree of freedom were 9. 
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4.3.2.2 Analysis. 
Independent transient transfections with the chimeric CAT/PrP- 3' UTR constructs 
were completed in primary cell lines derived from brain and liver tissue from the 
Icelandic sheep to investigate the role of the 3'UTR in gene expression and tissue 
specificity. As described in Section 4.2.2, the CAT data tended to vary in magnitude 
between experiments. For statistical analysis on the calculated relative CAT activty 
(%) was transformed onto the loge scale and ANOVA completed (Appendix B, 
Section 2.5). ANOVA showed that again transfection efficiency did not effect the 
expression of the transfected plasmids and that the pattern of variation between the 
plasmids themselves was consistent and significant. Further analysis on the 
standardised data was completed using t-test (Tables 4.4 and 4.5). 
In both cell lines expression from the constructs resembling the in vivo PrP mRNA 
3' UTRs (pEYR and pD 17) was lower than the remaining constructs, with the 
exception of pD20 in the cerebellum cell line (Figure 4.5A). As before, the level of 
detectable CAT activity from the constructs the 3 'UTR deletions increased when 
compared to pEYR. For 1S120.Cer this increase began sharply when sequence 
upstream of 3 'UTR nucleotide (nt) position 2700 had been deleted (construct pD27), 
and remained high with deletions up to nt 3600 (constructs pD34 and pD36, p= 
:!~0.06 and 0.05 respectively, Table 4.4, Figure 4.5A). Furthermore in 1S120.Cer, the 
largest and most significant increase in CAT activity was detected between construct 
pD20 and pD27 (p=:!~0.02,  Table 4.4). For 1S120.Liv a steady increase in CAT 
activity was observed during sequential deletion of the 3'UTR, peaking with a 
deletion upto nt position 3400 (construct pD34, Figure 4.513). Expression of the 
CAT/PrP-3'UTR constructs in 1S120.Liv did not reveal significant CAT from any 
one construct on comparison with pEYR. A direct comparison of expression from 
the CAT/PrP-3 'UTR constructs in the two cell lines did show a tendency for the 
level of CAT expression from pD20 to be lower in IS 1 20.Cer compared with 
IS I 20.Liv, although this was not highly significant (p=:! ~0.08, Table 4.5). 
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4.4 Comparison of Transient Expression Chimeric CAT-PrP 
3'UTR Plasmids in Mouse and Sheer) Derived Cell Lines. 
4.4.1 Introduction 
To identify a sheep specific regulatory region within the PrP 3'UTR which may 
influence gene expression a comparison was made between the published CAT/PrP-
3'UTR data in the mouse N2a cell line (Goldmann etal., 1999) and the sheep tissue-
derived cell lines. In all experiments, expression of CAT from the experimental 
plasmids was standardised against the level of CAT from the control plasmid 
pCAT3-Promoter (Promega Ltd, UK), which was assumed to be 100% on each 
occasion, and the relative CAT activity calculated. For the purpose of this 
comparison, the previously published CAT data in mouse N2a cell was standardised 
on the loge scale and the mean CAT activities from each cell line plotted. A 
comparison between the mean CAT activity in all cell lines was completed (Figure 
4.6, Table 4.6). Also considered was a comparison of CAT/PrP-3'UTR constructs 
expressed in the stable and primary brain cell lines (Table 4.7). 
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Comparison of the mean CAT activity following transient expression of chimeric CAT- 
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Figure 4.6. A comparative study of the mean transient CAT expression levels from chimeric CAT-PrP/3'UTR 
plasmids in ovine immortal (sA80BR and pA80BR) and primary (1S120.Cer and 1S120.Liv) cell lines with the 
published data from a mouse N2a cell line (Goldmann et a!, 1999) 
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Table 4.6 Statistical analysis of expression from CAT/PrP-3'UTR constructs in cell 
lines sheep cell lines compared with mouse N2a cell line (Goldmann et al., 1999). 
Constructs expressed in Comparative Expression in cell line (p:! ~) 
N2a cells sA80BR 	pA80BR lS12O.Cer lS12O.Liv 
pEYR 0.31 0.47 0.72 0.49 
pD17 0.25 0.47 0.57 0.65 
pD20 0.006 0.51 0.13 0.009 
pD27 0.67 0.97 0.54 0.41 
pD34 0.81 0.83 0.64 0.75 
pD36 0.33 0.29 0.62 0.93 
Note. The significance of the change in CAT expression in the sheep cell lines compared to 
the mouse N2a cell lines as sequential deletions were introduced into the 3 'UTR is 
considered. Analysis was completed by a t-test on the transformed data summarised in 
Appendix B, Tables 2.2.7 and 2.4.6. Mouse data presented in Goldmann et al., 1999 and 
provided by Dr Gerard O'Neill for analysis. 
Table 4.7 Statistical analysis of expression from CAT/PrP-3'UTR constructs in 
stable Cheviot brain cell lines 5A80BR and pA80BR compared with the primary 
cerebellum cell line, 1S120.Cer. 
Constructs expressed in 
1S120.Cer cells 	Comparative Expression in cell line (p:! ~) 
5A80BR 	 pA80BR 
pEYR 0.31 0.58 
pD17 0.36 0.84 
pD 20 0.01 0.79 
pD27 0.77 0.41 
pD34 0.008 0.27 
pD36 0.016 0.16 
Note. The significance of the change in CAT expression in the stable cheviot-brain cell lines 
compared to the primary sheep-cerebellum cell line as sequential deletions were introduced 
into the 3'UTR is considered. Analysis was completed by a t-test on the transformed data 
summarised in Appendix B, Tables 2.2.7 and 2.4.6. 
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4.4.2 Results. 
4.4.2.1 Effect of tissue origin. 
The standardised mean CAT activity measured from transient expression of plasmids 
pEYR (in vivo 4.6kb PrP mRNA 3'UTR, Figure 4.1) and pDl7 (in vivo 2.1kb PrP 
mRNA 3'UTR) in mouse N2a cell was not statistically different on comparison with 
1S120.Liv, 1S120.Cer and pA80BR cell lines. There was a tendency for expression 
of pEYR and pDl7 to be lower in CAT activity in sA8OBR cell line compared to 
N2a (Figure 4.6). However, due to the large standard variation observed for pEYR 
and pD 17 expression in sA80BR this difference in not significant (Table 4.6). No 
significant difference in transient CAT expression was observed from plasmids with 
PrP- 3 'UTR sequence in either the pA80BR or the IS 1 20.Cer cell line compared with 
the N2a cell lines. In contrast, the mean value of CAT measured from construct 
pD20 was significant higher in both sA80BR and 1S120.Liv compared with 
equivalent expression in N2a cells (p=:! ~0.006 and 0.009 respectively, Table 4.6). 
4.4.2.2 Effect of stable or primary cell lines. 
There was no significant difference in expression from any of the constructs between 
cell line 1S120.Cer and cell line pA80BR (Table 4.7). However, deleting sequence 
upstream of nt positions 2000 (pD20) and 3400 (pD34) lead to significantly higher 
CAT expression in sA80BR cell lines compared with 1S120.Cer (p=:!W.Ol and 0.008 
respectively Figure 4.6 and Table 4.7). In contrast a deletion upto nt position 3600 
resulted in significantly lower CAT expression in sA80BR compared with 15120.Cer 
(p=:!~0.016, Figure 4.6 and Table 4.7). 
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4.6 Discussion. 
4.6.1 Effect of the Ovine PiP genotype on in vitro CAT-PiP 3'UTR 
Expression 
Transient transfection experiments show that the amount of detectable CAT protein 
can be controlled by presence of particular 3'UTR sequence of the ovine PrP gene. 
Interestingly there was no significant difference in CAT expression from CAT/PrP-
3'UTR constructs which resembled the in vivo PrP mRNAs (pEYR and pDl7, 
Figures 4. 1, Tables 4.3, 4.5, 4.6 and 4.7). In general, an increase in CAT activity 
was observed as deletions were introduced in the 5' to 3' direction (Figures 4.3 and 
4.5). This may be suggestive of increasing efficiency of transcription/ translation as 
the transcripts become shorter, allowing for quicker processing -and loss of instability 
motifs. However, a comparison of the CAT activity detected with regards to the 
length of UTR sequence shows this is not the case. CAT expression from pEYR 
(UTR length= 1.9kb) and pD 17 (UTR length = 0.7kb) are the same level in each of 
the cell lines, also pD36 (UTR length= 0.9kb) is not significantly higher than the 
longest length. 
An alternative explanation is the deletion of sequence that is capable of repressing/ 
inhibiting expression in the full-length transcript. Data presented here shows that the 
presence of sequence between nt positions 2000-27000 of the ovine PrP 3 'UTR can 
significantly repress transient CAT expression in sheep derived cell lines. Over and 
above general trend of increased expression, as deletions are introduced into the 
3 'UTR sequence in the 5' to 3' direction a significant increase in protein expression 
was observed when sequence 2000-27000 was deleted in cell lines sA80BR (scrapie 
susceptible Cheviot brain-derived) and IS 120. Liv  (scrapie susceptible Icelandic 
liver-derived). This response was not observed in either the pA80BR (scrapie 
resistant Cheviot brain-derived) or IS 1 20.Cer (scrapie susceptible Icelandic brain-
derived) cell lines. 
163 
The association between genotype and scrapie susceptibility is well documented with 
the VV 136RR154QQ171 genotype linked to highest susceptibility in all breeds and 
AA1 3 6RR154RR171 the lowest. (Section Lx). The presence of V at codon 136 shows 
increased susceptibility with A136 may offer resistance. When V 136 is rare in a 
breed, scrapie predominantly occurs in carriers of the A 136 allele. This is the case 
with the Icelandic sheep breed. If the function of the putative repressor element at 
PrP 3'UTR sequence 2000-2700 was to act on susceptible genotypes alone it might 
be expected that the same pattern of transient CAT expression would have been 
observed in the cell lines of the same scrapie status. However both sA80BR and 
IS 1 20.Cer are derived from brain tissue from scrapie-susceptible sheep but show 
significantly different CAT protein expression patterns from three of the CAT 
constructs (Table 4.7). Instead cell lines pA80BR and 1S120.Cer, which have similar 
PrP genotypes (AA 136RR154QR171 and AA 136RR154QQ 171 respectively), show similar 
CAT expression profiles. This observation argues for an alternative hypothesis that 
an additional factor may also be involved in influencing scrapie susceptibility. 
This thesis proposes that a repressor element functioning through the ovine PrP 
3'UTR at nt sequence 2000-27000 may be involved in controlling gene expression 
and that loss of this control may increase scrapie susceptibility. It is proposed that 
the sequence contained with in the nt 2000-2700 may reduce protein levels to 
greater effect in sheep with genotypes normally associated with resistance. The 
putative repressor region could function alone as a structural motif or recognition 
factor for nucleic acid binding proteins but does not appear to function efficiently in 
ovine brain tissue containing at least one A 136R154Q 171 allele. Alternatively, this 
region may interact with sequences at the 5' or 3' region of the PrP gene. It is 
interesting to note that this repressor region is 5' of the polymorphic EcoRI site 
(nucleotide position 3440), loosely associated with scrapie incidence (Hunter et al., 
1991). These issues will be the subjects of more discussion in Chapter Six. 
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4.6.2 Effect of peripheral or neuronal tissue origin on gene expression. 
In the previous section, a putative repressor was described within the 3 'UTR, 
nucleotide position 2030-2700, which may function to increase scrapie susceptibility 
with regards to gene expression in brain-derived cell lines. Although this result may 
lead to further study in scrapie susceptibility it fails to address whether the 3 'UTR 
shows any tissue specific control over gene expression besides alternative 
polyadenylation. Results presented here again confirm that sequences within the 
3'UTR are capable of influencing in vitro protein levels but are not responsible for 
tissue specific expression. The level of PrP expression within liver tissue has been 
difficult to determine. To date, in liver tissue PrP protein has not been reported 
(Horiuchi et al., 1995) and PrP mRNA has only been shown at very low levels in 
normal liver (Goldmann et al., 1999) but has been shown to increase in activated 
hepatic cells (Ikeda et al., 1998). If the 3'UTR was responsible for controlling 
selective tissue expression it may have beenexpected that CAT protein levels would 
have been drastically different, or negligible, in the liver cell line compared with the 
cerebellum cell line. However there was no significant difference in the overall 
mean level of CAT protein expression, and only marginal differences in expression 
of some of the plasmids. 
CAT protein levels detected in the cerebellum cell line from the plasmid containing 
sequence deleted upstream from nt position 2000 (pD20) were significantly lower 
when compared to expression from the construct with sequence upstream from nt 
2700 (pD27). Expression from pD20 also had the tendency to be lower in the brain 
cell line compared with the liver cell line. Deleting sequence inclusive of nts 2000-
2700 did not significantly alter expression in the liver cell line. These observations 
would suggest that the putative repressor region was not functional in ovine liver 
cells. In general, protein levels were higher in the liver cell line compared to the 
cerebellum cell line, in contrast to the in vivo pattern of expression of PrP. This may 
indicate that brain tissue is more efficient in controlling gene expression. 
In context with the results presented for PrP genotype and susceptibility, the increase 
in CAT expression as a result of deletions between nucleotides 2000 and 2700 may 
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be due to the presence of a repressor element which is not functional in peripheral 
tissue of sheep. Whether this statement can be applied generally to sheep peripheral 
tissues or to tissues from scrapie susceptible sheep is unknown, as only one 
peripheral tissue has been tested within this study. The issues raised in this Chapter 
will be discussed in full in Chapter Six. 
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Chapter 5: The Ovine PrP 3'UTR: Differential Control of PrP 
Gene Expression in Ovine Brain and Peripheral Tissue? 
5.1 Introduction. 
Although the genetic structure of the ovine PrP gene has been determined (Chapter 1, 
Section 1.8), factors controlling the expression of the gene are still unclear and may 
be vital to our understanding of scrapie development. Hunter et al. (1994) reported 
that PrP gene expression was not exclusive to the CNS when they demonstrated that 
PrP mRNA could be detected in neural and non-neural tissues of developing sheep 
and mice. It was also found that in sheep peripheral tissues in addition to the 
previously reported 4.6kb mRNA (Goidmaim et al., 1990), a second mRNA species 
of 2kb was present (Hunter et al., 1994; Horiuchi etal., 1995). The 4.6kb niRNA is 
found in all tissues, with the highest expression level in brain. The 2.1kb mRNA is 
found in peripheral tissues at levels of up to 30% of total PrP mRNA, but only at 
very low levels in the brain (Horiuchi et al., 1995; Goldmann et al., 1999). The 
smaller mRNA is also found in goats at comparative levels to sheep but only at very 
low levels in cattle (Goldmann etal., 1999). The sheep 2.1kb mRNA is the result of 
an alternative polyadenylation signal at an upstream site in the 3'UTR at position 
1522 (Goldmann etal., 1990). The 4.6kb transcript is polyadenylated oly(A)) at 
position 4046. The truncated PrP inRNA lacks several features present in the 4.6kb 
mRNA, such as repetitive sequences, instability motifs and a highly conserved 
3'region (for more detail refer to Chapter 1, Section 1.8.4). At present there is no 
data regarding the stability of either the 4.6kb or 2.1kb PrP mRNA. Further more, 
semi-quantitative RT-PCR on constructs encoding the CAT reporter gene and PrP 
3'UTR sequence resembling the in vivo 4.6kb and 2.1kb mRNAs showed no 
difference in stability or translatability associated with the 3 'UTR (Cheung, 1996). 
Horiuchi etal. (1995) confirmed the findings of Hunter et al. (1994) and also reported 
that PrPC was detectable in neural and non-neural tissues such as spleen and lungs. 
Comparing PrP mRNA and PrPC protein levels in sheep, the proportional relationship 
of PrP mRNA and PrPC  varied between the brain and other tissues (Horiuchi et al., 
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1995). For example: PrP mRNA was found at levels 5 x higher in brain than kidney but 
the amount of PrPC  detected in brain was 40 x more than kidney. The presence of the 
second PrP transcript in sheep suggests the possibility of a complex control mechanism 
in gene expression where two different PrP mRNAs could result in differential 
expression or cellular location of the PrP protein. As a result of differential expression 
processes such as translational efficiency and/or the course of PrP synthesis, including 
degradation, may differ between brain and other tissues. Although it is not known 
what contribution each sheep mRNA makes to the overall level of detectable P rPC, 
Goldmann et al, 1999, proposed that the 2.1kb PrP mRNA may be the predominantly 
expressed mRNA in peripheral tissues (Goldmann et al., 1999). 
The aim of this Chapter is to confirm whether both in vivo 3 'UTRs are capable of 
supporting PrP protein synthesis and estimate the contribution each sheep PrP 
mRNA makes to PrP protein levels (Chapter Four, this thesis; see also Cheung, 1996; 
Goldmann et al., 1999). As with the chimeric CAT studies, tissue specificity of PrP 
expression and any associations with PrP alleles linked to resistance or susceptibility to 
scrapie was to be studied in sheep cell lines of known PrP genotype and tissue origin. 
The cell liens described in Chapter Three were used in this study. Three ovine PrP 
constructs were created encoding the ovine PrP promoter region (500bp upstream of 
transcription start site), the ovine PrP ORF, and various lengths of the PrP gene 
3'UTR. The constructs were designed to produce transcripts representing the full 
length mRNA (4.6kb), the short mRNA species (2.1kb) or an intermediate mRNA 
species, formed by alternative processing at potential poly(A) sites (conserved sites 
at nucleotide(nt) positions 2221,2284,2668) downstream from the 1522 site 
(Goldmarm et al., 1990). To detect transient PrP protein expression from these 
constructs, the cloned sheep PrP open reading frame (ORF) was manipulated to 
encode the hamster PrP specific 3F4 epitope in the amino acid sequence. These 
vectors were transiently transfected into ovine brain cell lines and any difference in 
expression was observed by Western analysis with the 3F4 anti-PrP antibody. 
5.2 Designing Constructs for Transient PrP Expression. 
5.2.1 Introduction 
To allow study of differential expression of PrP in vitro due to alternative 
polyadenylation, constructs were designed to encode identical 5' and coding 
sequences but different lengths of ovine PrP 3 'UTRs. Work completed at the NPU 
has shown that a 550bp region upstream from the Cheviot PrP transcription start site 
is capable of driving expression of CAT reporter gene in vitro (O'Neill, in 
preparation). The mouse PrP promoter has also been shown to be a strong driver of in 
vitro CAT expression (Baybutt and Manson, 1997). The constructs created for 
transient expression of ovine PrP were cloned to contain the Cheviot sheep promoter! 
exon I region and a Suffolk sheep exon III, PrP allele A 136R154Q 171 and el. The 
cloned regions of the Cheviot PrP gene used in the new constructs were available at 
the NPU, full graphical representation found in Appendix A, Figures A. 1-A. 10. 
The plasmid pNPU7PM carries the full length PrP exon III, and is expected to 
generate transcripts equivalent to the two in vivo PrP mRNAs by processing at 
known active poly(A) signals (nt 1522 and 4046; Goldmann etal., 1990; Cheung, 
1996; Goldmann etal., 1999). Transcripts may also be produced from other 
conserved poly(A) signals between the two known functional sites (nt 2221, 2281, 
2668). Construct pNPU2PM differs in the 3' region to pNPU7PM as it contains a 
truncated exon III which will allow transcription of one niRNA species only using 
the poly(A) site at 1522. Construct pNPU3PM contains an exon III of intermediate 
length encoding consensus polyadenylation signals at sites 1522, 2221, 2281 and 
2668, of which the signal at 1522 is already known to be active. There is the 
possibility that any of the remaining signals could be used to form intermediate 
length mRNAs. At the start of the cloning project the levels of endogenous sheep 
PrPC expression in the sheep cell lines were unknown, as the cell lines were not 
available. The original expression constructs, which would also express sheep PrPC, 
later had to be redesigned to contain sequence encoding the hamster 3F4 epitope 
which allows for detection of protein produced by the reporter gene against a 
background of sheep PrPC  by means of using the anti-hamster PrP antibody 3174 
(Kascsak etal., 1987; Section 5.3). 
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5.2.2 Construct pNPU7PM. 
To study protein levels in relation to the full length PrP gene 3 'UTR construct 
pNPU7PM was designed (Figure 5.1). The full length Suffolk PrP exon III, PrP 
allele A 136R154Q 171 and el, has been previously cloned and published (Goldmann et 
a! 1990, accession number M31313.emom). The fragment was available at NPU 
(construct p71, Appendix A, Figure A.3). The Cheviot promoter/exon I region was 
also available at the NPU, plasmid pNPU1 10-1, cloned from an NPU Cheviot sheep, 
PrP genotype AA136RR 154QQ 171 (Goldmann, personal communication, Appendix A, 
Figure A.4). 
To facilitate cloning of the promoter/exon I fragment upstream of exon III, restriction 
sites were created by PCR into the 5' and 3' ends of the promoter/exon I fragment 
generated from clone pNPU110- 1  (Appendix A, Figure A.4) as no suitable cloning 
sites were present. Restriction digestion sites Sail and SstI were introduced by PCR 
to flanking regions of the promoter/exon I region using primers SstPM and Sa1PM 
(Table 2.1, Chapter 2 for full details). The 550 base pair fragment produced by PCR 
was sequenced in full before further cloning to ensure no mutations had been 
introduced (Section 5.2.5). Using restriction sites Sail and SstI, the promoter 
fragment was cloned upstream of PrP exon III in p71 to create vector pNPU7PM 
(Figure 5.1). The structure of the final construct was confirmed by restriction 
mapping and PCR with primers available at NPU (A025 and A045, Chapter Two, 
Table 2.1) which target sequence 3' of the promoter and 5' of the PrP open reading 
frame respectively. 
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PrP promoter/exon I Sstl 	
fragment (0.5kb) 
Clone into plasmid p71 at sites Sall and 
Sstl upstream of PrP exon Ill 
HindIll Sail Sst EcoRl 	 EcoRl 
PrP promoter! exon I 	 PrP exon Ill 	 pNPU7PM 
0.5kb 	 7.1 kb (10.1kb) 
Figure 5.1 :Construction of clone pNPU7PM 
Synthesis of 550bp promoter/exon I fragment by PCR from pNPU1 10-1. 
Restriction sites Sail and SstI were introduced by PCR into the flanking sequence 
of the promoter/exon I region and cloned upstream of PrP exon Ill in p71 to 
create vector pNPU7PM. For full details on all plasmids see Appendix A. 
PCR primers • PrP promoter D PrP exon UTR 
• PrP open reading frame 
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5.2.3 Construct pNPU3PM. 
It is not yet known whether polyadenylation signals other than those at 1552 and 
4046 present in the 3 'UTR are actively selected to produce alternative PrP mRNA 
transcripts in vivo at low levels. Construct pNPU3PM was therefore designed to 
display the conserved polyadenylation signals upstream from the signal at 4046bp, 
encoding niRNAs of intermediate lengths. The Cheviot sheep PrP promoter/exon I 
from pNPU1 10-1 was cloned into pBluescript (Stratagene, UK, Appendix A, Figure 
A.6) then into pGEM-7Zf(+) (Promega, UK) by Apal - XbaI digestion to form 
pGEM.promoter (Appendix A, Figure A.7). The two step cloning strategy of the 
promoter region was necessary due to the high number of repeated restriction sites 
within the 3 'UTR sequence. It was not possible to produce pNPU3PM by truncating 
pNPU7PM for the same reason. Instead, restriction digestion of p71 by EcoPJ and 
ClaI produced a PrP exon III fragment of 3.6kb which was cloned into pGEM-7Zf(+) 
to create pGem3kb (Appendix A, Figure A.8). The promoter/exon I fragment was 
cloned upstream of the truncated PrP exon III in pGem3kb by X7oI digestion to 
create pNPU3PM (Figure 5.2). The structure of the final construct was confirmed by 
restriction mapping as well as PCR targeted to the promoter region and the S'region 
of the PrP open reading frame. 
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A) 	
Apal XhoI 	Xhol Xbal Ns,1 
I 	I 	 ji 	I I 
promoter/exon I 
- 	- - - - (05kb) - - - - 	 pOem .promoter 
Apal Xh&EcoRl 	 C/al 	Ns,1 
PrP exon III 
(3.9kb) 	 pGem.3kb 
6.9kb 
(b) 
Xhol 	Xhol EcoRl 	 C/al 
Apal 	 Nsil 
	
I 	j I 
PrP promoter! exon I 	 PrP exon l I I 	
pNPU3PM 0.5kb 	 (3.9kb) 
7.4kb 
Figure 5.2: Construction of clone pNPU3PM. 
A) Restriction digestion and purification of Xhol PrP promotor/ exon I fragment 
from pGem-promoter. B) Cloning of the PiP promoter! exon I fragment upstream 
of the PrP modified exon III in pGem.3kb at site Xhol. For full details on all 
plasmids see Appendix A. 
• PrP promoter 	PrP exon UTR • PrP open reading frame 
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5.2.4 Construct pNPU2PM 
To study protein expression in vitro in association with the 2.1kb PrP mRNA 3 'UTR 
the vector pNPU2PM was designed to contain the ovine promoter, exon I and a 
truncated exon III with consensus polyadenylation signal nt 1522. A 1.5kb fragment 
was removed from pNPU3PM exon III (Section 5.2.3) by KpnI-NsiI digestion 
which, after gel purification, followed by PstI digestion. The resulting 0.4kb KpnI-
PstI fragment was again gel purified and inserted into the 5.9kb fragment produced 
by KpnI-NsiI digestion of pNPU3PM. The restriction digestion ends of PstI and 
NsiI are complimentary and were religated successfully to reform a circular plasmid 








PrP promoter! exon I 	 PrP exon III 	 (7.4kb) 
(0.5kb) 	 (3.9kb) 
Kpnl-NsiI restriction digestion 
Nsil 	 Kpnl 	Kpnl Pstl 
Nsil 
(5.9kb) 	 (1 .5kb) 
Pstl digestion of the 1 .5kb fragment and 
ligation of the purified 0.4kb fragment 
with the 5.9kb fragment 
Kpnl 	PstlI Nsil 
HI 
PrP promoter! exon I 	PiP exon Ill 	 pNPU2PM 
(0.5kb) 	 (2.5kb) 6.3kb 
Figure 5.3: Construction of clone pNPU2PM. 
A) KpnhINsiI digestion produces a 5.9 kb and 1 .5kb fragment, which were 
isolated, the 1.5kb fragment was further manipulated by Pstl digestion and a 
0.4kb fragment purified. B) Ligation of 0.4kb KpnlIPstl fragment to Ns,1/ Kpnl 
5.9kb PrP fragment possible due to complementary ligation of sites Pstl and Nsil. 
For full details on all plasmids see Appendix A. 
jay. • PrP promoter 	PrP exon UTR M PrP open reading frame 
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5.2.5 In vitro expression of RNA from PrP constructs. 
5.2.5.1 Introduction 
Efficient gene expression requires recognised transcription promoter/ enhancer 
sequences, a transcription start site, correct splicing, and transcriptional termination 
signals (Lodish et al. 1995). Assuming that the full length PrP exon 3 contains the 
intact 3' acceptor site of splicing and 3' polyadenylation signals it was necessary to 
confirm that, following cloning, the ovine PrP constructs contained the consensus 
sequences for transcription initiation and splicing and so were capable in vitro 
expression. 
5.2.5.2 Experimental approach. 
Confirmation that transcription initiation and 5' donor splice sites were present was 
carried out by partial sequencing of the promoter region cloned into plasmids 
pNPU7PM and pNPU2PM (Section 5.5.5.3). Transcriptional activity from 
pNPU7PM and pNPU2PM was investigated by transiently expressing the constructs 
in mouse N2a cells as a protocol had not been developed for the ovine cell lines at 
this time. Expression from the constructs was determined by reverse transcription-
polymerase chain reaction (RT-PCR, Section 5.2.5.4). Full details of the sequencing 
and RT-PCR protocols can be found in Chapter 2, Sections 2.3. As construct 
pNPU2PM was cloned from manipulating exon III of pNPU3PM, constructs 
pNPU2PM and pPU3PM had the same 5' PrP sequence. Therefore, in vitro 
expression detected from pNPU2PM was assumed to also represent transcriptional 
activity possible from pNPU3PM. 
176 
5.2.5.3 Sequencing promoter region for 5' donor site 
Sequencing of cloned ovine promoter/ exon I region was completed as described in 
Section 2.3.4. Using different nucleotide primers targeted to the 5' and 3' regions of 
the promoter region, both strands of the promoter region were sequenced. The 
sequence data gathered was incomplete, perhaps due to difficulties encountered in 
attempting to sequence a region with a high GC content. However, a conserved 5' 
donor sequence was detected which suggests that splicing at the promoter! exon I 
region should occur (Figure 5.4). 
	
PrP plasmids; 	1 	. . . gccc ccgcagctcc tcctctgcac ggcgactcac 
1111 	1111111111 	1111111111 	1111111111 
pNPU110-1; 	391 ctccccgccc ccgcagctcc tcctctgcac ggcgactcac 
PrP plasrnids; 	35 cagccctagt tgccagtcgc nnacngnngc agagnngaga 
1111111111 	1111111111 	HI 	111111 	liii 
pNPU110-1; 	431 cagccctagt tgccagtcgc tgacagccgc agagctgaga 
PrP piasmids; 	75 gcgncttctc tcccagaggc aggtaaa... 
III 	111111 	1111111111 	1111111 
pNPU110-1; 	451 gcgtcttctc tcccagaggc aggtaaatag 
+ splice site 
Figure 5.4: Sequence of ovine PrP promoter! exon I region cloned into 
plasmids pNPU7PM and pNPU2PM. Consensus 5' splice site shown in bold text, 
splice site indicated by arrow. 
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5.2.5.4 In vitro detection of PrP mRNA expressed from PrP constructs. 
Following transient transfection of mouse N2a cell lines with plasmid pNPU7PM 
and pNPU2PM mRNA was isolated and reverse transcribed. The protocol used is 
described in full in Section 2.3.6. Briefly, total RNA was precipitated following lysis 
of the cells using RNAzo1. The same amount of total RNA was used for each RT-
PCR reaction. PCR amplification of the purified mRNA molecules was completed 
using primers which were available at the NPU: A023 (targeting exon I region) and 
13741 (targeting 5' region of exon III). The product of PCR on the reverse 
transcribed mRNA templates with primers A023 and 13741 (available at NPU, 
Appendix A) was predicted to be 250 bases in length if splicing occurred. If splicing 
did not occur a PCR product of approximately 750 bases would be detected as the 
cloned 3' sequence of intron II (approximately 500 bases) would not be spliced out. 
Furthermore, cross reaction of the primers with N2a cell endogenous PrP mRNA 
should lead to a PCR product of approximately 350 bases. 
The result of one RT-PCR reaction is shown (Figure 5.5). Control parameters 
included within the experiment were RT-PCR and PCR on non-transfected N2a cells 
(lanes 4 and 7) and as a positive control for primers A023 and 13741, PCR was 
carried out on an ovine cDNA (RL1 10) supplied by Wilfred Goldmann (lane 3). 
PCR of the ovine cDNA clone should give a product of 350 bases as exon II will be 
present in the transcript. PCR-only was completed on total RNA extract from the 
transfected N2a cells to determine the level of remaining PrP constructs after 
transfection (lanes 5 and 6). RT-PCR products of 750 bases and 250 bases were 
detected following transient expression of the PrP constructs in N2a cells (lanes 8 
and 9). The product at 250 bases is equivalent to successfully spliced mRNA 
transcribed from plasmids pNPU7PM and pNPU2PM. The product at 750 bases may 
reflect the presence of non-spliced mRNA or remaining plasmids template from the 
transfection reaction as determined in lanes 5 and 6. No PCR or RT-PCR products 
were detected in the negative controls, also PCR on the ovine cDNA produced a 
band of approximately 350 bases as expected. Therefore PrP constructs pNPU7PM 
and pNPU2PM have been shown by RT-PCR to be actively transcribed in a mouse 







2 	3 	4 	5 	6 	7 	8 	9 
5Ont 
Ont 
Figure 5.5:cDNA analysis of PrP constructs pNPU2PM and pNPU7PM in N2a cell 
line. Cell were harvested 49 hours post-transfection and total RNA extracted. 
Equivalent amounts of RNA were used for each RT-PCR reaction. Lane 1; 1 OObp 
ladder: lane 2;PCR negative control: lane 3; PCR positive control, ovine cDNA: lane 
4; PCR of total RNA extracted from non transfected N2a cells: lane 5; PCR of total 
RNA extracted from N2a cells transfected with pNPU2PM: lane 6; PCR of total RNA 
extracted from N2a cells transfected with pNPU7PM: lane 7; RT-PCR on total RNA 
extracted from non-transfected N2a cells: lane 8; RT-PCR of total RNA extracted 
from N2a cells transfected with pNPU2PM: lane 9; RT-PCR of total RNA extracted 
from N2a cells transfected with pNPU7PM. 
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5.3 Creating the Hamster 3F4 Epitope by Site Directed 
Mutagenesis. 
5.3.1 Introduction and approach. 
To study expression of the PrP protein in ovine cell lines an assay system had to be 
developed to distinguish transiently expressed PrPC  from endogenous PrPC.  At the 
start of this study, the monoclonal antibody 3F4 was known to recognise specifically 
hamster PrP while not cross-reacting with sheep PrP at the sensitivity required for 
Western blot analysis (Kascsak et al., 1987). It follows then that introduction of the 
3F4 epitope into the sheep PrP amino acid sequence by mutation of the PrP 
nucleotide sequence should allow for the detection of transiently expressed PrP in 
sheep cell lines. 
Mutations can be introduced into known cloned gene sequences by various methods 
that involve cleavage, degradation or synthesis of DNA. One advantage of this 
method is the precision with which the mutation can be introduced. The DNA 
template for oligonucleotide-mediated mutagenesis is normally ssDNA. When 
designing primers for single nucleotide mutagenesis several features must be 
considered; 
1 Oligonucleotide primer must be generated complimentary to the correct strand of 
plasmid template for replication with DNA polymerase. 
2 Length of the oligonucleotides must be sufficient to allow promoter annealing to 
the target sequence (approximately 17-19 nucleotides) with the desired mutation 
in the middle of the sequence. 
3 Target DNA sequence should contain little sequence capable of forming complex 
secondary structure i.e. palindromic sequences. 
4 Oligonucleotide should be unlikely to bind to regions on the DNA template other 
than the target sequence. 
Alignment of the sheep and hamster PrP amino acid sequence (Figure 5.6) across the 
3F4-recognition site shows that the sequences differ at one codon only. The sheep 
gene encodes for valine at position 115 as opposed to methionine in the hamster 
equivalent codon 112. Mutating the sheep coding region at nucleotide position 424 
from G to A would convert codon 115 from valine to methionine, thus creating the 
potential 3F4 recognition site. This mutation also creates the restriction site NdeI 
within the PrP mutated ORE which can be used for screening during the cloning 
procedure. 
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Comparison of the hamster and ovine 31F4 epitope amino acid (aa) sequence: 
Hamster: ' °4K P K T N M K H M A G A A A117 
Ovine: 107KPKTNMKHVAGAAA 120  
Primer design for ovine PrP site directed mutagenesis. 
Ovine aa sequence: 	114H V 	A G 	A 	A A 	A 	G A'23 
Ovine nt sequence: 5' 411 CAT GTG GCA GGA GCT GCT GCA GCT GGA GCA440 3' 
Mutagenic primer: 3' 29GTA TAC CGT CCT CGA CGA CGT CGA CCT CG' 5' 
(designated E439) 
Mutated .aa sequence: 107K P K T N M K H M A G A A A'2° 
Figure 5.6: Mutating the sheen PrP nucleotide seauence to create the hamster 3F4 
epitope in the amino acid sequence. A) Comparison of the hamster 3F4 epitope with 
the equivalent ovine amino acid (aa) sequence. Ovine sequence deviates from the 
hamster sequence at one codon only: codon 115 (red). B) Method used to design a 
reverse primer (E439) for mutagenesis of the ovine PrP nucleotide (nt) sequence 
spanning 411-439 to convert the sheep PrP codon 115 from valine to methionine thus 
creating the 3F4 recognition site. 
182 
5.3.2 Experimental Approach 
Two variations on the oligonucleotide- mediated mutagenesis method were used in 
the attempt to introduce the single nucleotide substitution in the sheep ORF 
necessary to create the hamster 3F4 epitope. The first used a single mutagenic 
primer to induce synthesis of a DNA template, which would be amplified in a 
bacterial system. The second method was PCR based, introducing the mutation via a 
set of primers designed to amplify a precise region of the ORF, with one of the 
primers containing the mutation. 
For both methods, primers were designed using the published Suffolk PrP exon III 
sequence (accession number M313 13.em_om, Goldmann et al 1990). Full details of 
the primers sequences used can be found in Section 2.3, Table 2.1. Site directed 
mutagenesis was attempted using the clone pPSHPrP which was available at the 
NPU and contains only the PrP open reading frame and so increasing the likelihood 
of correct annealing of the primer to the target sequence (see Appendix A, Figures 
A.1 1-A.14). 
5.3.2.1 Single-primer Oligonucleotide- mediated mutagenesis. 
The method used for single primer oligonucleotide mutagenesis is full described in 
Section 2.3.3. Briefly, the oligonucleotide H3F4 was designed and used in 
mutagenic experiments with pPSHPrP. After annealing the phosphorylated 
mutagenic primer (lOpmoIJml) to single stranded DNA (1pg) of pPSHPrP, the 
primer extension was allowed to occur over 15 hours at the appropriate temperature. 
DNA synthesis was initiated at the 3' terminus of the mutagenic primer and extended 
by DNA polymerase along ssDNA template to form a heterodulex. Once DNA 
synthesis was complete, XL-Blue E.coli cells were transfected and plated onto 
ampicillin agar plates. Colonies were screened for positive clones by differential 
hybridisation (refer to Section 2.3.3.2). Briefly, for screening large numbers of 
colonies, duplicate colony filters were produced by pressing nitro-cellulose 
membranes onto the experimental ampicillin plates. The filters were then treated to 
lyse cells and the DNA fixed to the membranes by UV irradiation. After four hours 
hybridisation, at 37'C, with radio-labelled oligonucleotides 1131 74 (mutated PrP 
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sequence; Chapter Two, Table 2.1) or E377 (normal PrP sequence; Chapter Two, 
Table 2.1) the filters were washed twice at room temperature for 10 minutes, 
followed by a further 10 minutes at 47 °C to remove any unbound probe then 
exposed to autoradiography film. 
Colonies that appeared positive by differential hybridisation were further analysed by 
restriction digestion. Digestion of pPSHPrP with restriction enzymes HindIII, EcoPJ 
and NdeI gives a defined pattern (Appendix A). The plasmid, pPSHPrP has a pUC 
10/11 backbone with the PrP coding region inserted in the BamHI site, digestion with 
EcoRI and HindIII cuts out the 0.8Kb PrP ORF fragment. Successful site directed 
mutagenesis at nucleotide 414 within the ORF would create a novel NdeI site, and is 
detected by digestion with EcoRI, HindIII and NdeI. The 0.8Kb EcoRJJ HindIII 
fragment should be digested with NdeI producing additional fragments of 0.35kb and 
0.4kb. 
5.3.2.2 Results - single primer mutagenesis. 
Single primer mediated mutagenesis was repeated several times and any colonies that 
seemed potentially positive for the required mutant plasmid were assayed. 
Restriction fragment length polymorphism for the presence of NdeI was not detected 
in any colonies screened (results not shown). Most transformed cells appeared to 
contain only unmutated plasmids. Control digests were carried out to ensure that all 
enzymes used were active. It was therefore concluded that single-primer mediated 
mutagenesis had been unsuccessful at introducing the desired mutation into the sheep 
PrP ORF. 
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5.3.2.3 PCR —mediated mutagenesis. 
Oligonucleotides specific to the sheep PrP ORF which were used to amplify a region 
approximately 250 bases in length (Chapter 2, Table 2.1). The first primer, p1, was 
available at the NPU and was homologous to the sense strand of the ORF from 
position 118-225, which includes aXmal restriction site. The other primer, E439, 
was designed to be homologous to the anti-sense strand except at position 414 where 
it encoded a T instead of a C (Figures 5.6B, 5.7). Following PCR, the amplified 
fragment was digested with XmaI and PstI, gel purified and ligated into pBluescript 
(Stratagene, UK) to create the construct pBSK-ORF.3F4. Potentially positive 
colonies for the mutated sequence were screened by restriction digestion with NdeI. 
Digestion with XbaI will linearize the transformed pBSK-ORF.3F4 (3.5kB), 
successful substitution at nucleotide 414 would have created a NdeI site therefore 
double digestion with XbaI! NdeI was expected to produce fragments of 0.25kb. 
5.3.2.4 Results - PCR mediated mutagenesis. 
In contrast to the single-primer mediated mutagensis method, following ligation and 
transformation, PCR-mediate mutagenesis did not produce high numbers of colonies 
for screening, it was therefore possible to screen all colonies efficiently by restriction 
digestion with NdeI and XbaI. After three repeated attempts at PCR mediated 
mutagensis, a positive clone was identified by restriction digestion, the result was 
confirmed further by PCR (result not shown). Full sequencing (Figure 5.7) of the 
mutated PrP ORF ensured that no further mutations had been introduced into the 
fragment by PCR other than the intended mutation at nucleotide position 414. This 
plasmid is known as pPSH.3F4. 
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Xmal 
pPSH3F4: 	1 	 • cccggga 7 
11111 	I 	I 
M31313: 151 GACCAAAACCTGGCGGAGGATGGAACACTGGGGGGAGCCGATAccccA 200 
P1 
pPSH3F4: 	8 cagggcagtcctggaggcaaccgctatccacctcagggagggggtggctg 57 
1111111 	I 	11111111111 	I 11111111 	IlIllIlIllIllIll 	III 
M31313: 201 CAGGGCAGTCCTGGGCAACCGCTATCCACCTCAGGGAGGGGGTGGCTG 250 
pPSH3F4: 	58 gggtcagccccatggaggtggctggggccaacctcatggaggtggctggg 107 
liii 	1111111111111111 	11111 	Iii 	IllilIllIllIllIll 	II 
M31313: 251 GGGTCAGCCCCATGGAGGTGGCTGGGGCCAACCTCATGGAGGTGGCTGGG 300 
pPSH3F4: 108 gtcagccccatggtggtggctggggacagccacatggtggtggaggctgg 157 
111111 	1111111111111 	11111 	111111111 	III 	111111111 
M31313: 301 GTCAGCCCCATGGTGGTGGCTGGGGACAGCCACATGGTGGTGGAGGCTGG 350 
pPSH3F4: 158 ggtcaaggtggtagccacagtcagtggaacaagcccagtaagccaaaaac 207 
I 	11111111111111111111 	I 	1111111 	1111111111111 	liii 
M31313: 351 GGTCAAGGTGGTAGCCACAGTCAGTGGACAGCCCAGTAJGCC JC 400 
Pstl 
pPSH3F4: 208 caacatgaagcatatggcaggagctgctgcag 
IIIIIIIIIIIII 	IIIIIIIIIIIIIIIIII 
M31313: 401 CAACATGAGCATGTGGCAGGAGCTGCTGCAGCTGGAGCAGTGGTAGGGG 450 
E439 
Figure 5.7: PCR mediated mutaqenesis of the ovine PrP open readina. The 
plasmid pPSHPrP was used in mutagenesis studies to modify the ovine PrP open 
reading frame to encode the hamster 31F4 epitope. The clone pPSH3F4 was 
successfully created by PCR mutagenesis. Comparison of pPSH3F4 sequence 
(upper line) to the published Suffolk PrP open reading frame (accession number 
M31313.em_om, lower line) shows the mutation from G to A at the equivalent 
pPSH3F4 nucleotide position. Oligonucleotides represented by dark blue arrows. 
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5.3.3 Conclusions. 
Site directed mutagenesis was successful in creating the hamster 3174 epitope 
nucleotide sequence within the sheep ORF using the PCR mediated method rather 
than the single-primer mutagenesis method. The single primer method was chosen 
first primarily on the basis of theory - priming ssDNA synthesis from a mutagenic 
oligonucleotide should have conserved the mutation during dsDNA formation. 
Secondly the planned screening method of hybridisation and restriction digestion 
should have been efficient and should have reduced the background of non-mutated 
clones. However the method was time consuming and did not produce any positive 
clones. Several reasons may explain the failure of the single primer mediated 
mutagenesis. For example: incomplete polymerisation, primer displacement by 
DNA polymerase, and host mismatch-repair in favour of the original sequence. 
Many new methods now described use two or more primers for mutagenesis. The 
presence of the other primers allow for selection or prevent displacement of the 
mutagenic primer. In contrast the PCR-mediated mutagenesis was successful and 
produced a positive clone quickly. This method was convenient and efficient in 
producing the desired mutagenesis. Sequencing was completed to ensure that no 
further mutations were introduced by PCR. 
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5.4 Insertion of 3F4 Fragment into Clones pNPU7PM and 
pNPU2PM. 
The mutated sheep nucleotide sequence in clone pPSH.3F4 (Section 5.3) was 
inserted into clone pNPU7PM and pNPU2PM to allow for detection of transiently 
expressed sheep PrP in sheep cell lines against a background of endogenous sheep 
PrP protein using 3F4 anti-PrP antibody. Due to time restrictions, a decision was 
taken to concentrate on transient expression of PrP from plasmids pNPU2PM and 
pNPU7PM as these constructs resemble the known ovine endogenous in vivo PrP 
mRNAs. Construct pNPU3PM was therefore not modified further by the insertion of 
the 3F4 sequence. 
5.4.1 Experimental approach and results. 
Briefly, the 3F4 epitope was created by PCR-mediated site directed mutagenesis in 
plasmid pPSHPrP to create the clone pPSH3F4 (Section 5.3). By restriction 
digestion with enzymes Dralli and HincII a 0.3kb fragment containing the mutated 
sheep sequence was isolated from pPSH3F4 and cloned into the construct pNPU2PM 
(Figure 5.8). Correct orientation and insertion of the fragment into pNPU2PM was 
confirmed by restriction mapping and partial sequencing. The presence of the 3F4 
epitope was confirmed by restriction digestion with NdeI (Figure 5.lOa, lane 3). The 
resulting plasmid, pNPU2.3F4, contains the PrP promoter/exon I, a truncated exon 
III to position 1929, and encodes for the 3F4 epitope in the amino acid sequence. 
Following conformation of the structure of plasmid pNPU2PM.3F4 it was possible to 
clone the 3F4 epitope into plasmid pNPU7PM to create pNPU7PM.3F4 (Figure 5.9). 
Restriction digestion of PNPU2.3F4 with BamHI and XbaI lead to the purification a 
1.5kb fragment carrying the PrP ORF mutated to encode the 3F4 epitope. The 1.5kb 
fragment was inserted into pNPU7PM using BamHI and XbaI and confirmed by 
partial sequencing and restriction mapping. Again the presence of the 3F4 epitope 
was confirmed by digestion with NdeI (Figure 5.1OB). Purification of the 
Bam}iTI/Xba I site from pNPU7.3F4 and further digestion with NdeI produced a 
fragment of 1kb (Figure 5.1013, lane 5) 
A) 
DraHI 	HincIl 	Dralll 	 DralII 	HincII 
I h 
PuP ORF 	 PrP promoter! exon I PiP exon III 




$ SAP treatment 
B) DralIl 	Hincll 	DraIlI 	 Dralli 
	
ii 	 I 	H 




Hind l 	DralIl 
(4kb) 
Dralli HincII 
Dralli 	 I 
pNPU2.3F4 
PrP promoter! exon I 	PrP exon III 	 (6.3kb) 
0.5kb 	 (2,5kb 
Figure 5.8: Cloning of DNPU2.3F4. 
A) Restriction digestion with Dralll/ HinclI and shrimp alkaline phosphatase 
(SAP) treatment of plasmids pNPU2PM and pPSH3F4. B) Fragments 2kb and 
4kb were purified from pNPU2PM digestion and set up in a three way ligation 
with the 0.3kb fragment from pPSH3F4 digestion. The 0.3kb fragment carries 
the PrP coding region encoding the 3F4 epitope. 
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Figure 5.9: Cloning of PNPU7.3F4 
Restriction digestion with BamHlI Xbal of plasmids pNPU3F4.2 and pNPU7PM. 
The 1.5kb fragment from pNPU3F4.2 digestion, carrying the 3F4 epitope, was 
ligated into the 8.6kb fragment of pNPU7PM after BamHl/XbaI digestion to form 
pNPU3F4.4 
Key. ! PrP promoter 0 PrP exon UTR 	• PrP open reading frame 
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Figure 5.10: Screening pNPU2.3F4 and pNPU7.3F4 clones for mutagenic Ndel site. 
A)Restriction digestion of pNPU2.3F4 with Ndel to confirm presence of mutated 
ovine sequnce. Digestion of pNPU2.3F4 with Ndel should produced a 0.8kb 
fragment if the mutagenesis is successful. Lane 1; 1 Kb markers: lane 2; Ndel 
restriction digest of pNPU2PM; lane 3; Ndel restriction digest of pNPU2.3F4: lane 4; 
BamHl IScal restriction digest of pNPU2PM: lane 5; BamHlIScal restriction digest of 
pNPU2.3F4. B) Restriction digestion of pNPU7.3F4 to confrim the presence of 
mutated ovine PrP sequnce. Purification and digestion of the BamHl/Xbal fragment 
from pNPU2.3F4 and pNPU7.3F4should produce a 1.1kb fragment if mutagensis 
has been successful. Lane I; markers VI: lane 2; Ndel resitriction digest of 
BamHlIXbaI fragment of pNPU7PM; lane 3; Ndel restriction digest of BamHl/Xbal 
fragment of pNPU2.3F4: lane 4; Ndel digestion of BamHl Mal fragment of 
pNPU7.3F4 clone7: lane 5; Ndel digestion of BamHI/Xbal fragment from 
pNPU7.3F4 clone 8. 
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5.5 Immunological Detection of Transiently Expressed Ovine 
P rPC Protein in Mouse and Ovine Cell Lines 
5.5.1 Introduction 
In vitro expression is frequently used for the study of protein structure and function, 
protein—protein interactions, antibody production and mutagenesis. It can also be 
employed to assess the levels of protein synthesis as a result of enhancer/ repressor 
elements controlling gene expression at the level of transcription or translation. 
Analyse of a protein sample often involves purification which can be dependent on 
the biochemical properties of the protein i.e. solubility or size. Sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) has become the most 
popular method for analysis and isolation of small amounts of protein. Successful 
SDS-PAGE allows for individual gel bands to be visualised and recovered, or 
transferred onto a membrane, for further analysis. The most commonly used 
methods for visualising bands after gel electrophoresis are Coomassie blue and silver 
staining which often require stringent conditions making proteins difficult to 
manipulate further. Coomassie and silver stains do not differentiate between proteins 
within a sample, staining the majority of proteins present within the isolated fraction. 
For more specific analysis of particular proteins immunological detection is essential. 
Immunological detection of proteins is possible using either monoclonal or 
polyclonal antibodies. Antibodies are widely used to detect antigens in a variety of 
methods; immunodetection can be classified as either solution based (enzyme-linked 
immunosorbent assay (ELISA), immunoprecipitation) or sample-immobilisation 
based (i.e. Western, dot blotting). In general the method for inimunodetection is 
determined by the sensitivity and specificity of the antibodies available, nature of 
sample or tissue, and ease of purification/ extraction of target protein. Always of 
importance are the conditions for stringency in antibody-antigen detection as changes 
in the environment (i.e. temperature, salt concentration, and presence of detergents) 
may cause non-specific binding or limited antibody-antigen binding. Furthermore, 
antibodies may recognise epitopes that may be denatured or buried during processes 
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such as SDS-PAGE or Western blotting and so antibody-binding sensitivity may be 
reduced. 
Developing a reliable method for PrPC  protein extraction was vital for the study of 
endogenous and transient PrPC  expression studies. Methods for PrPSC  isolation are 
well established (first described by Hope et al., 1986), however this is not the case 
with PrPC .  PrPC differs in physical properties to PrPSC  which means different 
isolation methods must be used to isolate PrPC.  Firstly  PrPC  is detergent soluble (e.g. 
Sarkosyl) but detergents can make samples viscous and difficult to analyse by SDS-
PAGE. Secondly, PrPC  is not as physically stable as PrPSC  and may be degraded by 
the presence of strong denaturing agents or heat treatment. Further, as PrPC  is 
proteinase K sensitive, steps must be taken to prevent proteinase contamination. PrP 
protein has a distinctive band pattern on SDS-PAGE, it has a molecular weight of 33-
35kDa (Meyer et al., 1986) and separates into three bands due to the glycosylation 
status (un-, mono-, di- glycosylated)( Oesch et a!, 1985; Barry and Prusiner, 1986). 
The development of a suitable method for PrP extraction and detection was greatly 
assisted by the advice and guidance of Angela Chong, Neuropathogenesis Unit, 
Edinburgh. 
As discussed in Section 1.9 the level of PrPC  protein detected in different cell types and 
tissues can vary considerably, with the highest level of PrPC  protein recorded in the 
brain levels (Oesch et al., 1985; Caughey etal., 1988; Manson etal., 1992a and b; Sales 
etal., 1998; Goldmann et al., 1999). Within the brain PrP expression is thought to be 
largely associated with neurones and astrocytes (Kretzschmart etal., 1986; Manson et 
al., 1992a; Harris et al., 1993; Moser et al., 1995 Raeber et al., 1997). It was 
necessary to determine the level of endogenous PrPC  expression, if any, within the 
ovine cell lines as this may have implications for the detection level of transiently 
expressed PrPC  from the PrP constructs. For instance, although the immortalised brain 
cell lines (sA80BR and pA80BR) tested positively for the presence of neurones and 
glial cells (Chapter 3) they may be altered intrinsically so that they express low, or high, 
levels of PrPC.  Also, one may expect PrPC  expression from the primary cerebellum 
cells, IS 1 20.Cer (positive for neuronal cells, Chapter 3) as PrP expression in neurones is 
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well established (Kretzschmart et al., 1986; Manson et al., 1992a; Harris et al., 1993). 
The reported level of PrP expression in peripheral tissues can vary greatly (Horiuchi 
et al., 1995; Goldmann et al., 1999). In sheep, PrP mRNA expression has been 
shown to be relatively high in the kidney despite the apparent absence of detectable 
PrPC (Honuchi et al., 1995). In contrast, heart tissue shows high level of both PrP 
mRNA and PrPC  protein (Horiuchi et al., 1995; Goldmann et al., 1999). 
The aim of this Section was to develop an immunological detection method for 
transiently expressed ovine PrPC  in brain and peripheral tissue-derived cell lines. 
Transient expression the PrP plasmids described in Section 5.4, may provide 
information relevant to the understanding of events leading to differential expression 
of the PrP protein and whether the factors that govern the level of PrP protein 
synthesis are found in the 3 'UTR of the PrP gene. 
5.5.2 Experimental Approach. 
At the start of this study the level of PrPC  protein expression in the cell lines was 
unknown and so the unmodified PrP plasmids (pNPU2PM, pNPU3PM, pNPU7PM) 
were transfected in to the sheep cells in the hope of being able to detect increased 
levels of PrP expression as a result of transient expression. Most emphasis however, 
was placed on the transient expression of the PrP constructs encoding the 3F4 
epitope (pNPU2.3F4 and pNPU7.3F4). The constructs were also expressed in mouse 
N2a cells as a control for extraction and immunological detection methods. 
N2a and ovine cell lines (5A80BR, pA80BR, pA80SK, 15120.Cer and 1S120.Liv) 
were transfected with the ovine PrP constructs (Sections 2.5 and 3.5). Successful 
transfection was confirmed by co-transfection and colorimetric assay of - 
galactosidase (n-gal). For approximately 6x10 7 cell, 3-gal assays completed on the 
recovered cell lysates allowed for differential transfection efficiency between 
experiments. Three methods were tested for efficient protein extraction from the cell 
lines: chloroform/methanol precipitation; Triton Xli 4 detergent extraction; 
immunoprecipitation. The level of purified PrPC  isolated was estimated by Western 
blot analysis. A full description of each method can be found in Sections 2.6. 
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Chloroform/ methanol extraction was the simplest of the methods involving lysis of 
the cells by shearing in the presence of SDS then precipitation in 
chloroform/methanol - a quick, crude protein preparation. Triton X114 detergent 
extraction is a laborious, precise process, temperature dependent, requiring several 
washes of a sucrose gradient with Triton Xl 14 solution to extract all protein. 
Extraction by Triton XI 14 can produce a sample collection that can be pooled and 
concentrated by methanol precipitation. Immunoprecipitation involves lysing cells 
in a cell lysis buffer, the antibody is applied overnight and isolated the next day by 
the addition of Sepharose A beads. Sepharose beads are covalently modified with 
isolated protein A molecules that occur naturally on the cell walls of Staphylococcus 
aureus and bind to the Fc region of IgG or 1gM molecules. The strategy behind 
immunoprecipitation is the interaction of the antigen with the antibody and then the 
addition of excess Sepharose A containing protein A to bind all appropriate 
antibodies. The immunoabsorbed antigen is purified from the crude extract by low-
speed centrifugation. Immunoprecipitation can be more sensitive than other methods 
if the antigen is in low concentration or sensitive to degradation. 
Both SDS-PAGE and Western blotting were completed after each extraction to 
determine the presence of PrP (Section 2.6.4). The antibodies used for Western 
analysis and immunoprecipitation are outlined in Table 2.3. Antibodies Fill 1 and 
3F4 were kindly supplied by Chris Birkett, IAH, Compton and Richard Kascsak, 
MRDD, New York, respectively. The secondary antibody was a peroxidase-
conjugated affinipure IgG complex. Purified PrPSC  samples were kindly provided by 
Angela Chong and Kasia Sobotnicki as positive controls for the SDS-PAGE and 
Western blotting procedures (full description of sample preparation and use in Section 
2.6). Positive controls were prepared from scrapie-affected mice or hamster brains 
available at the NPU. At the start of preparation a known weight of brain tissue (grams) 
was used for PrPSC  extraction. The purified sample is referred to as the amount of 
protein (gram Equivalent (gE)) extracted from a known weight of brain (Chong, 
personal communication). Within this thesis both proteinase K treated and non-treated 
sample were used. For SDS-PAGE, 25p1 of a control sample, dissolved in lOOjil lx 
sample buffer (Chapter 2, Section 2.6) was loaded on to a gel. Serum controls for the 
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antibodies available at the NPU were completed prior to this study (Angela Chong, 
personal communication: for 3F4 and 6H4 please refer to Kascsak etal., 1987 and 
Korth et al., 1997 respectively). 
5.5.4 Results. 
5.5.4.1 Chloroform/methanol extraction. 
Chloroform/ methanol extraction of mouse N2a cells transfected with plasmids 
pNPU2PM, pNPU3PM and pNPU7PM was repeated eight times. The ruminant-
specific antibody FH1 1 was used for immunological detection of transiently expressed 
ovine PrPC.  A typical Western bot is shown in Figure 5.11A. Despite several attempts, 
transiently expressed ovine PrP was not detected from any of the PrP constructs in the 
mouse N2a cell line (Figure 5.1 1A, samples 1-3). Successful extraction of endogenous 
N2a PrPC  by chloroform methanol extraction was demonstrated by immunoblotting 
with the polyclonal antibody 1B3 (Figure 5.11B. samples 1-3). Furthermore, the level 
of PrPC  extracted from N2a cells transfected with pNPU7PM does appear to be higher 
compared to the cells transfected with either pNPU2PM or pNPU3PM (Figure 5.1 1B, 
compare sample 3 to 1 and 2). However, this result was never repeated and no internal 
control was probed for, i.e a-actin, on the original blot which would have confirmed 
increased transient expression from pNPU7PM compared with the other PrP constructs. 
Similar transfections and extractions were carried out on the ovine cell lines sA80BR, 
pA80BR and pA80SK. A typical immunoblot result is shown in Figure 5.12. 
Chloroform/ methanol extraction was repeated four times on the transfected sheep cell 
lines and ovine PrP expression analysed by Western blotting coupled with antibodies 
1B3 and FH1 1. At the time of this study the monoclonal antibody 3F4 was not 
available at NPU and so the expectation at this stage was not to distinguish between 
endogenous and transiently expressed PrPC  but to detect an increase in PrPC  levels in 
the transfected cells compared to non-transfected cells. However, chlorofonn!methanol 
extraction was not efficient in extracting detectable levels of PrPC  from non-transfected 
or transfected ovine cells (Figure 5.12). 
196 
A 	Goat N2a 	I 	2 	3 








B 	Goat 	N2a 	I 	2 	3 
P rPSC control Mw (kD) 




Figure 5.11: Chloroform methanol extraction of endogenous and transiently 
expressed PrP' from a mouse N2a cell line. Following extraction, the precipitate 
was dissolved in lx sample buffer for SDS-PAGE and then transferred on to a 
charged nylon membrane for Western blotting. Antibody control was purified goat 
PrPSC ,0.002 gE; N2a control is non-transfected cells processed for extraction; 
sample 1, N2a cells transfected with pNPU2PM ; sample2, N2a cells transfected 
with pNPU3PM; sample 3, N2a cells transfected with pNPU7PM. A) 
Immunodetection with the ovine specific antibody FH1 1. B) Immunodetection with 
the polyclonal antibody 1 B3. Detection of lower molecular weight bands may 
indicate degradation of PrP and higher molecular weight bands may be PrP dimers 
or trimers. Alternatively extra bands may be due to cross reactivity of the 1 B2 
antibody (Chong, personal communicationO. 
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Figure 5.12: Chloroform/methanol extraction of endogenous ovine PrP from cell 
lines sA80BR. pA80BR and pA80SK. From chloroform/ methanol extraction, the 
protein precipitate was dissolved in lx sample buffer and loaded for SDS-PAGE. 
The antibody positive control was 0.002gE (left) and 0.0002gE (right) of mouse 
P rPSC which had been proteinase K treated. Following western blotting, the 
polyclonal antibody 1 B3 was used to detect PrPC  from sA80BR (sample 1), pA80BR 
(sample 2) and pA80SK (sample 3). 
I 
5.5.4.2 Detergent extraction. 
During development of Triton X-1 14 extraction from mouse and ovine cells, the 
antibodies 3F4 and 6H4 became available at NPU and were used in conjunction with 
1B3 and PHi 1 in an attempt to detect endogenous and transiently expressed P rPC . 
Detergent extraction using Triton X-1 14 was completed a total of eighteen times on 
N2a cells transiently transfected with the PrP constructs. Figure 5.13 shows a blot 
with one half probed with the polyclonal antibody 1B3 and the monoclonal antibody 
3174. The right-hand side of the blot is a typical result using 1B3, confirming protein 
extraction. Immunodetection with the hamster specific antibody 3F4 on the left-hand 
side of the blot shows in lane 2 a protein of approximately 27 kDa that is equivalent 
to truncated, un-glycosylated form of PrPC  protein. Using Triton X-1 14 extraction it 
was not possible to detect transiently expressed ovine PrP in N2a cells using the 
ruminant specific monoclonal antibody FH 11 (Figure 5.14) 
Purification of endogenous and transiently expressed ovine PrP by Triton X-1 14 was 
completed a total of nineteen times followed by immunodetection with the antibodies 
1 B3, FH 11, 3F4 and 6H4. In the majority of instances the level of PrP protein 
purified was not sufficient to be detected at the level of Western blotting using these 
antibodies. The immunoblot shown in Figure 5.15 is typical of control and 
transfected ovine cell lines after detergent extraction, SDS-PAGE purification and 
Western blotting with 1B3. On one occasion, ovine PrP was detected by the 
antibody FM 1 in sA80BR cells which had been transfected with the plasmid 
pNPU7PM (Figure 5.1513, lane 7), PrPC  detected had an apparent molecular weight 
of 3 lkDa which would be approximate to a un-glycosylated PrP protein. In Figure 
5.15 no endogenous PrPC  was detected, imunoblotting similar samples with hamster 
anti-PrP 3F4 antibody failed to confirm this result (Figure 5.16). Using detergent 
extraction it was not possible to detect transiently expressed PrP with the hamster 
specific antibody 3F4 (Figure 5.16). 
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Figure 5.13: Detergent extraction and detection of transiently expressed PrP' from 
N2a cells with 3F4.. Cell lysate was recovered from control N2a cells (sample 1) and 
N2a cells transfected with the construct pNPU2.3F4 (sample 2) and PrPC  purified by 
Triton X-114 extraction. The precipitate was dissolved in lx sample buffer and 
processed by SDS-PAGE, transferred onto PVDF membrane and membrane split into 
two equal halves; one half was probed with 1 B3, the other with 3F4. The positive 
antibody control was a purified hamster PrP (0.05gE), non proteinase K treated. 
200 
Goat 	1 	2 	3 	4 
PrPsc  







Figure 5.14:Detergent extraction of ovine PrP' from N2a cells and detection with 
antibody FH1 1 Cell lysate was recovered from control N2a cells (sample 1) and N2a 
cells transfected with the constructs pNPU2PM (sample 2), pNPU3PM (sample 3), and 
pNPU7PM (sample 4) and protein purified by Triton X-114 extraction. The precipitate 
was dissolved in lx sample buffer and processed by SOS-PAGE as shown above and 
then transferred onto a PVDF membrane (western blotted). The ruminant specific 
antibody FH1 1 was used to probe the membrane. The positive antibody control was a 
purified goat PrP&  (0.025gE) non proteinase K treated. 
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Figure 5.15: Detection of PrPC protein from ovine cell lines following detergent 
extraction. Cell lysate was recovered from control ovine sA80BR cells and ovine cells 
transfected with the PrP constructs and protein purified by Triton X-1 14 extraction. The 
precipitate was dissolved in lx sample buffer and processed by SDS-PAGE and 
western blotted. The positive antibody control was a purified mouse (A) and goat (B) 
PrP (0.1 gE) non proteinase K treated. A) Immunoblotted with antibody 1 B3. 
Samplel: non-transfected sA80BR cells; sample 2: sA80BR cells transfected with 
pNPU2PM; sample 3: sA80BR cells transfected with pNPU7PM. B) Immunoblotted 
with antibody FH1 1. Sample 4: non-transfected sA80BR cells; sample 5: sA80BR cells 
transfected with pNPU2PM; sample 6: sA80BR cells transfected with pNPU3PM; 
sample 7; sA80BR cells transfected with pNPU7PM. 
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Figure 5.16:Triton X-1 14 extraction of transiently expressed PrPC  in sA80BR 
with the antibody 3F4. Cell lysate was recovered from control ovine sA80BR cells 
and ovine cells transfected with the PrP constructs pNPU2.3F4 and pNPU7.3F4. 
Protein was purified by Triton X-100 extraction. The precipitate was dissolved in lx 
sample buffer and processed by SDS-PAGE and Western blotted with the hamster 
anti-PrP 3F4. The positive antibody control was a purified hamster PrP (0.05gE) non 
proteinase K treated. Samplel: non-transfected sA80BR cells; sample 2: sA80BR 
cells transfected with pNPU2.3F4; sample 3: SA80BR cells transfected with 
pN PU7. 3F4. 
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5.5.4.3 Immunoprecipitation. 
Protein purification by immunoprecipitation was carried out on five separate 
occasions for N2a cells and four times for ovine cell lines populations which had 
been transfected with the PrP constructs encoding the 31 74 epitope. After harvesting 
of the cell, the cell lysate was incubated for sixteen hours with antibodies 3F4 or 
6H4. SDS-PAGE and Western blotting with 1B3 to detect endogenous and 
transiently expressed PrPC  protein followed precipitation of the immunocomplex. 
Figures 5.17 and 5.18 show typical blots from PrPC  protein purified by 
immunoprecipitation from both N2a and ovine cell lines. 
As with chloroform/methanol extraction (Section 5.5.4.1) cross reactivity of the anti-
PrP antibody 1B3 was observed. This does make interpretation of the blots more 
difficult. Immunoprecipitation with complete culture medium was negative (data not 
shown) where as immunoprecipitation with all cell-extract preparations showed 
positive for PrP. The blots in Figures 5.17 and 5.18 show PrPC  extracted from N2a 
cells transfected with constructs pNPU2.3F4 and pNPU7.3F4. From Figure 5.17 all 
of PrPC  has been precipitated with the Sepharose beads and does not remain in the 
supernatant. PrPC  was detected in both non-transfected and transfected N2a cells 
despite using hamster anti-PrP 3F4 monoclonal antibody. Expression of the PrP 
constructs was also examined in ovine cell lines, Figure 5.18 shows PrPC  extraction 
from sA80BR. Despite detection of higher molecular weight proteins, extraction of 
PrPC protein also from both cell lines using immunoprecipitation was successful and 
on most occasions all three glycoforms of PrPC  were visible (i.e un-, mono- and di-
gylcosylated). It is apparent that although immunoprecipitation was capable of 
extracting PrPC  from cell lysate preparations it was not possible to distinguish 
transiently expressed PrPC  from endogenous PrPC,  despite the transient PrP 
constructs encoding the hamster 3F4 epitope. 
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Figure 5.17: Immunoprecipitate of PrPC  protein from N2a cells with 3F4. Cell lysate 
was recovered from N2a cells transfected with the constructs pNPU2.3F4 and 
pNPU7.3F4 for immunoprecipitation overnight with the hamster specific antibody 3F4. 
The precipitate was collected and protein eluted and processed by SDS-PAGE and 
Western blotting with the polyclonal antibody 1 B3. The supernatant collected from the 
precipitate was methanol precipitated and also processed. The antibody control for 
Western blotting was mouse PrP, (0.05gE) proteinase K treated. Sample 1, 
immunoprecipitate from mouse cells transfected with pNPU2.3F4: sample 2; 
immunoprecipitate from mouse cells transfected with pNPU7.3F4: sample 3; 
supernatant from sample 1: sample 4; supernatant from sample 2 
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Figure 5.18: Immunoprecipitation of PrPC  protein from N2a and sA80BR cell lines 
transfected with 3F4 encoding PrP constructs. Cell lysate was recovered from N2a 
and sA80BR cell lines from both controls and lines transfected with the constructs 
pNPU2.3F4 and pNPU7.3F4 for immunoprecipitation overnight with the hamster 
specific antibody 3F4. The precipitate was collected and protein eluted and processed 
by SDS-PAGE and Western blotting with the polyclonal antibody 1 B3. The antibody 
control for Western blotting was hamster PrP&  (0.05BE) non proteinase K treated. 
Sample 1, immunoprecipitate from non-transfected mouse cells; sample 2, 
immunoprecipitate from N2a cells transfected with pNPU2.3F4, sample 3, 
immunoprecipitate from N2a cells transfected with pNPU7.3F4; sample 4, 
immunoprecipitate from non-transfected sA80BR cells; sample 5, immunoprecipitate 
from sA80BR cells transfected with pNPU2.3F4, sample 6, immunoprecipitate from 
sA80BR cells transfected with pNPU7.3F4. 
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5.6 Discussion 
The ovine PrP gene 3'UTR has been shown to mediate in vitro protein levels. In 
vivo expression from the PrP gene is not fully understood. Hunter et al. (1994) 
described two PrP mRNAs transcribed mRNAs (2.1kb and 4.6kb), these transcripts 
are known to be identical in 5' sequence differing only in the length of the 3'UTR as 
a result of alternative polyadenylation (Goldmann et al., 1990). It is still not known 
whether the 2.1kb mRNA is a transcript for PrP protrein. As discussed in Chapter 
One (Section 1.9) the level of PrP mRNA, the ratio of the two transcripts and the 
amount of detectable PrP protein varies greatly between tissues (Horiuchi et al., 
1995; Goldmann et al., 1999). In an attempt to study the relationship between PrPC 
levels and the in vivo ovine PrP transcripts, PrP constructs were designed with 
3'UTRs as those described for the 4.6kb and 2.1 kb mRNAs. 
Expression from the constructs was to be driven by a region SOObp upstream of the 
transcription start site on the Cheviot PrP gene. This region has been shown 
previously to initiate transcription of a CAT reporter gene in ovine cell lines (O'Neill 
et a!, in preparation). The promoter region, which also includes exon I and the splice 
donor site, was cloned upstream of the Suffolk el PrP exon III for all constructs used 
in this study. Restriction digestion of the PrP exon III 3'UTR at defined sites created 
UTRs of varying lengths with known polyadenylation sites. Transient expression 
of the PrP constructs concentrated mainly on the plasmids pNPU2PM, pNPU23F4, 
pNPU7PM and pNPU7.3F4. Constructs pNPU2PM and pNPU2.3F4 are truncated at 
nucleotide (nt) 1929 and so only encoded one active pA site (nt 1523). Constructs 
pNPU7PM and pNPU7.3F4 contain the full length PrP gene 3'UTR and therefore 
encodes conserved pA sites at 1522, 2221, 2281, 2668 and 4046. RT-PCR analysis 
showed constructs pNPU2PM and pNPU7PM were actively transcribed in a mouse 
N2a cell line. The use of cell free translation assays may have confirmed protein 
synthesis form the PrP construct. 
Immunological detection of PrPC  proved difficult if not impossible. Although PrPC 
was easily extracted and detectable from the N2a cell line, endogenous PrP' from the 
ovine cell lines was more difficult to detect and the methods of PrPC  extraction 
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employed in this thesis had varying results. Protein extraction from N2a cells was 
successful using all methods described. Endogenous protein from ovine cell lines 
was only reliably determined by immunoprecipitation. Using N2a cells as a control 
for transfection and extraction, transient expression from the ovine PrP constructs 
was not detected by FH1 1, regardless of the extraction method. FH1 1 also failed to 
detect endogenous and transient PrPC  expression in the ovine cells. Following Triton 
X-1 14 extraction, a 3 1-32kDa protein was detectable by FH1 1 in sA80BR cells 
which had been transfected with pNPU7PM (Figure 5.15). The antibody FH1 1 
recognises an epitope in the PrP amino acid sequence (aa sequence 51-55; 
Somerville, personal communication) which is upstream of the proteinase K site in 
the N-terminus region. The protein detected in Figure 5.15 may indicate that the 
PrPC synthesised in vitro by sA80BR cells is un-glycosylated. It is not possible to 
state clearly that the PrPC  detected (Figure 5.15) was not endogenous, however from 
the same set of experiments no endogenous PrPC  was detected. Similar experiments 
in N2a cells using the monoclonal antibody 3F4 (Figure 5.13) showed detergent 
extraction of a protein with molecular weight 29kDa, suggesting a PrPC  protein that 
is both un-glycosylated and N-terminally degraded. Weighed with the failure of 
FH1 1 to detect transient and endogenous PrPC  expression and the detection of a 
truncated protein, the cell lines may not be synthesising/ modifying mature PrPC 
correctly. Alternatively the PrPC  may have been degraded by proteinases despite 
action taken to prevent protein degradation i.e. extraction carried out on ice and in 
the presence of proteinase inhibitors. 
Mutating the cloned ovine PrP ORF gene sequence in constructs pNPU2PM and 
pNPU7PM to encode the hamster 31 74 epitope hsould have allowed for the detection 
of transiently expressed PrPC  on a background of endogenous ovine PrPC.  Prior to 
the start of this study the hamster anti-PrP 31 74 antibody was recognised as not cross-
reacting with the sheep PrP protein (Kascsak et al., 1987). Probing for PrPC  with 
3F4 following detergent extraction of N2a cells successfully detected transient 
expression from PrP construct pNPU2.3F4 (Figure 5.13). However, despite several 
attempts PrPC  expression from constructs pNPU2.3F4 and pNPU7.3F4 was never 
detected in ovine cell lines following Triton X-1 14 extraction. Immunoprecipitation 
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with the antibody 3F4 was developed for extraction of transiently expressed PrPC 
from constructs pNPU2.3F4 and pNPU7.3F4 from both N2a and ovine cell lines. 
Results from immunoprecipitation were difficult to interpret but appeared to show 
precipitation of endogenous and transiently expressed PrPC  from both the mouse and 
sheep cell lines (Figure 5.17 and 5.18). Due to the absence of a cell lysate negative 
control for the PrP 3174 antibody it is difficult to say with confidence that PrP has 
been detected. However the pattern of protein detected between molecular 
weights30-36kD is characteristic for PrPC  as is the pattern of three distinct bands 
corresponding to the gylcosylation status (un-, mono- and di- glycosylated). 
Furthermore, from published data available at the start of this study, 3F4 was 
understood not to cross react with endogenous ovine PrP. From Figure 5.18 protein 
bands characteristic of PrP were detected in the non-transfected ovien cell line 
(Figure 5.18, lane4), indicating that ovine PrPC  was detectable by 
immunoprecipitation. In support of this idea, a recent report (Baron et al., 1999) has 
shown that in vitro expression of sheep PrP fusion proteins was detectable by 
Western blotting using the hamster monoclonal antibody 3F4. 
Despite detection of expression, at both the RNA and protein level, from the PrP 
construct in N2a cells, detection of transient expression within ovine cell lines was 
not achieved. There are several reasons for this failure. Firstly, the original paper 
describing anti-hamster PrP antibody (Kascsak et al., 1987) used purified PrPSC  from 
mice and hamsters brains infected with hamster scrapie strain (263k). At the start of 
this study the anti-hamster PrP antibody was thought to detect only hamster and 
human PrP while not detecting sheep, rat, cattle and rabbit PrP (Kascsak et al., 
1987). It was only recently that 3F4 has been described as cross reacting with the 
sheep PrP protein (Baron et al., 1999). Secondly, it has also been shown that the 
level of recoverable PrPSC  from different brain-tissue samples can vary depending on 
the method of protein extraction and the specific PrP antibody (Madec et al., 1998). 
Furthermore, within the same study the choice of anti-PrP antibody also lead to 
variable results. Madec et al, (1998) compared two widely used methods for 
extraction of PrP sc based on detergent methods (Sarkosyl) and showed that the 
methods varied on sensitivity, depending on the starting levels of PrPSC  within the 
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tissue (Madec et al., 1998). Also when coupled with a ruminant specific PrP 
monoclonal antibody the methods were again distinguishable in their efficiency to 
detect PrP. Madec et a!, 1999, speculate that such variation in extraction efficiency 
may be affected, for example, by the presence of lipid in the tissues. It may be 
expected then that extraction methods that worked for N2a cells did not work for the 
ovine cell lines as the ovine cells had different endogenous PrPC  levels and contained 
different cellular concentrations of molecules such as lipids. Optimising an 
extraction method solely for ovine cells may have led to detection of endogenous and 
transiently expressed P rPC . 
Also, it would appear that PrPC  synthesised from the PrP constructs was truncated 
and unmodified. Incorrect expression of the PrPC  construct may be a due to the 
absence of exon II or full length sequence of introns I and II. As discussed in Chapter 
one (Section 1.8.3) the mouse intron I has been shown capable of promoter activity 
and promoter suppresser activity (Baybutt and Manson., 1997). The absence of 
intron II from the PrP gene lead to undetectable levels of PrP expression in Purkinj e 
cells of the cerebellum without affecting the level of PrP expressed in other brain 
areas (Fischer et al., 1996), implying that intron II may contain sequences necessary 
for cell-specific PrP expression. Lacking full PrP gene sequence, in vitro expression 
from the PrP constructs may have lead to reduced (or abnormal) protein synthesis. 
The synthesis of a truncated PrPC  protein would account for why the ruminant 
specific antibody FH1 1 was unable to detect transiently expressed PrP. 
Transient expression of PrPC  protein from the ovine PrP constructs in mouse N2a 
cell lines has shown that the PrP gene 3'UTR associated with the 2.1kb transcript is 
capable of supporting translation. However, this was not confirmed in ovine cell 
lines. Work presented within this Chapter highlights the need for more research into 
PrP extraction methods. There is a concern that alternative extraction methods used 
in different laboratories may give rise to ambiguous reporting of the presence of PrP 
protein in various tissue samples. Finally due to the conserved nature of the PrP 
gene it is difficult to reliably obtain species specific antibodies to the PrP protein. 
Antibodies that recognise defined host-derived PrP proteins may be forced to cross- 
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react with PrP from other species if conditions for extraction do not denature the PrP 
protein sufficiently or do not allow for stringent protein purification. The 
development of improved extraction methods for PrPC  and sensitive PrP antibodies 
may give more accurate results for future PrPC  analysis. 
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Chapter 6: Final Discussion and Conclusions. 
Implications for Scrapie Susceptibility. 
6.1 Results Summary and Discussion. 
Prior to the start of this study, in vitro expression experiments with the 
chioramphenicol acetyl transferase (CAT) gene linked to the PrP 3 'UTR had 
revealed an inhibitor effect on translatability of the CAT reporter gene in a mouse 
neuroblastoma cell (N2a) (Cheung, 1996; Goldmann et al., 1999). The PrP 3'UTR 
fragment used for the CAT analysis work was originally cloned from a Suffolk 
sheep, with PrP allele ci and A 136R154Q 171 (Goldmann et al., 1991a). The CAT-PrP-
3 'UTR constructs available at the NPU were used to further study the role of the 
3 'UTR in determining protein levels in ovine cell lines derived from different tissues 
/ 	and PrP genotype origins. The cell lines used in this study were derived from Cheviot 
brain tissue, PrP genotypes VV 136RR154QQ 171 (scrapie susceptible) and 
AA 1 36RR154QR171 (scrapie resistant), and cerebellum and liver from an Icelandic 
sheep breed, PrP genotype AA136RR154QQ1 7 1 (scrapie susceptible). As observed in 
mouse N2a cells, the PrP 3 'UTR was capable of altering the detectable level of CAT 
protein in brain-derived sheep cells. 
In all ovine cell lines tested in this study, no significant difference was observed in 
the level of transiently expressed CAT protein between CAT/PrP-3 'UTR constructs 
pEYR and pDl7. Constructs pEYR and p1317 were designed to resemble in vivo PrP 
mRNAs 4.6kb and 2.1kb respectively. From the lack of indifferent control of protein 
synthesis from constructs pEYR and pDl7, the conclusion may be that tissue origin 
and PrP genotype does not affect gene expression. However there was a significant 
difference in the observed response of the cell lines transiently transfected with CAT 
constructs containing deletions within the 3 'UTR sequence (summarised in Figure 
6.1). CAT activity from a construct with sequence deleted upstream from PrP 3'UTR 
nt position 2000 was significantly up-regulated compared to pEYR and pDl7 in cell 
lines sA80BR (Cheviot VV 136RR154QQ 171 brain cell line) and 1S120.Liv (Icelandic 
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sheep AA 136RR154QQ 171 liver cell line). This response was not observed in the 
pA80BR (Cheviot AA136RR154QR 171 brain cell lines) and 1S120.Cer (Icelandic sheep 
breed cerebellum AA136RR 154QQ 171 cell line) (Figure 6. 1, Tables 4.2, 4.5 and 4.7). 
Instead, in cell lines pA80BR and 1S120.Cer, the level of expression from pEYR, 
pD 17 and pD20 increased gradually following deletions of sequences upstream from 
nt position 27000. Interestingly CAT/PrP-3 'UTR constructs produced a similar 
expression pattern in the Icelandic (AA136RR 154QQ 171 ) liver cell line as the Cheviot 
(VV136RR154QQ 171 ) brain cell (Section 4.4, Figure 4.6), both genotypes in these 
breeds are known to be scrapie susceptible. 
Results presented in this thesis confirm the inhibitory effect of the PrP gene 3 'UTR. 
It is further proposed that the sequence 2000-2700 (region E-part F) of the 3'UTR 
functions as a repressor of PrP gene expression in brain cells of sheep encoding PrP 
genotypes normally associated with scrapie resistance. The repressor element is 
proposed to be an RNA-binding protein acting through 3' UTR sequence 2000-2700 
(regions E-part F, Figure 4.1). 
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Figure 6.1. Summary diagram of transient CAT/PrP-3'UTR constructs in ovine derived cell lines (Chapter Four) 
Several points for discussion for PrP gene expression arise from the above 
observations. Firstly, the 2.1 kb and the 4.6kb PrP 3 'UTRs are capable of supporting 
the same level of protein synthesis regardless of PrP genotype, this observation 
suggests that sequence shared by both 3 'UTRs can mediate steady state expression. 
The 2.1kb mRNA may be responsible for constitutive expression in peripheral 
tissues. Furthermore in VV 136RR154QQ 171 brain cells, the 4.6kb mRNA may have 
potential for increasing protein levels on the removal of a repressor element. Factors 
binding to the repressor element of the 4.6kb PrP mRNA may reduce protein levels 
from the 4.6kb mRNA by increasing the rate of mRNA degradation or inhibiting 
translation. 
Over expression of the PrP gene is known to increase susceptibility of transgenic 
mice to infection with TSEs (Scott et al,, 1989; Prusiner et al., 1990), therefore loss 
of control, or up-regulation, of PrPC  protein expression would also increase scrapie 
susceptibility. Natural scrapie transmission must occur through a peripheral route. 
Expression of the PrP gene in ruminants is known to differ between brain and 
peripheral tissues through differential transcription of PrP niRNA species (Hunter et 
al., 1994; Goldmann et al., 1999). According to the prion hypothesis, increasing the 
amount of PrPC  protein would increase the amount of template for conversion of 
PrPC to PrPSC  (Janet and Lansbury, 1993; Prusiner, 1993). On the other hand, the 
virino hypothesis, the increased concentration of PrPC  would increase the number of 
replication sites of the scrapie agent. The function of peripheral tissue in scrapie is 
slowly being understood: perhaps in sheep susceptible to scrapie abnormal 
expression of PrP protein in peripheral tissues is induced by the scrapie agent to 
promote agent replication. Such an argument is proposed in this thesis where loss of 
control of gene expression through a repressor element in the PrP 3'UTR may lead in 
adherent expression of PrP which in turn allows for increased potential for PrPSC 
formation. 
The creation of PrP null mice has shown that expression of the PrP gene is vital for 
TSE development (Bueler et al., 1993; Sailer et al., 1994). In mice, TSE disease 
incubation period is also determined by the level of PrP gene expression (Scott et al., 
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1989; Prusiner, 1990; Bueler et al., 1992). To date there is little evidence that sheep 
of different breeds or genotypes show significantly different PrP gene expression 
levels which can account for increased scrapie susceptibility in known populations. 
For example, tissue distribution of PrPC  protein, determined by western blotting was 
similar in Suffolk sheep, PrP genotype AA 136RR154QR171 and Blue-dc-Dorset, PrP 
genotype AA136RR154QQ 171 but were found to be different in a second Suffolk sheep 
of genotype AA 136RR154QR171 (Horiuchi et al., 1995). Furthermore the observed 
PrPC glycosylation pattern between sheep and different sheep tissues varied, the 
authors speculated that heterogeneity might arise from cell type specific P rPC 
expression or the influence of PrP genotype. Considering the later point, published 
sequence data from different breeds acknowledges several point mutations within the 
PrP gene 3'UTR between different sheep breeds and between sheep of the same 
breed ( Goldmann et al., 1990; Westaway et al., 1994; Lee et al., 1998). The 
existence of polymorphic sites in the 3 'UTR may allow for differential regulation of 
the PrP mRNA and therefore regulation of PrP protein through translation of the PrP 
transcripts. 
6.2 PrP Genotype and Scrapie Susceptibility. 
PrP genotype strongly influences susceptibility of sheep to scrapie. In 1962, Parry 
concluded that natural scrapie was a genetic disease, caused by an autosomal 
recessive gene but which was also transmissible (Parry, 1962). The discovery of 
maternal and lateral transmission (Brotherston et al., 1968; Dickinson et al., 1965; 
Dickinson and Outram, 1988) and sheep with scrapie susceptible genotypes in 
scrapie-free countries (Hunter et al., 1997) indicates that scrapie is an infectious 
disease. The current view is that host genetics are important for natural scrapie 
incidence but that it is not purely a genetic disease (Hunter et al., 1995; Foster et al., 
1996b). 
Analysis of natural and experimental scrapie in the NPU South Country Cheviot 
sheep flock (section 1.7, Table 1.4) has made a considerable contribution to the 
understanding of scrapie susceptibility. With this flock it was demonstrated that a 
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major gene, now designated PrP, controlled scrapie susceptibility (Dickinson and 
Outram, 1988; Hunter etal., 1987; Hunter etal., 1989; Hunter et al., 1991; Hunter et 
al., 1996). Polymorphic variants of the PrP gene have been extensively characterised 
and associated with incidence of scrapie in sheep (Goldmann etal., 1991a;Hunter et 
al., 1994), goats (Goldmann et al., 1996) and humans (Collinge et al., 1991). To 
date, seven polymorphic amino acid codons have been described in sheep with three 
known to be vital in determining scrapie susceptibility, these are codons 136, 154 
and 171 (Goldmann etal., 1990; Goldmann etal., 1991; Laplance etal., 1993; 
Bosser etal., 1996; see also Chapter 1, section 1.7). 
In NPU Cheviots, sheep homozygous for valine at codon 136 (V 136) have a short 
incubation period after challenge with experimental scrapie (SSBP/1), whereas sheep 
heterozygous at codon 136 with alanine (A 136) have longer incubation periods 
(Goldmann et al., 1990). Alanine homozygotes, AA 136 , are linked with scrapie 
resistance. Different TSE strains respond to different PrP polymorphisms. For 
example, Cheviots homozygous for glutamine at codon 171 (QQI7I)  are susceptible 
to experimental challenge with BSE or scrapie strain CHI 641 where as arginine at 
codon 171 (R 171 ) leads to longer incubation periods (Goldmann et al., 1994). A 
polymorphism for histidine at codon 154 (H 154) has been associated with resistance 
to scrapie infection in NPU Cheviots (Hunter et al., 1996). PrP polymorphisms at 
codons 136 and 171 have been associated with natural scrapie infection in 
throughout the world and in various sheep breeds (Laplanch et al., 1993; Belt et al., 
1995; Ikeda etal., 1996). 
Intensive PrP genotyping studies have revealed five allelic variations associated with 
scrapie incidence, the frequency and distribution of the allelic variants differ from 
breed to breed (section 1.7, Table 1.4; Dawson et a!, 1998). For example, the PrP 
allele V 136R154Q 171 is rare in Suffolk sheep but not in Texels or Cheviots and in 
contrast A 136R154H 171 allele is common in Texels but not in other breeds. In breeds 
which encode V 136 alleles (valine breeds), e.g. Cheviots, Swaledales and Shetlands, 
the allele V 136R154Q 171 shows the strongest association with scrapie susceptibility, 
sheep homozygous for this allele almost always develop scrapie in affected flocks. 
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PrP allele A 136R154Q171 is often associated with scrapie susceptibility, especially in 
breeds where the V 136R154Q 171 allele is rare i.e. Suffolk and Icelandic sheep breed. In 
valine breeds the A 136R154Q 171 allele tends to show a lower or incomplete penetrance 
to scrapie infection, as shown by longer survival times or relative resistance 
compared to V 136R154Q171 encoding sheep (Goldmann et al., 1991a; Clouscard et al., 
1995). Also, in valine breeds combining the V 136R154Q 171 allele with A 136H 154Q 171 or 
A136R154R171 offers relative resistance to scrapie infection (Laplanche et al., 1993; 
Hunter et al., 1996). 
There are on occasion however, incidences of scrapie or resistance to scrapie, which 
defy the well-defined polymorphisms discussed above. For instance, sheep 
homozygous for PrP allele V 136R154Q 171 have been found, apparently scrapie free, at 
an age well past life expectance of a sheep with such a susceptible genotype (Hunter 
et al., 1997). In contrast sheep with the V 136R154Q 171 allele coupled to A 136R154R171 
allele, normally linked to relative resistance, were found to be affected by scrapie 
(Hunter et al., 1997). Additionally in non-valine breeds (Suffolk) sheep 
homozygous for allele A 136R154Q 171 do not always develop scrapie whereas scrapie 
did occur occasionally in sheep with genotype AA136RR154QR1 7 1 (Hunter et al., 
1997). To date on one case of scrapie has been identified in AA 136RR154RR171 
throughout the world (Ikeda et al., 1995) 
Due to the observed variation in PrP allelic variants in scrapie-affected sheep, factors 
other than known PrP gene polymorphisms must control susceptibility. Results 
presented within this thesis show detectable differences in in vitro protein levels 
between CAT/PrP-3 'UTR constructs transiently expressed in brain cell lines derived 
from sheep with different PrP genotypes and scrapie susceptibilities. Brain cell lines 
used in this thesis were derived from a Cheviot VV 136RR154QQ 171 (scrapie 
susceptible), Cheviot AA136RR 154QQ 171 (scrapie resistant) and an Icelandic sheep 
breed, AA 1 36RR154QQ171 (scrapie susceptible). The PrP gene 3'UTRs associated 
with the 2.1 kb or 4.6kb PrP mRNA did not result in varying amount of protein. 
However, constructs containing 3'UTR regions E-G (pD20, figure 4.1) did function 
differently in the brain cell lines with genotypes VV 136RR154QQ 171 compared with 
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AA136RR154QQ1 7 1 /AA 136RR 154QR171 . Brain cells derived from sheep with at least one 
copy of the A 136R154Q 171 allele appeared capable of repressing expression from 
constructs containing sequence 2000-2700 (i.e. pEYR and pD20) equivalent to the 
construct with UTR resembling the 2.1kb PrP mRNA (pD 17). In contrast, 
VV 136RR154QQ171 brain cell line appeared incapable of repressing expression from 
pD20 (Figure 4.3) 
The association between the speculative repressor quality of PrP 3 'UTR and PrP 
genotype does not apply to scrapie susceptibility. The Cheviot brain cell line 
VV 136RR154QQ171 is known to be scrapie susceptible where as the Cheviot 
AA 1 36RR154QR171 brain cell line is resistant to natural scrapie. The Icelandic sheep 
breed in contrast has a genotype of AA 136RR154QQ 171 , a genotype normally 
associated with resistance to natural scrapie in Cheviots, but scrapie susceptible in 
Icelandic sheep (Thorgeirsdottir et al., 1999). So despite sharing similar PrP 
genotypes and response to the CATIPrP-3'UTRs constructs, the Icelandic cerebellum 
and the AA 136RR154QR171 Cheviot brain cells are derived from sheep of different 
scrapie susceptibilities. PrP allele disease linkage is well established, therefore other 
factors must function to increase, or decrease, the susceptibility of a particular sheep, 
and breed to scrapie. Several reasons may be given for this: control of PrP 
expression may differ depending on the host genotype; susceptibility may also be 
determined by further, as yet unknown polymorphisms in the PrP untranslated region 
or other genes may have a role in TSE infection; different scrapie strains may have 
different affinities for different PrP alleles. 
The implications here are that breed differences may allow for differential control of 
PrP gene expression during scrapie infection i.e. variation in genes or gene products 
other than PrP influence scrapie susceptibility. PrP polymorphisms are strongly 
linked to incidence of scrapie however other factors may act co-ordinately with PrP 
to influence scrapie susceptibility. These genes may be involved in controlling 
expression of the PrP gene. It is feasible that expression of the PrP gene may, in 
part, be controlled by sequences within the 3'UTR as proposed within this thesis. 
Suppression of gene expression, either at the level of transcription or translation, will 
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reduce the amount of available PrP protein which has been strongly linked with a 
role in facilitating infection of TSEs. 
6.3 Brain and Peripheral ExDression of the PrP Gene. 
The discovery of selective polyadenylation of the PrP gene in brain and peripheral 
tissue first led to the idea that the function of the PrP 3'UTR is far more complex 
than previously believed (Hunter et al., 1994). The 4.6kb transcript is preferentially 
produced in sheep brain tissue, and both rnRNA species have also been shown to be 
present at low level in bovine tissue (Goldmann e t al., 1999). The level of PrP 
mRNA in peripheral organs is lower than in the brain (kidney PrP mRNA 
approximately seven times less than brain) despite the presence of two mRNAs. 
However the level of PrP protein is significantly higher in the brain than in 
peripheral organs (more than 40 times the level of the kidney). Although no 
significant difference in PrP mRNA level has been detected between scrapie-free and 
scrapie-infected sheep, an increase in the PrP protein is consistently observed. This 
is assumed to be due to accumulation of PrPSC which is not degraded by the cells. An 
increase in protein levels that are not associated with an increase in mRNA levels 
may also be the result of increased stability or translatability of the mRNA. 
Therefore, translational control of the PrP gene may be vital for maintaining protein 
levels. Sequence present within the 3 'UTR were shown to regulate in vitro protein 
synthesis (Cheung, 1996; Goldmann et al., 1999; this thesis.) 
Understanding the molecular events of differential PrP gene expression may lead to 
an understanding of scrapie susceptibility. The protein associated with TSEs, PrP 5', 
has been found in peripheral and neural tissues and expression of the PrP gene is 
known to vary in different tissues. Relating this to the disease, although the 
conditions for the conversion of PrPC  to PrPSC  are still unknown, the existence of 
PrPC in many tissues suggests that the scrapie agent may potentially be able to 
replicate in a variety of tissues. Natural scrapie must be transmitted via a peripheral 
rather than the intracerebral route so the differential expression of PrP in peripheral 
tissues is of particular interest (section 6.4). 
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To address whether the 3 'UTR also shows tissue specific control over gene 
expression, in vitro expression studies of the CAT/PrP-3 'UTR constructs were 
completed in ovine cells derived from cerebellum and liver tissues of the Icelandic 
sheep breed Ovis brachyura borealis pall (genotype AA 136RR154QQ 171 ). In general, 
CAT protein levels were higher in the liver cells compared to the cerebellum cells 
(Figure 4.7A and B), in contrast to the in vivo pattern of expression of PrP (Honuchi 
et al., 1995). This may indicate that brain tissue, the site of TSE pathology, is more 
efficient in controlling gene expression. As observed in the brain cell lines, there 
was no significant difference in the overall mean level of CAT protein expression, 
with the majority of the constructs displaying a characteristic expression pattern. 
However, expression from the construct with a 1.1kb deletion at the 5' end of the 
3'UTR (containing regions E-G, pD20) was significantly higher in the liver derived 
cell line compared to the cerebellum derived cell line (Compare figures 4.5A and 
4.5B). A further deletion of 0.7kb appeared to remove repression of protein 
expression in the cerebellum cell line. Interestingly, pD20 shows the same 
expression pattern in VV 136RR154QQ 171 Cheviot brain cells as in AA136RR1 54QQ 171 
Icelandic sheep liver cells (Figure 4.6, in that the observed repressor quality regions 
E-part F are not functional. Several reasons may explain this observation. Firstly 
PrP mRNA expression liver tissue is normally low with PrP protein detection limited 
(Horiuchi et al., 1995; Goldmann et al., 1999; Hunter personal communication). 
Therefore expression of CAT/PrP-3 'UTR constructs may not be representative of 
control exerted by the PrP 3'UTR in peripheral tissues. Or perhaps repression from 
the 4.6kb mRNA 3 'UTR is not necessary in peripheral tissue under normal 
conditions i.e. scrapie free, as the 2.6kb mIRNA is constitutively expressed. 
Alternatively the repressor may only be functioning in brain derived cells with the 
A136R154Q171 PrP allele. On consideration, the second account may be correct as the 
same region, nucleotides 2000-2700 also repressed expression in mouse N2a cells. 
Although the PrP genotype of the N2a cells is not known at this time, PrP protein 
expression is detectable in N2a cells. 
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In the brain, neurones were originally thought to be the site of agent replication and 
pathology as PrP mRNA was primarily located with neurones (Kretzschmart et al., 
1986; Manson et al., 1992a; Harris et al., 1993) suggesting that neurones were the 
site of synthesis for PrPSC  which was then transported axonally to the white matter. 
Support for this theory came from the study of scrapie development in transgenic 
mice expressing hamster PrP under the control of the neurone specific enolase (NSE) 
promoter (Race et al., 1995). Expression of PrP in neurones was only sufficient to 
sustain infection when the transgenic mice were inoculated intracerebrally with 
hamster derived scrapie isolate. However, it has been observed that PrPSC  deposition 
in astrocytes precedes neuronal loss (Diedrich et a!, 1991) indicating that astrocytes 
maybe a primary target for the scrapie agent (Diedrich et al., 1991) and are 
subsequently primary producers of PrP SC  which in turn leads to neuronal loss (Muller 
et al., 1993). Alternatively, astrocytes can be mopping up PrP SC  produced and 
exported by neurones. Recent studies have shown that a considerable amount of PrP 
mRNA within the brain is accounted to astrocyte expression (Moser et al., 1995). 
Furthermore, PrP null mice transgenic for the hamster PrP gene under the control of 
the glial fibrillary acidic protein (GFAP, astrocyte specific) promoter were 
susceptible to intracerebral inoculation with hamster scrapie (Raeber et al., 1997). 
These mice showed typical scrapie pathology with spongiform changes, astrocytosis 
in the neocortex and hippocampus and accumulation of PrPS.  The neurone and 
astrocyte specific expression studies described above highlight the relationship 
between neurones and astrocytes wherein astrocytes function to maintain the normal 
status of neurones and may indicate a co-operative relationship for astrocytes and 
neurone in TSE development. Loss of normal neuronal or astrocyte function during 
scrapie development may affect a common pathway and lead to dysfunction in both 
cell types. 
The cell type involved in the replication of the scrapie agent in vivo has not yet been 
identified, however evidence is growing in favour of follicular dendritic cells in the 
spleen functioning as sites of propagation for the agent (McBride et al., 1992, see 
also section 6.4). Strict control of PrP expression may be vital in tissues known to 
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express PrP at relatively high levels or those considered to be necessary for 
trafficking the scrapie agent to the CNS. Conversely the scrapie agent (or specific 
scrapie strains) may target particular PrP genotypes and tissues in which the PrP 
synthetic pathway can be modified to promote its replication. 
6.4 Transmission of Scrapie 
Natural transmission of scrapie is assumed to be via the oral route with the alimentary 
tract as a possible route of entry for the infectious agent. Ingestion of TSE-infected 
material is considered the major route of infection for TSE agents responsible for Kuru, 
vCJD, scrapie and BSE. Attempts to track the route of infection during scrapie 
development in mice and sheep have used two methods. Firstly immunoblotting and 
immunohistological detection of PrPSC  are widely used as a marker for infectivity due to 
the observation that PrP sc is never found in the absence of TSE infection. However it 
has been shown that infectivity can be detected without PrPSC  deposition so sensitivity 
of detection by the latter method may be limited. Mouse bioassay, although more time 
consuming can also be used to produce a lesion profile (section 1.4) and give further 
information on TSE strains. 
Hadlow et al, 1980, 1982, used a mouse bioassay to show infectivity was detectable, 
and persistent, in lymphiod tissues of naturally infected sheep months, or years, before 
becoming detectable in brain (Hadlow etal., 1982). This observation was confirmed by 
immunohistological detection of PrPSc  in spleen, retropharyngeal lymph nodes, 
mesenteric lymph nodes and palatine tonsils of naturally infected, clinical positive 
scrapie sheep (van Keulen et al., 1996). A similar PrP sc detection pattern was described 
recently during experimental transmission of BSE to lemurs (Bons et al., 1999). These 
data suggested that during oral exposure, the TSE agent crosses the intestinal barrier via 
cells in the lumen of the digestive tract (including the tonsils). The cell populations 
involved in this transport are unknown but could involve M cells (which have been 
shown to be responsible for the uptake of bacteria, Trier, 1991). Alternatively, 
lymphocytes present in the tissues may also be involved and transport the agent through 
the lymphoreticular system (LRS) to the lymph nodes and spleen. Within the spleen 
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cells thought to be vital for scrapie replication are follicular dendritic cells (FDC) 
(McBride et al., 1992). Severe combined immunodeficent (SCTD) mice, which lack B 
and T lymphocytes and mature FDCs, are resistant to peripheral (mtraperitoneal) 
challenge with scrapie and are unable to replicate the agent in their spleens (Fraser et 
al., 1996; Lasmezas etal., 1996; O'Rourke etal., 1994). Furthermore, transgenic 
models with immune systems manipulated to produce lymphocytes but not mature 
FDCs were resistant to infection with scrapie strain ME7 (Brown etal., 1999). 
Therefore the LRS, or specifically the gut associated lymphoid tissue (GALT), and the 
spleen may play a vital role in scrapie agent replication and spread of disease from 
peripheral tissues to the brain (CNS). 
Several studies have indicated a second route for the spread of the disease in a host. 
Kimberlin et al. (1989b) demonstrated that splenectomy did not prevent mice 
developing scrapie when challenged intragastrically with mouse-adapted scrapie strain 
139A. In hamsters, infection with scrapie strain 263K shows little involvement of the 
spleen in scrapie replication early in pathogenesis following oral infection (Beekes at 
el., 1996). More recently PrPSC  deposition was recorded in myentric and submucosal 
plexuses of the gut wall, stomach, caudal oesophagus and enteric nerves of sheep with 
clinical signs of natural scrapie (van Keulen et al., 1999). This was confirmed by 
Beekes and McBride (2000) where infection was detected early in pathogenesis in 
various GALT tissues and ENS ganglia which suggests that the enteric nervous system 
may be an alternative route. Once located in the ENS or GALT the agent is presumed to 
spread to the thoracic spinal cord or dorsal motor nucleus of medulla oblongata (van 
Keulen eta! 1999; Beekes and McBride, 2000) via nerve cell pathways. 
The route of infection and replication in the spleen would appear to be strain specific 
and host dependent. For example in hamsters, infection with scrapie strain 263K does 
not involve replication in the spleen (Kimberlin et al., 1989b). Similarly, the spleen 
does not seem vital to BSE infection in cows, however infectivity has been reported in 
sheep experimentally infected with BSE (Foster et al., 1996a). Also van Keulen eta!, 
1999, reported significantly more peripheral deposition of PrPSC  in the ENS of sheep 
with highest genetically determined scrapie susceptibility compared with those with a 
PrP genotype associated with scrapie resistance (van Keulen, et al., 1999). 
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The role of PrP gene expression in TSE susceptibility and development is slowly being 
understood. Fundamentally, factors known to increase TSE susceptibility are defined 
mutations and polymorphisms in the PrP coding region and, as determined by studies in 
transgenic mice, overexpression of the PrP gene. Scrapie is not a spontaneous genetic 
disease (Hunter et al., 1997), therefore an infectious agent must be involved in disease 
development. Following oral contamination the agent may begin replication within 
tissues, or cell types, in which it can interact with the normal PrPC  synthetic pathway. 
Differential control, or expression, of the PrP gene between tissues may dictate the 
route of infection taken by the scrapie agent. 
6.5 Controllinci PrPC  ExDression. 
Production of an active protein from a gene requires multiple regulated steps, many of 
these steps involve some aspect of RNA processing. Disease caused by mutations that 
affect RNA processing are relatively rare compared to mutations that disrupt protein 
function. The vast majority of RNA processing faults linked to disease are due to the 
loss of function of a single gene as a result of mutations in elements required for pre-
mRNA splicing. However, a few diseases are caused by alternations in transacting 
factors required for RNA processing. One interesting example of such a process was 
observed in expression of amyloid precursor protein (APP) mRNA (Amara etal., 
1999). Similar to TSEs, Alzheimer's disease (AD) is associated with deposition of an 
amyloid peptide (amyloid - 13 , A13) in the CNS and neurodegeneration (Ishiura et al., 
1991; Lendon etal., 1997). A13  formation is thought to be linked to abnormally 
processed, or high levels, of APPs as a result of over expression of APP mRNA 
(Johnson etal., 1990; Ishiura etal., 1991;Hardy, 1997). In vitro, APP mRNA levels 
were observed to increase in astrocytes in response to TGF-13 1 (Gray and Patel, 1993). 
Consequently, levels of transforming growth factor (TGF- 1 ) were found to be 
increased in AD patients, to associate with lesions (Peress and Perille, 1995) and to 
promoter amyloid deposition in transgenic mice (Wyss-Coray et al., 1997). Therefore 
TGF- 1 appeared to be a candidate for increasing APP mRNA levels and promoting 
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AD. TGF-3 1 is a known transcriptional regulator (Massague, 1990), however TGF-f3 1 
has also been shown to regulate genes involved in mRNA stability (Amara etal., 1996). 
In vitro analysis of APP mRNA expression in human astrocytes in response to TGF- 1 
confirmed the results of Gray and Patel, 1993, but also showed that in the presence of 
TGF-3 1 , APP mRNA stability increased five-fold (Amara et al., 1999). As 3'UTRs 
are known to function in controlling mRNA stability the authors examined any possible 
role of APP mRNA 3'UTR in TGF-13 1 induced stabilisation and discovered that the 
APP mRNA 3'UTR conferred stability on the CAT reporter gene product (Amara et al., 
1999). Band shift and UV cross-linking assays revealed that sequence in the 3 'UTR 
interacted with a cytoplasmic protein to form a 68kDa RNA-protein complex in 
response to TGF-3 1 treatment. Formation of the RNA-protein complex led to increased 
stability of the CAT mRNA. Deletion of the TGF-f3 1 response element (region of UTR 
the TGF-13 1 - responsive protein bound to) from the 3'UTR of APP mRNA prevented 
stabilisation of CAT mIRNA in the presence ofTGF-13 1 . Amara eta!, 1999, proposed 
that TGF-3 1 may increase and stabilise APP mRNA expression indirectly by regulating 
a responsive protein and its interaction with the 3 'UTR sequence. 
There is little knowledge on the PrP regulatory pathway and the role of PrPC  in 
peripheral and its contribution to scrapie agent infection and replication. Peripheral 
tissues are a potential source for scrapie replication and subsequent transport to the 
brain (section 6.4), understanding the mechanism of PrP expression is vital for 
elucidating the function of PrPC  in TSEs. From in vitro and in vivo studies there is 
evidence that the level of PrP mRNA expression may increase in the presence of 
specific cytokines and growth/differential factors such as interlukin —6 (IL-6), nerve 
growth factor (NGF), migratory inhibitory factor-related protein(IVIIRP8) (Mobley et al., 
1988; Wion etal., 1988; Lazarini etal., 1994; Kniazeva etal., 1997). In contrast, PrP 
expression is inhibited in human fibroblasts by the presence of platelet derived growth 
factor (PDGF). Therefore, known transacting factors (regulatory proteins) have already 
been shown to influence the level of detectable PrP expression. The majority of the 
transacting factors are transcription activators or regulators (Table 4.6). However as 
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discussed for Alzheimer disease (AD, Section6.5), transacting factors such as cytokines 
can also regulate at the post-transcriptional level. 
Work presented within this thesis confirms that the ovine PrP gene 3 'UTR contains a 
sequence capable of mediating PrP protein levels and proposes that sequence 2000-
2700 represses expression from the 4.6kb mRNA. This speculative repressor sequence 
may be in either secondary structure or specific sequence (cis-acting) for the binding of 
regulatory factors (nuclear or cytoplasmic). Alteration of the PrP metabolic pathway 
by the agent may be indirectly through interaction with transcriptional/ translational 
machinery or directly with the pre-rnIRNA or mRNA (Figure 6.2). Cheung (1996) 
observed no change in mIRNA levels but increased translatability (protein levels) from 
various CAT/PrP-3 'UTR constructs. This would suggest that different PrP mRNAs 
show either enhanced stability or translation efficiency. If the scrapie agent were 
capable of modulating PrP metabolism increasing stability/translation of PrP mRNA 
would increase PrP protein levels, which in turn would enhance agent replication. The 
agent may bind directly to PrP mIRNA or affect trans-acting factors that bind to the 
RNA. Genotype and scrapie susceptibility differences observed between, and within, 
flocks may be explained by efficiency of the scrapie agent to interact with PrP synthesis 
in sheep with different genetic backgrounds. 
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Figure 6.2 Potential sites for control of PrP gene expression. 
Within this thesis, control of in vitro gene expression has been examined in 
association with the PrP gene 3'UTR. A putative repressor of expression has been 
proposed within the 3'UTR which functions preferentially in brain cells with at least 
one ARQ allele. Sites for repression include: X 1 ; down regulation of transcription, 
repression of transcription termination: X 2 ; interaction with trans-acting factors 
preventing efficient processing; differential regulation of polyA degradation; X 3 ; 
association with cytoplasm trans-acting factors which prevent translation or stabilise 
mRNA; down regulation of translation efficiency. RER: rough endoplasmic 
reticulum. 
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6.5 Final Thoughts and Future Work. 
Expression of the PrP gene is vital for the development and spread of TSE disease.. 
Although scrapie in sheep and goats is known not to be spontaneous genetic disease, 
polymorphisms have been linked to increased susceptibility. However, how can a 
sheep of susceptible genotype remain apparently healthy when housed with an infected 
flock, or a sheep with resistant genotype develop scrapie? One explanation for selective 
development of scrapie in sheep of particular PrP genotype and breed is proposed in 
this thesis: differential control of PrP gene expression. Factors other than PrP genotype 
frequency may also influence scrapie susceptibility. A putative repressor —binding site 
in the PrP gene 3'UTR has been identified in the 4.6kb PrP mRNA 3'UTR sequence 
which acts specifically in brain cells derived from sheep with at least one A 1 36R 1  54Q 1 71 
allele. However the repressor element does not seem to be associate strictly with scrapie 
resistance as the regulatory function was operational in A 1 36R1 54Q1 71 brain-derived cells 
from known scrapie resistant and susceptible sheep. Perhaps highly susceptible breeds 
and genotypes already have reduced control over PrP gene expression which can be 
exploited by the scrapie agent. During the process of replication, the agent may 
interfere with the pathway of PrP synthesis by increasing stability of the 4.6kb mIRNA, 
leading to increased levels of the 4.6kb mRNA and may produce PrPSC  as a by-product. 
It is hypothesised that: 
Scrapie susceptibility, although strongly linked to PrP gene polymorphisms, may 
also linked to control of PrP gene expression 
In sheep with high-risk scrapie associated alleles the scrapie agent may be able to 
increase the level of PrP gene expression at the post-transcriptional level. 
PrP expression may be controlled through transacting factors at a 3 'UTR cis-
element (specific sequence). 
PrP gene expression is controlled in cell/tissue specific manner that may dictate the 
route of scrapie spread to the CNS. 
Work for the future should be aimed at confirming the regulatory role of the 3'UTR in 
gene expression. Transient expression of the CAT/PrP-3 'UTR constructs in cells 
derived from various non-neuronal tissues thought to participate in scrapie infection 
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(distal ileum, spleen, lymph nodes) would clarify whether or not the repressor was 
specific to the brain or not. It would be interesting to see if the CAT/PrP —3 'UTR 
constructs showed the same expression in tissues known to express PrP in peripheral 
tissue i.e spleen or lung. The spleen would be of particular interest as this is one of 
the few non-neural tissues in which natural scrapie infectivity can be detected. Also, 
expression in follicular dendritic cells, one of the assumed sites for scrapie 
replication outside the CNS may, lead to further understanding of PrP expression and 
the disease process. Furthermore, wider in vitro expression analysis in cell lines 
derived from sheep of other PrP genotypes would confirm the association of 
A1  36R1 54Q17 1 allele with reduced expressional control and indicate that other factors 
(based on genetic differences) may control PrP gene expression. If cells from PrP 
expressing peripheral tissues derived AA 136RR154QQ 171 or AA136RR154QR171 sheep 
also showed repression of the CAT/PrP-3'UTR vectors over sequence 2000-2700 
this would further imply that control of PrP gene expression is vital for maintaining 
scrapie resistance. Transient expression of the PrP gene should be possible in the future 
with development of more specific antibodies and extraction methods. Using this 
approach a clearer understand may be reached on specific control of the PrP gene. 
Studies should concentrate on potential binding of transacting factors to the PrP gene 
3'UTR. This could be achieved by DNA footprinting (Galas and Schmitz, 1978), DNA 
mobility shift assays or gel retardation (Fried and Crothers, 1981; Garer and Revzin, 
1981) and methylation interference assays (Sienbenlist and Gilbert, 1980). 
Confirmation of transacting factors by a combination of these methods could lead to 
purification and characterisation of the regulatory molecules, and then hopefully 
identification. Furthermore, the efficiency of in vitro expression could be monitored as 
cells response to chemical or physical treatments (growth factors, heat stress) 
potentially able to control gene expression through cell signalling pathways. 
If one function of the 3'UTR is regulation of PrP gene expression via sequence at 
nucleotides 2000-2700 what about the 2.1kb PrP niRNA? The 2.1kb transcript is 
processed upstream of this putative repressor region so can we assume that this mRNA 
is controlled in the same way? No major difference has been recorded in expression of 
230 
the PrP transcripts between scrapie free and infected animals. From in vivo 
observations, it would appear that expression of the 2.1kb mRNA and the ratio of two 
PrP transcripts in particular tissues is further controlled through regions not included in 
this study. 
Natural scrapie must be transmitted through the peripheral route, so understanding the 
differential expression of PrP gene is of particular interest. It cannot yet be speculated 
whether this putative repressor sequences functions as a structural motif or 
recognition factor for nucleic acid binding proteins. Further more, this region may 
indeed interact with sequences at the 5' region of the PrP gene, a matter not 
addressed within this thesis. It is interesting to note that this repressor region is 
immediately 5' of the polymorphic EcoRI site loosely associated with scrapie 
incidence (Hunter et al., 1991). However, it is feasible to imagine that expression the 
PrP gene may be, in part, controlled by sequences within the 3 'UTR. Suppression of 
gene expression, either at the level of transcription or translation, will reduce the 
amount of available PrP protein which has been strongly linked with a role in 
facilitating infection of TSEs. Consequently a loss of repressor function may lead to 
aberrant PrP expression. PrP gene expression is vital for scrapie development, 
therefore variation in gene expression control may alter the levels of PrP protein in 
tissue and hence scrapie agent infection, replication and ultimately pathology. 
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Appendix A: Solutions, Reagents and Plasmids 
General solutions. 
Agar Broth. 
20g of LB broth base to iLt of dH20. 
Autoclave as for agar plates. 
Add ampicillin to final concentration 1mg/mi. 
Agar Plates. 
32g of LB agar 
makeup to iLt with dH20 
Autoclave for 15mins at 121'C 
Agar can be poured immediately or stored for use. To melt, re-heat in microwave at low 
for 30 minutes, shake regularly. Leave for one hour to cool, then pour. 
1% Agarose Gels. 
ig agarose 
lOOmi lx TBE buffer 
4p.l Ethidium Bromide 
Alkaline lysis solution 1. 
50mIvI Glucose 
2.5mM Tris Cl (pH 8.0) 
2m1 0.5M EDTA stock 
Prepare in lOOm! aliquots, autoclave and store at 4 °C. Glucose added after autoclaving. 
Alkaline lysis solution 2. 
7m1 dH2O 
2m1 4M NaOH (final conc 20mM) 
lml 10%SDS 
Alkaline lysis solution 3. 
60m1 5M Potassium acetate (final conc 3M) 




As agar plates; when the agar is ready to pour add ampicillin to final concentration of 
ltg/MI. 
Ethidium Bromide. CAUTION 
0.25g Ethidium Bromide 
lOOml dH2O 
or lx 10mg tablet to im! dH20. Make up to 2m1. 
Loading buffer (agar gels) 
0.25% bromophenol blue (0.025g) 
50% glycerol + dH20 
TB. 
0.6g 10mM PIPES 
2.18g 55mMMnC12 
0.44g 15mM CaCl2 
3.73g 250mM KCL 
TBE (l Ox). 
108g Tris 
55g Boric acid 
40m1 0.5M EDTA pH 8.0 
Makeup toiL 
Tris-HC1 (pH7.5) 
0.1M Tris-HC1 , pH7.4 
pH to 7.4 with HC1 
Distilled water to lOOm! 
2XYT Medium 
1 Og LB Broth 
5g Bacto-tryptone 
Add dH20 to 500m1, autoclave to sterilise. oH to 7.05. 
Filter sterilise and store at 4 °C (there is a brown precipitate autoclave instead) 
A-u 
General Tissue Culture solutions 
Fetal Calf Serum (FCS). 
500m1 heat inactivated FCS aliquoted into 10x50m1, stored at -20 °C. FCS heat 
inactivated at 56°C for 45 mins. Immediately before use centrifuge at 2000rpm for 10 
minutes. 
FCS supplied by Gibco-BRL. 
Complete Culture Medium. 
500ml of IMDM (Gibco) 
50m1 of centrifuged, heat inactivated FCS 
Penicillin/Streptomycin to final conc. 100 units/ml 
Add 5m1 Pen/Strep to 500m1 medium 
Complete Culture Medium with Nerve Growth Factor(NGF). 
1 OOml of complete culture medium 
NGF to final conc. of lOng/mi (Sigma N-0153) 
Freezing Medium. 
30m1 of complete culture medium 
1 .5m1 heat inactivated FCS (centrifuged) 
5m1 of DMSO 
aliquot into 8x6ml and tore at -20 °C 
Trypsin! Versene. 
4ml 25%Trypsin 
16m1 0.02% Versene 
0.1% Gelatin. 
0.4g gelatin (Biorad gelatin electrophoretic grade) 
400m1 dH2O 
autoclaved for 15 minutes at 12 1 °C, store at 4°C 
TENS. 
40mM Tris-HCL pH 7.5 
1mM EDTA pH 8.0 
150mM NaCl 
A-iii 
FITC Blocking buffer 
0.2g BSA 
0.745g Tris pH 7.4 
To lOOm! H20 
General solutions and requirements for protein extraction 
Protein Standards. 
Prestained proein molecular weight Standards (Gibco BRL, 26041-020), 14,300-200,000 
molecular weight range, lyophilized 
Running conditions - 200V, 1 5OmA (2 gels) for 1 hour. 
Apparatus - Mini protean II Electrophoresis cell (Biorad) 
- Semi-dry transfer cell (Biorad) 
12% Acrylarnide Resolving gel 
10.02m1 Acryl/bis mix 
1.285g Tris 
3.Og Sucrose 
0.77m1 1M HC1 
8.75m1 TEMED 
H20to25m1 
Store at 4 °C. To pour gel, 7m1 12% acrylamide mix + 120tl APS 
3.5% Acrylarnide Stacking gel 
5.82m1 Acryl/bis mix 
0.327g Tris 
2.65m1 0.5M H2SO4 
55m1 TEMED 
H20 to 50m1 
Store at 4°C. To pour gel, 3.8m1 3.5% acrylamide mix + 60.tl APS. Apply on top of 
12% gel. 
A-iv 
10% Ammonium Persuiphate (APS) 
0.1g in 1 ml water 
NB - make fresh daily 
Sx Sample Buffer (SB) 
000.81g Tris 
1.25g SDS 
0.667m1 1MH2 SO4 
1 .25m1 -mercaptoethanol 
Lower Reservior Buffer 
28.22g Tris 
16.9m1 1M HC1 
Distilled water to 500m1. 
Note- make fresh on day of use. 
Upper Reservoir Buffer (20x) 
24.8g Boric acdi 
49.6g Tris 
10.Og SDS 
Distilled water to 500m1. 
For running: lOmi 20x stock to 190 ml distilled water for 2 gels. 
Solutions for Chemiluminescence blottinci. 





H20 to 1L 
Store at 4 °C 
TBS. 
6.05g Tris base 
8.76g NaCl 
H20 to 800m1, pH 7.5 with HC1 - top up to 1L with water 
A-v 
TBST 
For one blot: 0.25m1 TWEEN (Roche) in 250m1 TBS 
1% Blocking solution. 
Per blot: imI Blocking agent (Roche) in lOOmi TBS 
0.5% Blocking agent 
Per Blot: 5m1 Blocking agent in lOOm! TBS 
Detection solution. 
Pre-warm solution A for 30 minutes at 25°C 
Per blot: 1.5rn1 solution A, 15m1 solution B. Incubate at room temperature for 30 
minutes. 
BM Chemiluminescence Blotting Substrate (POD) Cat no: 1 500 694 (Roche 
Diagnostics,LJK) 
Solutions for Triton X-1 14 extraction. 
Extraction Buffer. 
For 50m1; 
Sm! 0.1M Tris-HC1, pH 7.4 (10mM) 
0.438g NaCI (150mM) 
4.385m1 Triton X-1 14 (1%) 
note - Triton X- 114 must be pre-condensed 
is 11%. Store at 4 °C 
Sucrose Buffer 
For 50m1; 
5m1 0.1M Tris-HC1, pH7.4 (10mM) 
3g Sucrose (6%) 
0.43gNaCl (150mM) 
H20 to 50 ml 
Store at 4 °C 
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Figure A. 1 Cloning vector pBluescript SK II (-) 




















Figure A. 2 Cloning vector pGEM-7Zf (+) 
A-vu 
EcoRI 












Figure A. 3 p71 pUCI8 derived (Goldmann et al, 1990) 
Hindu 














Ovine PrP promoter 
(0.5kb) 














Ovine PrP promoter 
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Ovine PrP exonill 
fragment (3.6kb) 
Figure A. 9pNPU3PM. Insertion of(XhoI)ApaI-Xhol digestion from pGem.Promoter into 







N / z Hind!! 
'iiePrP promoter 
pNPU2PM 	 Hind!! 	
(0.5kb) 
Xba! 6kb Xho! 
EcoRl 
Nsi 	
Ovine Pr? exonill 
fragment (2.5kb) 
Figure A. 10 pNPU2PM. Created by removing 1.5kb Nsi-Kpn digestion from pNPU3PM and 
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Figure A. 12 Construct pPSH3F4. Manipulation of the ovine ORF by PCR-mediated site directed 
mutagenesis introduced the hamster coding sequences for the amino acid epitope 3F4.. The 
manipulated ovine fragment (0.7kb) was cloned into clone pPSH3F4 (pBluescript backbone) using 
sites Pstl and Xn:al. 
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Ovine PrP promoter 
Hindu 	(0.5kb) 
pNPtJ2PM 	/ EcoRlf1 
6kb 	 Xhol 
Nsil 
Hindi 
Ovine PrP exonlll 
fragment (2.5kb) 
Figure A. 13 Manipulated ovine sequence was cloned from pPSH3F4 in to pNPU2.3F4 using 





Ovine PrP promoter 
(0.5kb) 
EcoR1 
Ovine PrP exon III 
(7kb) 
XbaBI 
Figure A. 14 Restriction digestion with BarnHIIXbaI of plasmids pNPU2.3F4 and pNPU7PM 
produced a 1.5kb fragment, encoding the nucleotide sequence for the 3F4 epitope, this was 
inserted into clone pNPU4.3F4. 
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\,rH 
Synthetic poly(A) signal 	
CAT 	 SV4O late and transcription 	SV40 	
poly(A) region siteSV40 promoter promoter 
Figure A. 15 pCAT3-Promoter vector (Promega, Southhamptom 15K). 
PiP 5' upstream 	 CAT 
	
SV4O late 
region 	 poly(A) region 
Figure A. 16 Construct pCAT5 was designed and supplied by Dr Herbert Baybutt and contains 
1.5kb insert of sequence 5' to the mouse PrP start site cloned upstream of the CAT coding region 
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Appendix B 
B 1.0 Optimisation of transfection protocol for ovine brain-derived cell line 
sA8OBR. 
Transfection methods tested are described in Chapter Two, Section 2.5.. The control vector 
pCAT3 -Promoter (Promega, UK, appendix A) which expresses chioramphenicol acetyl 
transferase (CAT), was used to optimise transfection methods by analysing CAT activity in cell 
lysates. The vector pSV--Galactosidase, which expresses 3-Galactosidase, was used to control 
for transfection efficiency or cell lysate recovery from transfection experiments. The cells, 
sA80BR, were harvested 48 hours post-transfection with the vector pCAT3-Promoter and a CAT 
assay was performed, the results of which were analysed by thin layer chromatography (TLC). 
Using the autorad developed from TLC, it was possible to isolate the acetylated products from 
the silica plate and the level of CAT activity determined by measuring [' 4C] by liquid 
scintillation counting (LSC, section 2.5.10). Relative CAT activity was determined by comparing 
the CAT activity of the reporter construct to a positive CAT control reaction (assumed to be 
100% for each experiment). The positive CAT control was 1 unit of purified CAT enzyme 
(Promega, UK). The negative control was cell lysate from non-CAT transfected cells 
Table B 1.1 Transient transfection sA80BR by calcium phosphate. 
Experiment Details 	1 	2 	3a 	4 	
5a 
Cell Passage Number 9 13 13 14 14 
[DNA] ug 
	
10 	10 	5 	5 	5 
Time (hours) 
	
6 	16 	16 	16 	16 
LSC (cpm) 815.00 42.70 58.59 622
• 84b 57173b 
Positive control 
	
n/d 	36178.48 	22744.32 22744.32 
Negative control 	n/d 47.66 277.12 	277.12 
Relative CAT % 0 	0 	0 	0 0 
a Experiment 3 was a duplicate of 2 and experiment 5 a duplicate of 4 
b  Results negative by TLC 
Table B 1.2 Transfection of brain sA80BR cell line by Electroporation. 
Experiment Details 1 2 3a 4a 
Cell Passage No. 12 5 5 5 
DNA (ug) 50 5 25 50 
Voltage, V 800 800 800 800 
Capacitance 300 300 300 300 
LSC (cpm) 1781.89 ob 0b ob 
Positive control 76458.28 54183.2 
Negative control 461.9 291.3 
Relative CAT % 1.74 0 0 0 
a Experiment 3 and 4 were duplicates of 2 
b Results negative by TLC 
Table B 1.3 Transfection of brain sA80BR cell line by Electroporation. 
Experiment Details 5 6a 7a 
Cell Passage No. 6 6 6 
DNA (ug) 20 20 20 
Voltage, V 200 250 300 
Capacitance 960 960 960 
LSC (cpm) 0* 0* 0* 
Positive control 34864.7 
Negative control 189.4 
Relative CAT % 0 0 0 
a Experiment 6 and 7 were a duplicate of 5 
b  Results negative by TLC 
IM 
Table B 1.4 Transfection of brain sA80BR cell line by Dosper reagent (Roche 
Diagnostics East Sussex, UK) 
Experiment Details I 2a 3a 
4a 
Cell Passage No. 11 
DNA(tg) 3 3 3 3 
Dosper (rd) 0 2 4 6 
LSC (cpm) 48276b 
35161b 31288b 48575b 
Positive control 4176.32 
Negative control 413.21 
Relative CAT % 1.85 0 0 1.93 
'Experiments 2-4 were duplicates of 1 
bResults  negative by TLC 
Table B 1.5 Transfection of brain sA80BR cell line by Dosper reagent (continued) 
Experiment Details 5 65 7a 8
5 
Cell Passage No. 13 13 13 13 
DNA(p.g) 3 3 3 3 
Dosper (tl) 0 2 4 6 
LSC (cpm) 655.63 501.64 424.15 1483.54 
Positive control 92427.94 
Negative control 406.26 
Relative CAT % 0.27 0.1 0 1.17 
aExperiments  6-7 were duplicates of 5 
Table B 1.6 Transfection of sA80BR cell line by Tfx5O (Promega, Southampton, UK) 
Experiment Details 1 2 3 1 	2 	3 
Cell line sA80BR pA80BR 
[DNA]ug 3 3 3 3 3 3 
Tfx50 ratio 2:1 3:1 4:1 2:1 3:1 4:1 
LSC(cpm) 1534.74 2413.98 744.88 10566.09 8275.89 1162.57 
Positive control 109272.6 
Negative control 634.07 748.84 
Relative CAT % 0.83 1.64 0.1 9.05 6.94 0.38 
Note: sA80BR, cell passage number 16. pA80BR, cell passage number 10 
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Table B. 17 Transfection of sA80BR cell line by Tfx50; serum free 
Experiment Details 1 2 3 	1 2 3 
Cell Passage No 17 
Medium serum serum serum 	serum serum serum 
free free free 
Tfx50 ratio 2:1 3:1 4:1 	2:1 3:1 4:1 
LSC (cpm) for 0.5 360.56 471.8 523.25 343.67 191.87 481.72 
DNA (tg); 	1 307.91 395.63 464.89 	395.65 226.49 520.29 
605.95 436.2 854.7 7876.72 5173.91 1879.3 
Positive control 107605.7 
Negative control 322.85 
Relative CAT% 0.04 	0.14 	0.19 	0.02 	0. 	0.15 
for; 	0.5jtg 
1tg 0 	0.07 	0.13 	0.07 	0 	0.18 
3jtg 0.26 0.11 0.5 7.04 4.52 1.45 
Table B 1.8 Transfection of sA80BR cell line by Tfx50 : serum free. 
Experiment Details 	1 	 2 	 3 
Cell Passage No 18 19 20 
DNA (ug) 3 3 2.5 2.5 1 1 
6 6 5 5 2.5 2.5 
10 10 10 10 4.5 4.5 
Tfx50 ratio 2:1 3:1 1:1 2:1 2:1 2:1 
LSC(cpm) 	3g 2108.88 1586.23 544.05 428.11 1103.84 814.62 
6jtg 5584.09 2232.76 391.68 581 4097.65 1883.18 
10.tg 15947.73 1122 663.57 3439.87 6207.42 8236.12 
Positive control 94705.14 80840.94 71577.68 
Negative control 499.65 297.98 540.38 
Relative 	3.tg 1.71 1.15 0.31 0.16 0.79 0.39 
CAT% 6.tg 5.4 1.84 0.12 0.35 5.01 1.89 
10.tg 33.3 1.85 1.28 8.17 16.72 22.5 
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Table B 1.9 Transfection of sA80BR cell line by Tfx20 (Promega Southampton, UK) 
Experiment Details 1 2 a 
3a 4 5 
Cell Passage No 4 6 7 
Tfx20 ratio 2:1 3:1 4:1 2:1 3:1 4:1 
CAT 	 0.25 471123.1 1309975 669431.69 0 0 0 
(net intensity) 360933.1 1411100 1248617.8 0 0 0 
for DNA (tg) 	0.5 
1075654 1465413 20131.39 0 0 0 
0.75 
1765868 2559327 1210601.4 0 0 0 
1.0 
Positive control 5222458 
Relative 	0.25 9.02 25.08 12.82 0 0 0 
CAT % 0.5 6.91 27.02 23.91 0 0 0 
0.75 20.6 28.06 0.39 0 0 0 
33.81 49.01 23.18 0 0 0 
a Experiments 2 and 3 were duplicates of 1 and 6 was a duplicate of 5 
Table B 1.10 Transfection of sA80BR cell line by Superfect (Qiagen West Sussex, UK) 
Experiment - 	1 2 3 
Detail 
Cell Passage 9 10 11 
No 
Superfect (.tl)I 3 	6 	15 3 	3 1 	2 
jig DNA 
Vector pCATpromoter PSV2 	pCAT5 pCATpromoter 
CAT (net 3601188 1110619 	0 2275107 2484897 1707032 	5002714 
intensity) 
Positive 3093140 1962786 12778997 
control 
Relative CAT 116.43 	35.9 	0 115.91 	126.6 13.58 	39.15 
Table B 1.11 Transfection of Ovine liver cells with Effectene 
Date of Experiment 	 1 
Effectene (j.tl): DNA 1tgItl) 	 5:1 	 25:1 
CAT (net intensity) for 
DNA (tg) 	 0.2 	0 	 0 
	
0.4 181978.2 	131910 
1 	833161.1 479150.4 
Note; Cell passage number was 5 
M. 
Table B 1. 12 Transfection of Ovine liver cells with Effectene 
Experiment Details 	2 a 	3 a 
Effectene (ml): DNA 25:1 	50:1 	10:1 
1mg/mi) 
CAT (net intensity) 2298265 	29017726 	42403465 
Positive control 45959099 
Relative CAT % 5 	63.14 	92.26 
a Experiments 3 and 3 were duplicates of 2 
Cell passage number for 2-4 was 4 
Table B 1.13 Transfection of Ovine liver cells with Effectene (continued) 
Experiment Details 1 	2 	3 	4 	5 	6 
Effectene(ml): 10:1 10:1 25:1 25:1 50:1 50:1 
DNA 1 mg/ml) 
CAT (net) 	0.2 0 N/a 1267876 745141.4 0 390912.4 
ForDNA (tg) 	0.4 2251224 N/a 43013453 0 5661907 2048627 
1.0 1093490 728756.4 4163298 4964755 0 1367386 
Positive control 4007509 
Relative CAT % 0 0 31.6 18.59 0 9.75 
56.17 0 107.33 0 141.28 51.12 
27.29 18.18 103.8 123.89 0 34.12 
Note: Passage number was 6. 
Table B 1.14 Transfection of Ovine Cerebellum cells with Effectene (Qiagen) 
Experiment Details 1 	2a 3a 	4a 
5a 
Effectene (.il): 10:1 25:1 50:1 
DNA 1tg/.tl) 
CAT (net) 	0.1 0 	0 0 	0 0 	0 
for DNA (tg) 	0.2 1023404 38819.91 0 	741990.1 0 0 
0.51 1341039 172436.41 0 	273313.91 0 	0 
Note : a Experiment 2 was duplicate of 1, 4 a duplicate of 3 and 6 and duplicate of 5. 
I. 
B 2.0 Raw and Standardised CAT Data. 
Following transient transfection of the various cell lines as drawn out in section 2.5, cell 
lysate was recovered and a CAT assay completed. The enzyme CAT catalyses the 
transfer of acetyl groups to acetyl choline, in this case the substrate is radio-labelled 
[ 14C]chloramphenicol. To ensure equivalent recover of cell lysate independent on 
transfection efficiency, the cells were co-transfected with the plasmid -galactosidase 
and the appropriate -ga1actosidase assay carried out. The acetylated products were 
separated by thin layer chromatograph, and visualised by autoradiography, or by 
centrifugation by solubility in solvent (ethyl acetate). 
After purification from unconverted substrate, the amount of radio-labelled product was 
quantified by liquid scintillation counting or by densometirc reading of the autoradiograph using 
the Kodac system. From scintillation counting the amount of 14C labelled product was measured 
as counts per minute (cpm). From densometirc quantification the amount of 14C product was 
calculated by measuring the density (Net intensity) of the acetylated product detected by 
autoradiograph. The net intensity was measured by a Kodak Image Station and processed 
using the Kodak 1D Image Analysis software (section 2.5). As a positive control for CAT 
activity, the cell were transfected with the plasmid pCAT3 -Promoter (Promega), the amount of 
CAT activity from this plasmid was assumed to be 100% on each transfection and the chimeric 
CAT- PrP 3 'UTRs were standardised against this value. 
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B 2.1 CAT activity recorded following transient transfection of chimeric CAT-PrP 3'UTR 
plasmids in cell line sA80BR 
Table B 2.1.1 Experiment 1 
Plasmid Intensity Relative 
(cpm) CAT% 
PEYR 0 0 
PDI7 220.44 3.32 
PD20 673.51 10.15 
pD27 1757.96 26.50 
pD34 2371.33 35.74 
pD36 2058.43 31.03 
pCAT3- 6634.08 100 
Promoter  
Note: Cell passage number 17. 
Table B 2.1.3 ExDeriment2 
Plasmid Intensity Relative 
(cpm) CAT% 
pEYR 101.75 12.64 
pD17 77.02 9.57 
pD20 120.54 14.97 
pD27 149.23 18.54 
pD34 536.01 66.58 
pD36 285.72 35.49 
pCAT3- 805.12 100 
Promoter  
Note; Cell passage number 18  
Table B 2.1.2 duplicate of Experiment 1 
Plasmid Intensity Relative 
(cpm) CAT% 
pEYR 57.59 0.87 
pDl7 0 0 
pD20 3192.2 20.67 
pD27 1346.4 8.72 
p034 4847.7 31.38 
pD36 1425.77 9.23 
pCAT3- 15447.4 100.00 
Promoter  
Table B 2.1.4 ExDeriment 3 
Plasmid Intensity Relative 
(cpm) CAT% 
pEYR 224.56 26.21 
p017 117.69 13.74 
p020 372.57 43.49 
pD27 321.91 37.58 
pD34 741.17 86.52 
pD36 288.13 33.63 
pCAT3- 856.69 100.00 
Promoter 
Note; Cell passage number 4 
Table B 2.1.5 Experiment 4 
Plasmid Intensity (cpm) Relative CAT% 
pEYR 264.08 6.87 
pD17 194.84 5.07 
p020 320.46 8.34 
pD27 784.46 20.40 
pD34 1499.10 38.99 
pD36 0 0 
DCAT3-Promoter 3844.62 100 
Note; Cell passage number 5 
B-viii 
B.2.2 CAT activity recorded following transient transfection of chimeric CAT-PrP 
3'UTR plasmids in cell line pA80BR 
Table B 2.2.1 Experiment 1 
Plasmid Net Relative 
Intensity CAT (%) 
pEYR N/A N/A 
pD17 23891.28 25.53 
pD20 4486.75 4.79 
pD27 N/A N/A 
pD34 86991.47 92.95 
pD36 89598.09 95.73 
pCAT3- 93592.05 100.00 
Promoter 
Note ;Cell passage number 6  
Table B 2.2.2 Experiment 2 
Plasmid Net Relative 
Intensity CAT (%) 
pEYR 182905.67 73.44 
pD17 117674.85 47.25 
pD20 148627.28 59.68 
pD27 522107.44 209.63 
pD34 659221.01 264.68 
pD36 18817.08 7.56 
pCAT3- 249061.13 100.00 
Promoter 
Note; Cell passage number 7 





pEYR 3942.81 2.41 
pD17 2932.98 1.80 










pD36 5408.90 3.31 
pD36 35153.57 21.52 
pCAT3- 
Promoter  
1 163359.34 1  100.00 
Note ;Cell passage number 10  




pEYR 547266.5 16.28 
pD17 146087 4.35 
pD20 152586 4.54 
pD27 325563.3 9.69 
pD34 113979.7 3.39 




Note; Cell passage number 11 
Table B 2.2.5 Exoerirnent 5 
Plasmid Net Relative 
Intensity CAT (%) 
pEYR 17675.97 2.93 
pD17 2222.69 0.37 
pD20 9802.06 1.62 
pD27 30553.70 5.06 
pD34 71699.00 11.86 
pD36 12636.38 2.09 
pCAT3- 583866.75 100.00 
Promoter 
Note: Cell passage number 11 
Table B 2.2.6 Exoeriment 6 
Plasmid Net Relative 
Intensity CAT (%) 
pEYR 15575.28 2.02 
pEYR 13201.65 1.71 
pD17 29188.72 3.79 
pD20 454.75 0.06 
pD27 29260.68 3.80 
pD34 53264.00 6.92 
pD36 68402.02 8.88 
PCAT3- 769940.13 100.00 
Promoter 
Note; Cell passage number 12 
Table B 2.2.7 Comparison of sA80BR and pA80BR relative CAT activity log e data. 
Cell line 	Vector Collated % CAT activity Mean st.dev 
sA80 BR pEYR -2.30 -0.03 2.54 3.27 1.94 1.08 2.26 
pD17 1.23 -2.30 2.27 2.63 1.64 1.09 1.97 
pD20 2.34 3.03 2.71 3.77 2.13 2.80 0.65 
pD27 3.28 2.18 2.93 3.63 3.02 3.01 0.60 
pD34 3.58 3.45 4.20 4.46 3.67 3.87 0.44 
pD36 3.44 2.23 3.57 3.52 -2.30 2.09 2.52 
pA80BR pEYR 0.75 4.30 0.92 0.00 2.79 1.11 0.59 1.74 1.51 
pD17 3.24 3.86 0.64 2.55 1.49 -0.78 1.36 1.77 1.59 
pD20 1.59 4.09 2.87 3.21 1.53 0.54 -1.90 1.70 1.99 
pD27 5.35 3.11 1.57 2.27 1.65 1.36 2.55 1.51 
pD34 4.53 5.58 5.36 5.42 1.25 2.48 1.95 3.79 1.84 
pD36 4.56 2.03 1.22 3.07 1.61 0.78 2.19 2.21 1.27 
B.2.3 CAT activity recorded following transient transfection of chimeric CAT-PrP 3'UTR 
plasmids in cell line 1S120.Cer 
Table 2.3.1 Experiment 1 
	
Table 2.3.2 Experiment 2 (duplicate of 1) 
Plasmid Intensity Relative Plasmid Intensity Relative 
(cpm) CAT (%) (cpm) CAT (%) 
pEYR 472.82 5.26 pEYR 310.57 3.45 
pD17 513.55 5.71 pD17 421.36 4.68 
p020 593.04 6.59 p020 707.28 7.86 
pD27 586.09 6.52 pD27 1024.84 11.39 
pD34 2583.35 28.72 pD34 911.11 10.13 
p036 1756.54 19.53 pD36 8995.92 100.00 
PCAT3- 845.8 9.40 PCAT3- 845.8 9.40 
promoter promoter 
Note: Cell passage number 10, 3rd  August, 1999 





pEYR 86787.96875 19.7454362 
p017 107231.1953 24.40 
p020 32432.16797 7.38 
pD27 281823.25 64.12 
p034 118816.8984 27.03 
p036 146027.7813 33.22 
PCAT3- 548012 124.68 
promoter 





pEYR 143812.75 32.72 
pD17 123573.4219 28.11 
pD20 38378.27734 8.73 
p027 238240.8438 54.20 
pD34 212682.9531 48.39 
p036 148989.2813 33.90 
PCAT3- 331056.625 75.32 
promoter 
Note: Cell passage number 7, 3 rd December, 1999. 
Table 2.3.5 Experiment 5 Table 2.3.6 Experiment 6 (duplicate of 5) 
Plasmid Intensity Relative Plasmid Intensity Relative 
(cpm) CAT (%) (cpm) CAT (%) 
pEYR 41931.85547 7.85 pEYR 19697.68945 3.69 
pD17 14404.44922 2.70 pD17 11226.77344 2.10 
pD20 19829.95313 3.71 pD20 40888.75 7.66 
pD27 45802.77344 8.58 pD27 226975.9531 42.52 
pD34 50073.15234 9.38 pD34 79789.0625 14.95 
pD36 99413.63281 18.62 pD36 95266.94531 17.85 
PCAT3- 282509.25 52.92 PCAT3- 785177 147.08 
promoter promoter 
Note: Cell passage number 8 
B 2.4 CAT activity recorded following transient transfection of chimeric CAT-PrP 3'UTR 
plasmids in cell line 1S120.Liv 
Table B 2.4.1 Experiment 1. 	 Table B 2.4.2 Experiment 2 
Plasmids Net Relative Plasmids Net Relative 
Intensity CAT (%) Intensity CAT (%) 
PEYR 0.0 0.00 pEYR 929.288 0.11 
PD17 30313.4 3.44 PD17 1511.5 0.17 
PD20 74007.9 8.39 PD20 81152.5 9.21 
PD27 139327 15.80 PD27 0 0 
PD34 616813 69.97 PD34 692904 78.60 
PD36 75743.2 8.59 PD36 184862 20.97 
PCAT3- 881595 100.00 
Promoter  
Note ; for both experiment I and 2 cell passage number was 11 
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Table B 2.4.3 Experiment 3 
Plasmids Intensity (cpm) Relative CAT (%) 
pEYR 576.68 86.63 
PD17 456.97 68.64 
PD20 445.11 66.86 
PD27 382.79 57.50 
PD34 2087.16 313.52 
PD36 380.81 57.20 
PCAT3-Promoter 665.73 100.00 
Note: Cell passage number 11, 12-08-1999 
Table B 2.4.4 Experiment 4 Table B 2.4.5 Experiment 5 (duplicate of 4) 
Plasmids Net Intensity Relative Plasmids Net Intensity Relative CAT 
CAT(%) (%) 
pEYR 51798.16 25.68 pEYR 52858.46 26.20 
PD17 46360.69 22.98 PD17 25038.26 12.41 
PD20 74095.64 36.73 PD20 14559.36 7.22 
PD27 25138.03 12.46 PD27 220116.6 109.11 
PD34 67181.86 33.30 PD34 16512.9 8.19 
PD36 164531.4 81.56 PD36 211291.2 104.74 
PCAT3- 201738.5 100.00 
Promoter 
Note; for both experiment 4 and 5 cell passage number 12 
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Table B 2.4.6 Comparison of 1S120.Cer and lS12O.Liv relative CAT activity log e data. 
Cell line 	Vector Collated % CAT activity Mean st.dev 
1S120.Cer pEYR 1.68 1.27 2.07 1.33 2.99 3.49 2.14 0.91 
p017 1.76 1.56 1.03 0.79 3.20 3.34 1.95 0.94 
pD20 1.90 2.08 1.34 2.05 2.01 2.18 1.93 0.31 
pD27 1.89 2.16 3.75 4.16 3.99 3.19 1.13 
p034 2.44 3.36 2.25 2.71 3.30 3.88 2.99 0.50 
p036 2.33 2.98 2.93 2.89 3.51 3.53 3.03 0.42 
1S120.Liv pEYR -2.30 -1.56 3.26 3.27 4.46 1.43 2.67 
pD17 1.26 -1.31 3.14 2.53 4.23 1.97 2.12 
p020 2.14 2.23 3.61 1.99 4.20 2.83 1.00 
p027 2.77 0.00 2.53 4.69 4.05 3.51 1.03 
pD34 4.25 4.37 3.51 2.12 5.75 4.00 1.33 
pD36 2.16 3.05 4.40 4.65 4.05 3.66 1.04 
B-xiv 
B 2.5 Analysis of variants. 
Despite co-transfection to ensure consistent transfection efficiency, variation was observed in the 
overall level of CAT activity detected from independent transfection experiments. However, 
although the level of CAT measured may have varied between separate experiments the pattern 
of CAT expression from the individuals plasmids remained constant. It was necessary to 
determine if the observed variance between CAT values was significant. Analysis of variance 
(ANOVA) on the logged data was completed to look for significant differences (F) between the 
effect of the vectors overall and transfection efficiencies between each experiment. The purpose 
of analysis of variance (ANOVA) is to test for significant differences between population means. 
The source of variation in these experiments are the CAT-PrP/3'UTR plasmids and the 
efficiency of transfection. Residual variation estimates the with-in group variability, a factor that 
can not readily be accounted for in the current design. Sum of squares of a measurement of the 
amount of variation due to each source. Degrees offreedom are appropriate to the various sum 
of squares and reflect the number of populations (individual transfection experiments or 
plasmids). Mean of squares is the variance estimates obtained by dividing each sum of square by 
its appropriate degrees of freedom. The variance ratio is a comparison between the variance 
estimates and is used to determine the importance of the different sources of variation. 
The overall effect of plasmids was found borderline significant in all cell lines (tables 1-4). This 
means that there are differences in the overall magnitudes of the standardised CAT results 
between samples, which may be a result of variable transfection efficiencies. However, the 
estimated variation when considering the both the overall plasmid effect and transfection effect 
together (interaction) was found significant. This indicates that although the overall level of CAT 
activity detected for individual transfection experiments may have varied, the differences in 
standardised CAT measurements between plasmids are reasonably constant across all samples. 
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Table B 2.5.1 Analysis of Variants (ANOVA) using CAT activity (log e) obtained from 
transient transfection studies of cell line sA80BR. 
Source of Degrees of Sum of Mean of Variance ratio F probability 
variation freedom squares squares (F) 
Plasmids 5 24.44 4.89 5.37 0.100>p>0.050 
Transfections 3 21.53 7.18 7.89 0.050>p>0.025 
Interaction 15 45.97 3.06 3.37 p> 0.100 
Residual 4 3.64 0.91 
Total 30 95.4 
Table B 2.5.2 Analysis of Variants (ANOVA) using CAT activity (log e) obtained from 
transient transfection studies of cell line pA80BR. 
Source of Degrees of Sum of Mean of Variance ratio F probability 
variation freedom Squares Squares (F) 
Plasmids 5 30.21 6.04 5.69 0.050>p>0.025 
Transfections 5 43.52 8.70 8.20 0.025>p>0.010 
Interaction 25 73.89 2.96 2.78 p>0 . 100 
Residual 6 6.37 1.06 
Total 42 154.15 
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Table B 2.5.3 Analysis of Variants (ANOVA) using CAT activity (log e) obtained from 
transient transfection studies of cell line 1S120.Cer. 
Source of Degrees of Sum of Mean of Variance ratio F probability 
variation freedom squares squares (F) 
Plasmids 5 17.6 3.52 4.58 0.010>p>0.005 
Transfections 2 7.52 3.76 4.89 0.025 >p> 0.01 
Interaction 10 11.82 1.18 1.54 p> 0.100 
Residual 18 13.84 0.77 
Total 36 50.79 
Table B 2.5.4 Analysis of Variants (ANOVA) using CAT activity (log e) obtained from 
transient transfection studies of cell line 1S120.Liv. 
Source of Degrees of Sum of Mean of Variance ratio probability 
variation freedom Squares Squares (F) 
Plasmids 5 24.5 4.91 2.7 0.1>p>0.05 
Transfections 2 48.9 24.4 8.213.50 p>O.OlO 
Interaction 10 31.9 3.19 2.781.8 0.2>p>0.15 
Residual 12 21.7 1.81 
Total 30 127 
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